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General Introduction
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#Tuberculosis: a global health problem
Tuberculosis (TB) is the second leading cause of death from infectious diseases 
worldwide, after human im m unodeficiency virus (HIV) infection.1 One-third of the 
world population is latently infected with TB and at risk of developing active TB.2 
According to recent estimates of the World Health Organization (WHO), there 
were 9.4 million new TB cases and 1.6 million deaths due to TB in 2009.3 
The TB case load distribution follows a strong socio-econom ic gradient: TB 
affects the poorest countries, the poorest comm unities within countries, and the 
poorest individuals w ithin comm unities most severely.4 Nineteen of the 22 
countries that account fo r 80% of the world 's TB cases are low or lower-middle 
income countries.35 Most TB cases occur in Asia (55%) and Africa (30%), and the 
TB incidence rates are highest on the African continent (Figure 1). Apart from 
poverty, the spread of TB is fuelled by the HIV-epidemic, particularly in 
Sub-Saharan Africa.1 The WHO estimated that 1.1 million of the 9.4 million patients 
with newly diagnosed TB in 2009 were co-infected with HIV, 80% of whom were 
living in the African region.3
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Figure 1 Estimated TB incidence rates worldw ide, 20093
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#From exposure to active disease
TB or ‘Koch's disease', referring to Robert Koch who discovered its causative 
agent in 1882, is spread by airborne m icro-droplets that contain Mycobacterium  
tuberculosis (MTB). The infectious droplets are expectorated by patients with 
active pulmonary or laryngeal TB when they cough, sneeze, sing or ta lk .6 Disease 
transmission occurs when the infectious droplets are inhaled by a second 
person. After inhalation, the TB bacilli are entrapped by macrophages in the 
alveoli of the host's distal airways. This initiates an immune response that can 
result in either successful containment of the infection (latent TB) or progression 
to active TB (primary progressive disease).1 The latter is most common in patients 
whose immune system is severely impaired, for example in patients with advanced 
HIV-infection.7 HIV-infection and other conditions such as diabetes mellitus, 
malignancies, malnutrition and vitamin A and D deficiencies, can trigger the 
development of active disease after successful containment of MTB; the lifetime 
risk of developing active TB from a new infection is around 10%, and even higher 
in HIV-infected patients.18
In the majority of patients, active TB manifests as pulmonary disease. 
Extrapulmonary TB, for example tuberculous meningitis or miliary TB, is relatively 
common in HIV-infected patients.79 The main pulmonary symptoms are persistent 
cough, chest pain, haemoptysis and shortness of breath. The symptoms of 
extrapulm onary TB depend on the disease's location.10 Common, generalized 
symptoms of active TB include fever, night sweats and weight loss.1 Because of 
its wasting effect, TB used to be called consumption disease or phthisis (Greek 
fo r consumption).11
Diagnosing active tuberculosis
There are several methods to diagnose active TB but all have lim itations. The 
gold standard is specimen culture, which allows for drug susceptib ility testing as 
well.1 The method is time consuming (1-3 weeks in liquid media and up to 6 
weeks in solid media) and requires the presence of well-equipped laboratories 
and trained personnel. Hence, culture is not feasible for routine practice in re­
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source-lim ited settings with a high burden of TB.110 In most resource-lim ited 
settings, TB diagnosis is based on clinical symptoms, smear m icroscopy and 
radiography, as recommended by the WHO and the International Union Against 
TB and Lung Disease (lUATLD).1012 Smear m icroscopy to detect acid-fast bacilli 
(AFB) in stained smears of sputum or other specimens is a relatively cheap and 
simple method that is available in most settings with a high burden of TB. 
However, the method has limited sensitivity: only 50-80% of patients with cul­
ture-confirm ed TB have AFB-positive smears.1 Chest radiography can be of help 
to diagnose pulmonary TB in patients with AFB-negative sputum smears. 
However, radiographic features of TB can be very subtle or atypical, especially in 
HIV-infected patients and patients with primary progressive disease.113
First-line tuberculosis treatment
Until the 1940s, no chem otherapeutic agent was available for the treatment of TB 
and patients were referred to hospitals and sanatoria for bed rest and fresh air. 
In 1944, the injectable drug streptomycin was discovered and appeared to be an 
effective anti-tuberculosis agent. However, monotherapy with streptomycin was 
soon found to provoke mycobacterial drug resistance. Combination therapy with 
streptomycin, para-am inosalicylic acid (PAS) and, later, isoniazid reduced the 
risk of resistance development substantially.1415 Although the new triple therapy 
yielded favourable results, the length of treatment (18-24 months) and the risk of 
adverse effects were important drawbacks.15 From the 1950s onwards, several 
randomized controlled trials were conducted by the British Medical Research 
Council to evaluate drug com binations that could shorten the duration of 
treatment and reduce the risk of adverse effects.16 The discovery of rifampicin in 
1959 was of major im portance in this respect (although it was not until 1971 that 
the drug became w idely available),1517 as was the substitution of PAS by 
ethambutol and the addition of pyrazinamide to the available combinations. 
Since mutant (resistant) bacilli are most likely to emerge from large, vital bacilli 
populations that are present at the onset of treatment, it was reasoned that 
resistance prevention with multiple drugs was most essential in the initial phase 
of treatment. Thus, the treatment regimen was split in an initial intensive phase
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#
#General In troduction  | 11
with multiple drugs and a continuation phase with fewer drugs. It became clear 
that the vast majority of TB bacilli are killed rapidly in the intensive phase of 
treatment by drugs with ‘bactericidal activity' such as isoniazid and rifampicin, 
but that few bacilli enter a state of persistence with sporadic bursts of activity 
only. These persistent bacilli are eradicated in the continuation phase of treatment 
by drugs with ‘sterilizing activity' (mainly by rifampicin).16,18 
Since 1993, the WHO recommends a first-line regimen for newly diagnosed TB 
that consists of a 2-months intensive phase of rifampicin, isoniazid, pyrazinamide 
and ethambutol followed by a 4-months continuation phase of rifampicin and 
isoniazid.1219 The regimen can be administered daily or interm ittently (thrice 
weekly) and the drugs are preferably supplied in fixed dose combination (FDC) 
tablets which reduce the daily pill burden from as many as sixteen to as few as 
four tablets.19
The ongoing transmission of tuberculosis
One of the key-elements in the fight against TB is adequate treatment of patients 
with active TB. The first-line treatment regimen for newly diagnosed TB is highly 
effective: it can achieve cure rates of over 95% under optimal, experimental 
conditions.14 Yet, global treatment success rates are 86% on average, and below 
the target of 85% in 13 of the 22 countries with the highest burden of TB.3 In other 
words, despite the availability of an effective treatment regimen, TB continues to 
affect m illions of people around the world.3 One of the factors that are responsible 
fo r the continuing spread of TB, is HIV-infection as this increases the risk of 
primary progressive TB and activation of latent TB.8 The other major contributor 
to the ongoing transmission of TB is non-adherence to treatment by patients. It 
can result in treatment failure, relapse and drug-resistant TB, and thus in 
suboptimal cure rates.319 Unsuccessfully treated patients are at risk of severe 
m orbidity and m ortality and can affect entire comm unities by transm itting the 
disease to others.20 The emerging m ultidrug-resistant (MDR) and extensively 
drug-resistant (XDR) TB, both associated with non-adherence,21 constitute 
particular threats to public health. The treatment of MDR and XDR TB is costly 
and by far not as effective as the treatment of drug-susceptib le TB. According to
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the WHO, only 12% of the estimated 250,000 prevalent MDR TB cases were 
identified in 2009 and of these, only one-third were enrolled in treatment 
programmes.3
Thus, by resulting in unfavourable treatment outcomes, non-adherence to 
treatment is a major cause of the continuing transmission of TB in communities 
(Figure 2) and hence, addressing the problem of non-adherence is an important 
strategy to control TB.
Figure 2 Transmission of tuberculosis: a v ic ious cycle
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#Non-adherence to tuberculosis treatment
The problem of non-adherence to treatment, i.e. deviation from a prescribed 
treatment regimen by for example irregular medication intake or premature 
term ination of treatment, is known to all medical disciplines; between 30% and 
60% of medicines are not taken as prescibed.22 Poor treatment adherence is 
associated with severe m orbidity and mortality, and it contributes significantly to 
the overall cost of healthcare.2223
Non-adherence to TB treatment has been a concern ever since the introduction 
of am bulatory treatment in the 1950s.24 Researchers in Madras, Hong Kong and 
London started to experiment with supervised treatment that required daily clinic 
visits by am bulatory patients fo r observed medication intake.1624 Regimens that 
allowed fo r interm ittent treatment were introduced as less frequent dosing could 
make supervised treatment easier and cheaper.24 In the early 1990s, when the 
HIV-epidemic caused a dramatic increase in the TB incidence and TB was 
recognized as a global health problem again, the WHO launched the Directly 
Observed Treatment Short-course (DOTS) strategy to control TB. The DOTS 
strategy is based on five pillars: (1) political comm itment to TB control; (2) case 
detection by smear m icroscopy in patients who present with prolonged cough; 
(3) standardized short-course (6 months) chemotherapy under direct observation 
of treatment; (4) guaranteed regular drug supply; and (5) a standardized recording 
and reporting system. Its third pillar, D irectly Observed Treatment (DOT) by a 
trained supervisor, became the key-strategy in most national TB control 
programmes to improve the patients' adherence to TB treatm ent.25
Studies on the effectiveness of DOT started to appear in the late 1990s.26-29 The 
results were ambiguous and did not prove convincingly that DOT yields more 
favourable treatment outcomes than self-adm inistered treatm ent.30 Advocates of 
DOT reasoned that the results of these studies should be interpreted with caution 
because most studies did not have a randomized controlled design (the gold 
standard to evaluate the effect of an intervention) and did not compare relapse 
rates (long-term treatment outcome) between the intervention- and control-group. 
They argued that DOT in the real-life setting comprises more than the observation
General In troduction | 13
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of pill intake only; other important advantages of DOT are the possibility of 
closely monitoring the effects of treatment and rapidly responding to treatment 
interruptions.31-33 Opponents of DOT stated that by forcing TB patients to take 
their medication under direct observation of a treatment supervisor, DOT is an 
imposition rather than a service to patients. They argued that DOT should only 
be applied to patients who are considered to be at risk of non-adherence or have 
proved to be non-adherent.2024
By the time most countries had started to implement the DOTS strategy, an 
additional drawback of DOT came up. The provision of DOT by healthcare 
personnel caused overburdened healthcare facilities in countries with a large TB 
caseload. This, and the fact that the daily clin ic visits for observed medication 
intake were a burden to many patients, led to the prioritizing of certain patient 
groups for DOT (i.e. patients who are at highest risk of transm itting the disease 
to others and patients who are most likely to be non-adherent)2 and the 
involvement of comm unity-members in the provision of DOT.34-36 Although com ­
munity-based DOT proved to be as effective as facility-based DOT in experimental 
settings,2937-44 concerns have been raised about its effectiveness in the real-life 
setting as there is little control on how strictly DOT is applied in com m unities.45 
Therefore, alternative adherence promoting interventions are being explored.3346-48
Solving the problem of non-adherence to tuberculosis 
treatment: the challenges
The debate on the pros and cons of DOT reveals a number of challenges that 
hinder solving the problem of non-adherence to TB treatment. First, predicting 
who will be non-adherent to TB treatment (for example to be able to provide DOT 
to a selected group of patients only) is hardly if at all possible.49 Several risk 
factors of non-adherence, including patient characteristics such as gender, age, 
educational level and socioeconom ic status, have been identified in quantitative 
research,50-54 but obviously, such factors cannot serve as reliable predictors of 
non-adherence in individual patients. Health behaviour theories could help to 
understand adherence behaviour and thus provide insight in who might be at
General Introduction
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#risk of non-adherence. Unfortunately, none of the existing health behaviour 
theories provide satisfactory explanation of adherence behaviour.55,56
Second, in the absence of reliable predictors of non-adherence, it would be 
useful to have a validated tool to identify non-adherence patients. Unfortunately, 
there is no agreement on how to detect non-adherence.57 In studies on the 
effectiveness of adherence promoting interventions, non-adherence is often 
detected indirectly by evaluating treatment outcome. However, treatment 
outcome depends on pathogenic, immunological and pharm acological factors 
as well (Figure 2) and thus is an unreliable indicator of non-adherence in individual 
patients.23 In addition, it is a retrospective indicator that is of no help in early 
detection of and response to non-adherence. Monitoring the patient's adherence 
would be more useful but so far there is no simple, reliable and affordable method 
available to measure adherence.57 Currently used methods include direct 
measures such as tests that detect TB drugs in plasma or urine, and indirect 
measures such as self-reports and pill counts. Direct measures prove that the 
patient took a dose of medication but cover brief medication intake periods only; 
ndirect measures cover longer periods but assume rather than prove the patient's 
actual medication intake.2357
Third, most global efforts to improve adherence are centred around the currently 
available 6-months TB treatment regimen. M odifications of the conventional 
facility-based DOT to a form of comm unity-based DOT34 or ‘enhanced DOT' (DOT 
plus adherence enabling interventions and the provision of incentives)2 are ways 
to optimize adherence to the lengthy treatment regimen. However, such 
operational interventions require extensive comm itment of governments, 
healthcare providers, comm unities and patients; a degree of commitment that 
may not be realistic to expect from all stakeholders in settings with a high burden 
of TB. Moreover, operational interventions do not change one of the general 
impediments of adherence to TB treatment: the length and com plexity of the 
treatment regimen.17
An alternative strategy to optimize adherence is to shorten TB treatment duration 
with com binations of new TB drugs.58 Reducing the first-line treatment regimen
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from 6 months to for example 6 weeks or even less, will help patients to complete 
treatment and healthcare providers to monitor the patients' adherence behaviour 
with DOT. In fact, shorter and simpler TB treatment regimens would be beneficial 
to the implementation of all elements of the DOTS strategy in national TB control 
programmes.25 Unfortunately, the development and testing of new TB drugs is a 
costly and lengthy process. Pharmaceutical industries are reluctant to invest in 
TB drug development as the TB drug market is regarded as insufficiently 
profitable.5960 Because of the reluctance of pharmaceutical industries, 
governmental and nongovernmental organizations have started to invest in TB 
drug research and a number of research consortia are currently testing new 
drugs in preclinical and clinical tria ls.586162 However, it will take several years 
before the first new agents have made it all the way from preclinical testing to the 
global drug market.60
A strategy to avoid the tim e-consum ing process of making a new, effective TB 
drug accessible to all patients is to revise the potential of drugs that are already 
available. For example, results from studies in mice and men suggest that higher 
than standard doses of rifampicin, the cornerstone drug of the current TB 
treatment, could shorten treatment duration substantia lly.63-65 Currently, clinical 
trials are ongoing to evaluated the to lerability and efficacy of high doses of 
rifampicin in TB patients.66 Although rifampicin is a promising agent to shorten 
treatment, the drug is potentially hepatotoxic.67 Therefore, the safety of using 
higher than standard doses of rifampicin has to be evaluated carefully.
Other ‘old' drugs that have the potential to shorten TB treatment duration are the 
fluoroquinolones, a class of antibacterial drugs that are already in use for the 
treatment of MDR TB and for treating patients with intolerance against the 
first-line TB drugs.6869 Fluoroquinolones are also prescribed for a variety of other 
infections including respiratory, gastro-intestinal and urinary tract infections. 
From studies in Europe and the United States it is known that fluoroquinolones 
constitute a significant part of the total antibacterial drug sale,7071 but the extent 
to which they are used in resource-lim ited settings is unknown.72 The use of fluo ­
roquinolones for treatment of other infections than TB could provoke the 
development of resistance to fluoroquinolones in MTB, for example in patients 
with yet undiagnosed active TB who have been prescribed a fluoroquinolone for
General Introduction
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containing regimens are useless in the treatment of patients with fluoroquinolone- 
resistant MTB and thus widespread use of fluoroquinolones for other infections than 
TB could be a major drawback to the promising potential of the agents to shorten 
TB treatment duration.73
Clearly, to solve the problem of non-adherence to TB treatment, researchers, 
politicians, healthcare workers, pharmaceutical companies and patients should 
join forces to improve knowledge of how non-adherence can be predicted, 
measured and prevented. Solving the problem of non-adherence to TB treatment 
will contribute s ignificantly to achieving the Stop TB Partnership goal of reducing 
the global incidence of active TB cases to less than one per 1 million population 
per year in the year 2050.74
Aim and outline of this thesis
The general aim of the studies presented in this thesis is to contribute to the fight 
against non-adherence to TB treatment by addressing the questions of how 
non-adherence can be measured and prevented.
Except for the study presented in Chapter 6, all studies described in this thesis 
were conducted in Tanzania. Tanzania is one of the 22 countries with the highest 
burden of TB3 and provides excellent ground for research on adherence to TB 
treatment since a number of adherence promoting interventions have been 
implemented (community-based DOT in a patient centred treatment approach)75 
or are being evaluated (shortening TB treatment duration with higher than 
standard doses of rifampicin and with fluoroquinolones)6676 in the country.
Table 1 provides an overview of the outline of this thesis. In the studies presented 
in Part I, the problem of non-adherence to TB treatment is explored in more 
detail to get insight in the difficu lties of predicting non-adherence and its 
consequences. In C hapter 2, the complex relationship between non-adherence 
to TB treatment and treatment response is unravelled. C hapter 3 presents an
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ana lys is  of the de te rm inan ts  of adherence  as perce ived by Tanzanian TB patien ts 
and in troduces  a the o re tica l m odel tha t cou ld  he lp to exp la in how adherence 
behav iou r is estab lished .
Table 1 An in tegra l ap p ro ach  to so lve the p rob lem  of no n -adhe rence  to TB 
trea tm en t
Chapter Research question(s)
Part I. Exploring the problem of non-adherence to TB treatment
Chapter 2 Why are we still in the dark with respect to understanding the adherence- 
response relationship in TB treatment and how can we get out?
Chapter 3 How is adherence behaviour established in the perception of Tanzanian TB 
patients?
Part II. Measuring adherence to long-term treatment regimens
Chapter 4 Which combination of methods is valid and feasible to measure adherence 
to TB treatment in resource-limited settings? How adherent are Tanzanian 
TB patients on community-based DOT?
Chapter 5 Is the use of MEMS to monitor adherence to antiretroviral treatment 
acceptable to Tanzanian HIV-patients?
Chapter 6 Could the determination of TB drug concentrations in blood (TDM) be a 
valid method to measure adherence?
Part III. Preventing non-adherence to TB treatment
Chapter 7
Chapter 8 
Chapter 9
Chapters 
10a & 10b
Is community-based DOT in the Tanzanian patient centred TB treatment 
approach an effective alternative to facility-based DOT with respect to 
treatment outcome?
What are the challenges of developing new TB drugs that could shorten 
treatment ? Which new drugs are currently in clinical development?
What is the rate of TB drug-induced hepatotoxicity in Tanzanian TB 
patients?
To which extent are the fluoroquinolones sold in northern Tanzania?
Chapter 11 Is fluoroquinolone resistance in MTB common in patients from northern 
Tanzania and is this related to previous fluoroquinolone exposure?
TB = tuberculosis; DOT = directly observed treatment; MEMS = medication event monitoring system; 
HIV = human immunodeficiency virus; TDM = therapeutic drug monitoring; MTB = Mycobacterium 
tuberculosis.
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#The s tud ies  in P a rt II describe  several m ethods to m easure adherence  to 
long -te rm  trea tm en t reg im ens. In C h a p te r 4, a s tudy  is presen ted in w h ich 
e lec tron ic  m on ito ring , a sop h is tica ted  m ethod to m easure adherence, is used as 
a go ld  s tandard  to va lida te com b in a tion s  of s im ple and a ffo rdab le  adherence 
m easures tha t cou ld  be used in resource -lim ited  se ttings. The a cce p ta b ility  of 
us ing e lec tron ic  m on ito ring  devices fo r routine p ractice  in resource -lim ited  
se ttin gs  is eva luated in C h a p te r 5. This chap te r focu ses  on the experiences of 
H IV -in fected pa tien ts w hose adherence to an tire trov ira l trea tm ent, w h ich  is also 
assoc ia ted  w ith  se rious p rob lem s of non-adhe rence ,77 is m on ito red  e lec tron ica lly . 
C h a p te r 6 describes  the use of ano the r adherence m easure -the de tec tion  of TB 
d rugs  in p lasm a- fo r a d iffe ren t pu rpose in a d iffe ren t se tting : the ra pe u tic  drug 
m on ito ring  (TDM) to op tim ize drug doses in ind iv idua l pa tien ts w ho appear to 
have low drug con cen tra tion s  desp ite  adequa te  adherence.
The s tud ies  in p a r t III address w ays to prevent non-adherence  to  TB treatm ent. 
In C h a p te r 7, the e ffec tiveness  of com m u n ity -b ased  DOT as com pared  to 
fac ility -ba sed  DOT is eva luated in the Tanzanian se tting . C h a p te r 8 sum m arizes 
the  cha llenges of deve lop ing  new TB trea tm ent reg im ens of sho rte r du ra tion  and 
p rov ides an up -to -da te  review of the new d rugs tha t are cu rre n tly  in c lin ica l 
deve lopm ent. In C h a p te r 9, the inc idence  of TB d ru g -in du ced  he pa to to x ic ity  in 
Tanzanian pa tien ts  on s tandard  firs t-line  trea tm ent is described  as to an tic ipa te  
on the po tentia l risk of he pa to to x ic ity  w ith  h igher doses of rifam p ic in  in TB 
trea tm ent reg im ens of sho rte r duration. C h a p te rs  10 and 11 focu s  on the flu o ro ­
qu ino lones, the o the r c lass of d rugs  tha t are a lready availab le  and curren tly  
be ing investiga ted fo r the ir po ten tia l to shorten TB trea tm ent duration. In 
C h a p te rs  10a and 10b, the extent of fluo ro q u in o lo n e s  sale fo r all k inds of 
in fec tions  in the Tanzanian K ilim an ja ro  Region is described. In C h a p te r 11, the 
hypo thes is  tha t the w ide use of fluo ro q u in o lo n e s  in the trea tm ent of o ther 
in fec tions  induces m ycobacte ria l res is tance to the flu o ro q u in o lo n e s  is tested.
Finally, the im p lica tions  of the fin d in g s  of the s tud ies  presen ted in th is  thes is  w ith 
respect to so lv ing  the prob lem  of non-adherence to TB treatm ent are d iscussed  
in the G en e ra l D is c u s s io n .
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#Abstract
N on-adherence to tub e rcu lo s is  (TB) trea tm ent is a m ajor cha llenge  to g loba l TB 
con tro l because it increases the risk of trea tm en t fa ilure, re lapse and the 
em ergence of drug res is tan t TB. A lthough  the p rob lem  is w ide ly  acknow ledged, 
there is s till no c la rity  abou t the exact im pact of d iffe ren t levels and pa tte rns of 
non-adherence  on trea tm ent ou tcom e. This ham pers the p rov is ion  of adequate 
advice  to pa tien ts and c lin ic ians, and it cha llenges  the deve lopm ent and 
eva luation of adherence  p rom oting  in te rven tions.
In th is  artic le , we exp la in  w hy we are s till in the  da rk  w ith  respect to pred ic ting  
how d iffe ren t type s  of non-adherence  to TB trea tm ent a ffec t trea tm ent ou tcom e. 
We show  tha t we lack u n ifo rm ity  in how we de fine  and m easure non-adherence, 
tha t we have no easily  access ib le  trea tm ent success ind ica tors , and tha t the 
re la tionsh ip  between trea tm ent adherence and ou tcom e is in fluenced  by a 
num ber of pa thogen ic , im m uno log ica l and ph a rm a co lo g ica l fac to rs  tha t are on ly 
pa rtly  unders tood .
We con c lu de  tha t an in tegra l ‘bench and  bedside  app roach ' tha t incorpora tes 
experim enta l s tud ies  w ith  in vitro m ode ls and an im a ls as well as observa tiona l 
s tud ies  in pa tien ts  w ith  TB, is needed to he lp us get out of the da rk  regard ing the 
adherence -response  re la tionsh ip  in TB treatm ent.
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#Introduction
Tuberculosis (TB) is a m ajor cause of m orb id ity  and m orta lity  worldw ide. More than 
9 m illion people are d iagnosed w ith active TB each year, and 1.6 m illion people die 
of the disease.1 The recom m ended treatm ent regimen fo r newly d iagnosed drug- 
susceptib le  TB consists of a 2-m onths intensive phase of isoniazid, rifampicin, 
pyrazinam ide and, optionally, etham butol, fo llowed by a 4-m onths continuation 
phase of isoniazid and rifampicin, adm in istered daily or in term ittently.2 The regimen 
can achieve treatm ent success rates of >95%  in patients w ith sm ear-positive 
pu lm onary TB who are treated under optim al conditions. However, the actual 
treatm ent success rates are 86% on average and below 80% in one-fourth of the 22 
countries w ith the highest burden of TB.1 Unfavourable treatm ent outcom es are 
largely attribu tab le  to non-adherence to treatm ent, as th is increases the risk of 
treatm ent failure, relapse and drug-resistant TB.3 In particular, the em ergence of 
m ultidrug- and extensively drug-resistant TB is an immense threat to global health 
wh ich is related to non-adherence to treatm ent.4
A lthough  the p rob lem  of non-adherence  to  TB trea tm ent is w ide ly  acknow ledged, 
little  is known abou t how trea tm en t ou tcom e is a ffec ted  by various levels and 
pa tte rns of non-adherence. The fac t tha t in te rm itten t dos ing  is poss ib le  in TB 
trea tm ent sug ge s ts  tha t a certa in  degree of f le x ib ility  in dos ing  schedu les  is 
a cce p ta b le .2 Moreover, a lthough  prem ature  te rm ina tion  of trea tm en t increases 
the  risk of trea tm ent fa ilu re  and re lapse,56 the exact re la tionsh ip  betw een th is  risk 
increm en t and the du ra tion  of trea tm ent until te rm ina tion  is unknow n. G uide lines 
fo r the m anagem ent of pa tien ts  w ho in te rrup ted  TB trea tm ent are based on 
expert op in ion s  but lack p lain sc ie n tific  evidence. M ost gu ide lines  d iffe ren tia te  
betw een trea tm ent in te rrup tions  in the in tensive phase versus con tinu a tio n  phase 
of trea tm ent, and take into acco un t the du ra tion  of in te rrup tions, the seve rity  of 
the d isease (cavita ry versus non -cav ita ry  disease) and spu tum  sm ear resu lts 
a fte r 2 m onths of trea tm en t.7 The usual recom m endation  is to extend the duration 
of trea tm ent, but ev idence regard ing  how long trea tm ent shou ld  be extended is 
rare ly if ever ava ilab le .3 In the absence of a c lear unde rs tand ing  of the re la tionsh ip  
betw een d iffe ren t levels and pa tte rns of non-adherence  and trea tm en t outcom e, 
it is im poss ib le  to prov ide un am b iguous adv ice  to c lin ic ian s  and patients.
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#In th is  a rtic le , we w ill exp la in w hy we are s till in the da rk  w ith  respect to pred ic ting  
how d iffe ren t type s  of non-adherence  to TB trea tm ent a ffec t trea tm ent ou tcom e. 
We w ill e labora te  on the d ifficu ltie s  of de fin ing  and m easuring  trea tm ent 
adherence and trea tm en t success, and we w ill b rie fly  con s id e r the in te rm ed iate 
fac to rs  tha t shape the pathw ay from  trea tm en t adherence  to outcom e. Finally, we 
w ill sum m arize  the s tra teg ies  and research ap proaches tha t are needed to 
unravel the adhe rence -response  re la tionsh ip  in TB treatm ent.
How to define and measure non-adherence to 
tuberculosis treatment
A dherence to trea tm en t is genera lly  de fined as the extent to w h ich  a patient 
fo llow s  the p rescribed  trea tm ent reg im en. N on-adherence can be: (i) fa ilu re  to 
take any m ed ica tion  at all, (ii) d iscon tinua tion  of trea tm ent prem ature ly, or (iii) 
devia tion  from  the prescribed  trea tm en t in ano the r way, inc lud ing  brief trea tm ent 
in te rrup tions  and under- o r ove rdo s ing .8 The la tte r ca te go ry  is in fac t a reservo ir 
of any pattern of non-adherence other than term ination of treatm ent all together. 
D iffe ren tia ting  betw een ca tegories  and pa tte rns of non-adherence, w h ich  is 
se ldom  exp lic itly  done in the ex is ting  lite ra ture  on TB trea tm ent adherence, is 
im portan t fo r tw o reasons. First, the im pact of non-adherence  on trea tm ent 
ou tcom e depends on the type  and tim ing  (i.e. in w h ich  phase of trea tm ent) of 
non-adherence. Second, d iffe ren t k inds of health behav iou r are tho ugh t to 
underlie  the d iffe ren t type s  of non-adherence, and hence adherence p rom oting  
in te rven tions m ay not be equa lly  e ffec tive  to all type s  of non-adhe rence .9 
TB con tro l p rogram m es fo cu s  p rim arily  on defau lte rs, i.e. pa tien ts  w ho 
d iscon tinued  trea tm en t fo r at least 2 consecu tive  m on ths.10 A lthough  default 
rates are relatively easy to obtain, they do not inform us about other types of non­
adherence.
A m ore accu ra te  but less easily  m easurab le  in d ica to r is adherence rate, w h ich  is 
the p ro po rtion  of p rescribed  doses taken by a pa tien t in a spec ified  pe riod .11 The 
main prob lem  w ith  respect to adherence rate is the absence of a go ld  s tandard  
to m easure adherence. O verestim ation  or unde restim ation  of adherence  rates 
are com m on when using a s ing le measure, and there fore a com bination  of direct
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#and ind irec t m easures is advised though  se ldom  p ra c tice d .8 D irect m easures 
inc lude  those  tha t de tect the presence of d rugs  in p lasm a or urine. Urine assays 
fo r ison iaz id  are increas ing ly  used in c lin ica l se ttings  as they  are easy to use, 
h igh ly  sensitive  and spe c ific .12 However, d irec t adherence  m easures do not 
cap tu re  pa tte rns of non-adherence, as they  cover brief m ed ica tion  in take periods 
only. Ind irec t m easures, such as assessm en t by s tandard ized  questionna ires  
and pill counts, cover longer pe riods  but they im ply  ra ther than prove tha t pa tien ts 
a c tu a lly  to o k  the m ed ica tion .8
How to define and measure treatment success
A part from  de fin ing  the s ta rtin g -p o in t in the  adhe rence -response  re la tionship, 
we need to agree on w h ich  m easurable en d -po in t is ta rge ted . The m ost obv ious 
en d -p o in t is ou tcom e at te rm ina tion  of trea tm ent. The ou tcom e c lass ifica tion  that 
is used in TB con tro l p rogram m es is of lim ited va lue in th is  respect because it 
in co rp o ra tes  both disease and treatment ou tcom es. It d iffe ren tia tes  between 
‘cure', ‘fa ilu re ' and ‘death ' as disease ou tcom es, and between ‘trea tm ent 
com p le ted ', ‘de fau lted  from  trea tm en t' and ‘transfe rred  ou t' as treatment 
o u tcom es.10 The d iffe ren tia tion  betw een the disease  ou tcom es ‘cure ' and ‘fa ilu re ’ 
is based on sm ear m ic ro scopy  a fte r 5 and 6 m onths of trea tm en t in pa tien ts 
d iagnosed  w ith  spu tum  sm ear-pos itive  pu lm onary  TB.10 The prob lem  is that 
sm ear m ic ro scopy  has lim ited se n s itiv ity  and sp e c if ic ity  and canno t be used in 
the  fo llow -u p  of pa tien ts  w ith  sm ear-negative  TB, w ho cons titu te  m ore than half 
of the active  TB cases w o rldw id e .1 On the o ther hand, treatment ou tcom es reflect 
the  pa tien t's  behav iou r ra ther than the b iom ed ica l response to trea tm ent. The 
treatment ou tcom e ‘trea tm ent com p le te d ' is used as a m easure of trea tm ent 
success  in pa tien ts  w ho com p le ted  trea tm ent and of w hom  no spu tum  sm ears 
cou ld  be ob ta ined , but clearly, it is no d irec t m arker of b iom ed ica l response to 
trea tm ent.
A cqu ired  drug res is tance is an in d ica to r of non-adherence  as well and cou ld 
serve as an en d -po in t in the adhe rence -response  re la tionsh ip . D iagnosing 
acqu ired  drug res is tance involves rou tine p re -trea tm en t drug susce p tib ility  
tes ting  (to be sure tha t the re  is no p rim ary  drug resistance) and repetition  a long
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#the trea tm ent course. It requires the ava ila b ility  of cu ltu re  and drug susce p tib ility  
tes ting  fac ilit ie s  tha t are lack ing  in m any resou rce -lim ited  s e ttin g s .2 
Relapse rate is ano the r im portan t in d ica to r of trea tm ent success. Relapse is 
de fined as the recurrence of active TB a fte r success fu l trea tm en t.10 In c lin ica l 
tria ls, fo llow -u p  pe riods of 1-2 years a fte r trea tm ent com p le tion  are usually 
nc luded  to de term ine re lapse rates. However, long -las ting  fo llow -u p  of ind iv idua l 
pa tien ts in o rder to assoc ia te  re lapse rates w ith  levels of adherence  to  the initial 
trea tm ent course re trospec tive ly  is hard ly  feas ib le  in the rea l-life  setting. 
Moreover, in the absence of m o lecu la r techn iques, it is d iff ic u lt to d iffe ren tia te  
between true  re lapse and new in fec tion .13
The intermediates between adherence and treatment 
success
Ideally, one w ou ld  use trea tm en t success as an in d ica to r of the pa tien t's  
adherence to trea tm ent. However, apart from  the fac t tha t the re  is no clear-cut, 
easily  m easurab le  in d ica to r of trea tm ent success, the  pathw ay from  adherence 
to trea tm ent response is shaped by fou r fac to rs  tha t are on ly  pa rtly  unders tood : 
pa thogen ic, im m uno log ica l, ph a rm a cok in e tic  and pha rm acodynam ic  factors. 
First, m any of the cha rac te ris tics  of Mycobacterium tuberculosis  (MTB) are not 
yet clear. MTB is a s lo w ly  m u ltip ly ing  pa thogen w ith  the cap ac ity  to adap t to 
va rious ph ys io log ica l environm ents. It can pers is t in so lid , caseous m ateria l and 
in the ac id ic  in te rio r of m acrophages and m onocy tes  fo r years w h ile  m u ltip ly ing  
on ly  spo rad ica lly . It is tho ugh t tha t th is  state of ‘do rm ancy ' is respons ib le  for 
re lapse TB.14
S econd, the hos t's  com plex, m u lti-ce llu la r im m une response to  MTB con tribu tes  
to e ffec tive  subvers ion  of active TB, and hence, the hos t's  im m une sta tus 
co -de te rm ines  TB trea tm en t ou tcom e.1516
Third, in te rpa tien t va ria b ility  in p lasm a con cen tra tion s  of TB d rugs is com m on 
and not a lways a ttr ibu tab le  to the pa tien t's  non-adherence  to trea tm ent. V ariab ility  
in pharm acok ine tics , i.e. the re la tionsh ip  betw een the adm in is te red  drug dose 
and consecu tive  drug p lasm a con cen tra tion s  (F igure 1), p lays a role as w e ll.17
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Fourth, the m echan ism s by w h ich  drug p lasm a con cen tra tion s  eventua lly  lead to 
the  e rad ica tion  of ac tive ly  m u ltip ly ing  and pe rs is ting  bacilli (pharm acodynam ics, 
F igure 1) are in com p le te ly  unde rs to od .18 Recent in vitro and an im al s tud ies  have 
show n tha t the bac te ric ida l a c tiv ity  of the firs t-line  TB d rugs is m ain ly  driven by 
the  ratio betw een exposure, expressed as the Area U nder the p lasm a co n ce n tra ­
tion -tim e  Curve (AUC) and m ycobacte ria l suscep tib ility , m easured by the 
M in im um  Inh ib ito ry  C oncen tra tion  (MIC; see F igure 2).19-24 This im p lies tha t 
m axim iz ing  exposure  (by m eans of increasing  the dose and hence increasing 
peak p lasm a concen tra tions , and /o r increasing the dose frequency) ra ther than 
m a in ta in ing  p lasm a con cen tra tion s  above a m in im um  level th rou gh ou t the dosing 
in terva l is a requ irem en t fo r e ffec tive  TB trea tm ent. It is one of the exp lanations 
fo r the po ss ib ility  of in te rm itten t dos ing  in TB treatm ent.
Figure 1 C lin ica l p h a rm a co lo g ica l v iew  on a n tim ic ro b ia l the rapy
Pharmaco- Pharmaco-
Adherence kinetics dynamics
(PK) (PD)
Finally, the m echan ism s by w h ich  sub op tim a l drug con cen tra tion s  lead to 
m ycobacte ria l res is tance are not fu lly  unrave lled yet. A cco rd in g  to one theory, 
the  risk of m ycobacte ria l res is tance is re lated to the ratio betw een peak p lasm a 
con cen tra tion  (Cmax) and MIC fo r rifam p ic in ; the ratio betw een exposure  (AUC) 
and MIC fo r ison iazid ; and the tim e du ring  w h ich  the drug concen tra tion  is above 
the MIC fo r pyraz inam ide and e th am bu to l.20'2123-25 A cco rd in g  to ano the r theory, 
the  risk of am p lifica tion  of res is tant m utan ts increases w ith  the tim e du ring  w h ich 
the  drug con cen tra tion  is in the m utan t se lection  w indo w  (MSW; see F igure 2), 
w h ich  covers the con cen tra tion  range between the m in im um  concen tra tion  that 
in h ib its  99%  of bacteria l g row th  (M IC99) and the con cen tra tion  tha t prevents 
am p lifica tion  of the least d ru g -su scep tib le  m utant sub po pu la tio n  (m utant 
preven tion  concen tra tion ; MPC).26
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Figure 2 The A rea U nder the  p lasm a co n ce n tra tio n -tim e  Curve (AUC)
time (h)
Cmax = Maximum plasma drug concentration; AUC = Area Under the plasma concentration - time 
Curve; MIC99 = Minimum Inhibitory Concentration that prevents 99% of bacterial growth; MPC =
Mutant Prevention Concentration; MSW = Mutant Selection Window.
#  #  
The way ahead
t is c lear tha t we are still in the dark w ith respect to pred ic ting  the im pact of d ifferent 
levels and patte rns of non-adherence to TB trea tm ent on trea tm ent outcom e. We 
lack un ifo rm ity  in how we define and m easure non-adherence, we have no easily 
accessib le  trea tm ent success indicators, and the re la tionship between treatm ent 
adherence and ou tcom e is in fluenced by a num ber of pathogen ic, im m unolog ica l 
and pharm aco log ica l fac to rs  tha t are on ly partly  understood.
To avoid con fus ion  to pa tien ts  and c lin ic ians, the best advice  is to ensure 100% 
adherence to trea tm ent. For th is  purpose, the W orld Health O rgan iza tion  (WHO) 
in troduced  the d irec tly  observed trea tm ent (DOT) s tra tegy  in the early  1990s.10 
However, apa rt from  the fac t tha t the provis ion  of DOT is not feas ib le  in all se ttings 
because of the large w o rk load  involved and the p rob lem s it creates fo r many 
patients, DOT does not guarantee op tim al adherence by all pa tien ts .27 
The a lte rna tive  m ajor s tra tegy tha t m ight he lp to ensure 100% adherence  is to 
shorten  trea tm ent dura tion . Several new com p ou nds  tha t have the po ten tia l to
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#shorten  TB trea tm en t are in (pre-) c lin ica l de ve lopm e n t.28 However, the cha llenges 
of deve lop ing  e ffec tive  TB trea tm ent reg im ens of sho rte r du ra tion  are m ultip le  
and it w ill p robab ly  take at least ano the r decade before new reg im ens cou ld  be 
ava ilab le to pa tien ts  w o rldw ide . M eanw hile , ex tend ing  research ac tiv ities  tha t 
con tribu te  to a m ore de ta iled  un de rs tand ing  of the adhe rence -response  
re la tionsh ip  in TB trea tm en t w ill prove to be rew arding. It w ill prov ide  gu idance  in 
the  m anagem ent of non-adheren t pa tien ts  and it w ill he lp to  deve lop  adherence 
p rom oting  in te rven tions. Moreover, it w ill con tribu te  to the un de rs tand ing  of the 
pa thogen ic , im m uno log ica l and ph a rm aco log ica l fac to rs  tha t in fluence  trea tm ent 
ou tcom e. The la tte r w ill be of he lp in the deve lopm ent of new, e ffec tive  trea tm ent 
reg im ens.
Two ap p roaches cou ld  be taken to m ap out the re la tionsh ip  betw een treatm ent 
adherence  and ou tcom e: observa tiona l s tud ies  in pa tien ts  w ith  TB and 
experim enta l s tud ies  in in vitro and an im al m odels (Table 1). W ith regard to 
obse rva tiona l s tud ies  in hum ans, we firs t need m easures tha t a llow  fo r a s im p le  
assessm en t of adherence  in ind iv idua l pa tien ts. M ed ica tion  Event M on ito ring  
S ystem s (MEMS; pill bo ttles  w ith  a m ic ro e le c tro n ic  ch ip  tha t reco rds every tim e 
a m ed ica tion  bo ttle  is opened) were su cce ss fu lly  used in s tud ies  tha t he lped to 
estab lish  the requ ired  m in im um  level of adherence to an tire trov ira l the rapy .29 
E lectron ic  m on ito rs  cou ld  serve as a m easure to assess adherence  to TB 
trea tm ent as w e ll,30 and they  cou ld  be used as a re ference standard  to valida te 
a lte rna tive  m easures tha t are a ffo rd ab le  and feas ib le  fo r use in a w ide range of 
se ttin g s .31 C ons iderab le  eng ineering  e ffo rts  are in p rogress to im prove the 
e lec tron ic  m onitors. For exam ple, dev ices are be ing deve loped tha t con firm  
w he the r pa tien ts have ingested the m ed ica tion .32
A pa rt from  m easures to assess adherence, easily  and early  access ib le  ou tcom e 
m arkers shou ld  be developed. Surroga te  m arkers fo r trea tm en t ou tcom e such as 
seria l spu tum  co lon y  counts, w ho le  b lood bac te ric ida l assays, tim e to cu ltu re  
po s itiv ity  in liqu id  m edia, and im m uno log ica l and m o lecu la r m arkers shou ld  be 
eva luated fo r the ir se n s itiv ity  and s p e c if ic ity  in c lin ica l p ractice  and in ongo ing  
tr ia ls  fo r new TB trea tm ent reg im ens.13'1533 The use of such tech no log ies  requires 
an upg rad ing  of the la bo ra to ry  cap ac ity  in hea lthcare  fac ilit ie s  of reso u rce -lim it­
ed cou n trie s  w here m ost pa tien ts  w ith  TB live. Cu lture and drug susce p tib ility
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Table 1 O verv iew  of s tra teg ies  and research ap p ro a ch e s  tha t are needed to 
m ap ou t the  a d h e rence -resp on se  re la tio nsh ip  in TB trea tm e n t
Study type Strategies and research 
approaches needed
Examples®
Observational 
studies in TB 
patients
1. Validation of adherence 
measurement instruments
a. Medication Event Monitoring 
Systems (MEMS)
b. Combination of direct and 
indirect measures
2. Validation of surrogate markers 
for treatment response
a. Serial sputum colony counts
b. Time to culture conversion
c. Time to culture positivity in 
liquid media
d. Whole blood bactericidal 
assays
e. Immunological markers 
(such as T cell counts)
f. Molecular makers (such as 
mycobacterial RNA)
3. Upgrading laboratory capacity in 
resource-limited countries with a 
high TB burden
a. Culture facilities
b. Drug susceptibility testing 
facilities
c. Molecular technique facilities
Experimental
studies
Development of in vitro and animal 
models in which different levels 
and patterns of non-adherence can 
be mimicked and the effects on 
treatment response studied
a. Hollow fibre models
b. Whole blood cultures
c. Mice models
* References: 8, 13, 15, 33, 34, 36; TB = tuberculosis.
tes ting  fac ilit ie s  shou ld  becom e m ore w ide ly  ava ilab le  to be ab le to detect 
acqu ired  drug resistance, an im portan t in d ica to r of non-adherence  to  TB 
treatm ent.
To avo id the cha llenges  of m app ing  out the e ffec ts  of non-adherence in hum an 
observa tiona l stud ies, experim enta l m odels shou ld  be used as well. In such 
m odels, d iffe ren t pa tte rns and levels of adherence  can be m im icked by vary ing
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#drug exposure  in a con tro lled  fash ion . H o llow  fib re  m odels, i.e. sem i-perm eab le  
in vitro system s in w h ich  ce lls  or bacteria l pa thogens can be grow n and in w h ich  
exposure  to  fluc tu a ting  drug con cen tra tion s  can be sim u la ted, are be ing 
eva luated fo r th e ir use in s tud y ing  the e ffec t of va rious levels of non-adherence  
on trea tm ent fa ilu re  and the em ergence of res is tance .34 The re la tion between 
non-adherence  and the risk of re lapse cou ld  be exp lo red by us ing w ho le  b lood 
cu ltu res  tha t con ta in  m ycobacte ria  tha t have undergone phag ocy tos is  by 
m acrophages and as such represent pe rs is ten t in fe c tion .35 Finally, TB m odels  in 
m ice can be used to eva luate the im pact of various pa tte rns and levels of 
non-adherence  on the risk of trea tm ent fa ilu re  and re lapse.36 Such m odels  can 
be useful in the deve lopm ent of surrogate m arkers fo r trea tm ent ou tcom e as well.
In conc lus ion , an in tegra l ‘ bench and  beds ide ' app roach  is needed to m ap out 
the  re la tionsh ip  between adherence  to TB trea tm ent and trea tm en t success, and 
to  p red ic t how the d iffe ren t type s  of non-adherence  a ffec t trea tm en t ou tcom e. A 
de ta iled  un de rs tand ing  of the adhe rence -response  re la tionsh ip  in TB trea tm ent 
w ill prov ide us w ith  fundam en ta l know ledge  tha t he lps in m on ito ring  and advis ing  
patien ts, and w ith  a ta rge t to aim  fo r when deve lop ing  adherence  prom oting  
in te rven tions.
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#Abstract
O ur aim  was to exp lo re  pa tien t pe rcep tions  of adherence  to tub e rcu lo s is  (TB) 
trea tm ent in Tanzania and con s tru c t a the o re tica l m odel of trea tm ent adherence 
behaviour. We recru ited  eleven w e ll-adheren t TB pa tien ts by pu rposive  sam pling  
fo r p a rtic ip a tion  in open sem i-s truc tu red  in te rv iew s tha t we analyzed by con tent 
analysis.
The pa rtic ip an ts  revealed tha t the in tention  to adhere is the m ost im portan t 
de te rm inan t of adherence  behaviour. This in tention  is p receded by the decis ion  
to seek b iom ed ica l healthcare, and based on know ledge  and be lie fs  abou t TB 
trea tm ent and the m otiva tion  to get cured. The in tention  to  adhere he lps patien ts 
to cope w ith  perce ived barrie rs to adherence  such as so c ioe cono m ic  d ifficu ltie s , 
and create an adherence  enab ling  env ironm en t in w h ich  the presence of socia l 
sup po rt plays an im portan t role.
O ur p re lim ina ry  adherence  behav iou r m ode l shou ld  be va lida ted  in larger, 
non-adheren t pa tien t po pu la tio ns  and eva luated fo r its a p p lic a b ility  to the 
deve lopm ent of adherence p rom oting  stra teg ies.
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#Introduction
Despite  the ava ilab ility  of e ffec tive  trea tm ent, tub e rcu lo s is  (TB) rem ains one of 
the  main in fec tious  d iseases w o rldw id e  tha t is assoc ia ted  w ith  severe m o rb id ity  
and m orta lity. Every year, m ore than 9 m illion peop le  are d iagnosed  w ith  TB and 
1.6 m illion peop le  die of the d isease.1 A m ajor cha llenge  to g loba l TB con tro l is 
non-adherence  to trea tm ent. The extent of non-adherence  to TB trea tm ent is 
d iff ic u lt to assess, but it is estim ated tha t up to one -fou rth  of TB pa tien ts  fa il to 
com p le te  the 6 -m on ths  trea tm ent cou rse .2 N on-adherence increases the risk of 
trea tm ent fa ilu re  and relapse, and is cons ide red  to be the  m ost im portan t cause 
of d ru g -re s is tan t TB.3 In particu lar, m u ltid rug -res is ta n t (MDR) and extensive ly  
d rug -re s is tan t (XDR) TB cons titu te  serious th rea ts  to pub lic  health. A cco rd in g  to 
recent estim ates of the W orld Health O rgan iza tion  (WHO), a lm ost half a m illion 
peop le  were d iagnosed  w ith  MDR TB in 2008 .1
To im prove adherence to TB treatm ent, the W HO recom m ends the d irect 
observa tion  of trea tm en t (DOT) by a tra ined  person w ho m on ito rs  the pa tien t's  
m ed ica tion  in take.4 However, DOT is labour in tensive w hen p rovided in healthcare 
fac ilit ie s  (fac ility -based  DOT), and m ight not be app lied  s tr ic tly  w hen p rovided by 
a m em ber of the  pa tien t's  com m u n ity  (com m un ity-based  DOT).5 
An in-depth understanding of the factors that affect adherence to TB treatm ent could 
facilitate the developm ent of com plem entary adherence prom oting strategies. 
Several m ainly quantitative stud ies have been conducted fo r th is purpose and over 
200 determ inants of adherence have been described, includ ing social, dem ographic 
and other patient factors. However, the relationship between these factors and 
adherence is not very consistent and reveals little about causality.6 In few  studies, 
a ttem pts were made to evaluate theoretica l m odels that could be applicab le to 
adherence behaviour but none of the existing health behaviour theories suffic iently 
expla ined adherence behaviour to TB treatm ent.78 Most theories do not address the 
context-specific sociocultural aspects of adherence behaviour and are not applicable 
to long-term  m edication adherence.8
In th is  qua lita tive  research, we con du c te d  open sem i-s truc tu red  in te rv iew s w ith 
TB pa tien ts  from  Tanzania's no rthern  K ilim an ja ro Region to  analyze fac to rs  that
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#in fluence adherence  to TB trea tm ent in the pe rcep tion  of TB patients. O ur aim 
was to con s tru c t a the o re tica l trea tm ent adherence behav iou r m odel based on 
con ten t ana lys is  of the in te rv iew  data.
Methods
Study setting
Tanzania is one of the 22 coun tries  w ith  the h ighest burden of TB. The cou n try 's  
annual trea tm ent success rate of new TB cases is reaching the W HO ta rge t of 
85% . However, am ong those  w ith  an unsuccess fu l trea tm ent ou tcom e a lm ost 
one-th ird  are defau lte rs, m eaning tha t they te rm ina ted  trea tm en t prem ature ly .1 
Except fo r de fau lt rates, no data is ava ilab le on the levels and pa tte rns of 
non-adherence  to TB trea tm ent by Tanzanian patients.
The s tandard  Tanzanian trea tm ent reg im en fo r new ly d iagnosed , d ru g -su sce p ti­
ble TB in adu lt pa tien ts  cons is ts  of a 2 -m onths in tensive phase of rifam p ic in , 
ison iazid , pyraz inam ide and e tham bu to l adm in is te red  in th ree  or fou r fixed dose 
com b ina tion  (FDC) tab le ts  taken once daily, fo llow ed  by a 4 -m on ths  con tinua tion  
phase of rifam p ic in  and ison iaz id  in three or fou r FDC tab le ts . The N ational TB 
and Leprosy Program  (NTLP) em pow ers pa tien ts  to dec ide  w hethe r the ir da ily 
m ed ica tion  in take is supe rv ised  by hea lthcare  s ta ff at the hea lthcare  fa c ility  or by 
a trea tm ent sup po rte r from  the pa tien t's  com m u n ity  (usually a fam ily -m em ber or 
spouse). F ac ility-based DOT is m ain ly  p rov ided  to pa tien ts  w hose m edica l 
con d ition  requ ires hosp ita l adm iss ion ; over 80% of ou tpa tien ts  op t fo r com m u n i­
ty -based  DOT.9 Patients on com m un ity -based  DOT are supposed  to co llec t the ir 
m ed ica tion  at the hea lthcare  fa c ility  once w eek ly  du ring  the firs t 2 m onths of 
trea tm ent and once every 2 w eeks du ring  the rem a in ing  4 m onths.10
Study participants
We recru ited  the s tud y  pa rtic ip an ts  from  a coh o rt of 50 adu lt TB pa tien ts  on 
com m un ity -based  DOT w ho pa rtic ip a ted  in a lo ng itud ina l trea tm ent adherence 
study. In th is  study, the levels and pa tte rns of the pa tien ts ' adherence  to trea tm ent 
were assessed by us ing a com b in a tion  of m ethods inc lud ing  the  M ed ica tion  
Event M on ito ring  System  (MEMS; pu rchased from  Aardex Ltd, Sw itze rland); a
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#m ed ica tion  con ta in e r w ith  a m ic ro e le c tro n ic  ch ip  tha t records every open ing  of 
the  conta iner. O ther adherence m easures used in th is  s tud y  were a urine test to 
de tect rifam p ic in  and isoniazid , pill coun ts  at m ed ica tion  refill v is its, reg is tra tion  
of the regu la rity  w ith  w h ich  pa tien ts  a ttended  the hea lthcare  fa c ility  fo r m ed ica tion  
refills, and s tandard ized  questionna ires . P artic ipan ts  in the lo ng itud ina l s tudy 
were recru ited  betw een February and A pril 2010 from  one rural and three urban 
hea lthcare  fac ilit ie s  in the  K ilim an ja ro Region.
We se lected  the pa rtic ip an ts  in the curren t s tud y  pu rpos ive ly  from  the g roup  of 
pa tien ts  in the long itud ina l s tud y  w ho had com p le ted  at least the firs t 2 m onths 
of trea tm ent. We used the techn ique  of pu rpos ive  sam p ling  to ob ta in  a m axim um  
varia tion  sam ple  w ith  respect to age, sex, res idency and con com ita n t d iseases 
tha t he lped us to unde rs tand  the processes unde rly ing  adherence behaviour, 
and enab led us to con firm  or d iscon firm  ten ta tive  con ne c tion s  betw een them es 
tha t s ta rted  to evolve from  in terim  data ana lyses.1112 We con tinued  w ith  the 
sam p ling  process until them es s ta rted  to  recur in the  in te rv iew s and no new 
them es cam e up anym ore (saturation). This po in t w as reached a fte r eleven 
pa tien ts  from  the long itud ina l s tudy  had been in terviewed.
The open semi-structured interview
In the p repa ra to ry  phase of the study, we con du c te d  a review  of the lite rature on 
the  de te rm inan ts  of adherence  to TB trea tm ent to define key con cep ts  tha t 
p rov ided  s ta rting  po in ts  fo r the process of da ta  c o lle c tio n .1213 The literature 
review  ind ica ted  tha t adherence is a fo rm  of health behav iou r tha t re lates to the 
presence (or absence) of barrie rs and fac ilita to rs . These key con cep ts  (adherence 
behaviour, fac ilita to rs  of adherence and barrie rs to adherence) he lped us to  set 
the con text fo r our study. We used the key co n cep ts  to design  a to p ic  list w ith 
fou r item s: (1) m ed ica tion  in take habits; (2) se lf-d esc rib ed  adherence behaviour; 
(3) experienced barrie rs to adherence ; (4) experienced fac ilita to rs  of adherence. 
The to p ic  list served as a backbone in the in terviews, but the actual question ing  
fo llow ed  the flo w  of the pa rtic ip a n t's  answ ers and was d irec ted  by them es 
evo lv ing  from  in terim  analyses of the interviews.
The pa rtic ip an ts  were in te rv iew ed in a private room  in the c lin ic  from  w h ich  they 
were recru ited . The in te rv iew s were con du c te d  by an E ng lish -speak ing  researcher 
w ith  a fa ir unde rs tand ing  of Tanzania's national language K isw ahili (A uthor JB;
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#herea fter referred to as ‘the researcher'), and a Tanzanian research assis tan t 
(Author EM) w ho trans la ted  the researcher's  ques tions  from  English to K isw ahili 
and the pa rtic ip an ts ' answ ers from  K isw ahili to English. The in te rv iew s were 
tap e -reco rded  and lasted betw een one and one and a half hour each. The 
researcher and research ass is tan t m ade notes of the ir ob se rva tions  of the verbal 
and non-verbal com m un ica tion  du ring  the in terviews. The E ng lish-spoken parts 
of the in te rv iew s were transc ribe d  and these tra n sc rip ts  were used fo r data 
analysis, tog e the r w ith  the o rig ina l tape -reco rd ings .
Data analysis
We con du c te d  the data ana lys is  in para lle l to data co llec tio n  and s ta rted  w ith  the 
c on s tru c tion  of a cod ing  schem e tha t we deve loped du ring  the in terim  analyses 
of the in terviews. For the deve lopm en t of the cod ing  schem e, the three key 
con cep ts  tha t were derived from  the in itia l lite ra ture  review  (i.e. adherence 
behaviour, fac ilita to rs  of adherence  and barrie rs to adherence) served as initial 
‘m aster codes ' from  w h ich  second - and th ird -leve l codes fo llow ed  to  capture 
them es and sub them es, respective ly .14 We grouped  connected  them es and 
sub -them es into ca tegories  (that re flected to a large extent the in itia l key 
concep ts) and inco rpo ra ted  them  as such in the cod ing  schem e.
The fina l cod ing  schem e was used to code the transc rip ts  of all in te rviews. This 
was done by the researcher and the research ass is tan t independently . We 
com pared  the cod ing  resu lts and the in itia l ag reem ent be tw een the tw o  coders  
was ‘sub s tan tia l' (kappa value of 0.74).15 For each interview, we d iscussed  the 
cod ing  d iffe rences  and reached consensus.
The fina l s tep involved the genera tion  of a the o re tica l m odel in w h ich  the 
ca tegories, them es and sub -them es w ere in te rconnected . The la rgest part of th is  
process had a lready taken place du ring  data co llec tio n ; we had con firm ed the 
re la tionsh ips betw een them es tha t em erged from  the in terim  ana lyses of 
in te rv iew s w ith  pa rtic ip an ts  in consecu tive  in terviews. We con s tru c ted  the 
u ltim ate m odel a fte r we had reached consensus abou t the re la tionsh ips between 
them es.
The p rocess of da ta ana lys is  is best sum m arized as con ten t ana lys is16 and 
resu lted in the genera tion  of a the o re tica l m odel tha t was d irec ted  by, but not 
res tric ted  to our in itia l key con cep ts .1213
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Standards for qualitative inquiry
The researcher and research ass is tan t d iscussed  the cha llenges of con du cting  
c ross -cu ltu ra l and c ross-language  qua lita tive  research extensive ly  in the 
p re pa ra to ry  phase of the study. The researcher, a Dutch m ed ica l d o c to r w ho has 
been liv ing in Tanzania fo r 4 years, has a fa ir unde rs tand ing  of K iswahili, but 
does not speak  the language fluently . The research assis tant, a Tanzanian 
research nurse, is a native K isw ahili speake r and fluen t in English. She has a 
w ide  experience in trans la ting  betw een English and K isw ahili in in -depth 
in te rv iew s fo r c lin ica l and research purposes. W ith respect to the trans la tions  
du ring  in terviews, the key con cep ts  ‘adherence  behaviour', ‘ba rrie rs ' and 
‘fac ilita to rs ', and frequ en tly  used keyw ords such as ‘trea tm ent adherence ', ‘non­
adherence ' and ‘trea tm ent sup p o rte r' were exp lo red and trans la ted  beforehand. 
To ve rify  the accu racy  of trans la tion  in the in terviews, the  K isw ahili spoken parts 
of the firs t in te rv iew  were transc ribe d  and consecu tive ly  trans la ted  into English 
by an independen t Tanzanian trans la to r w ho did not have access to the English 
spoken  pa rts  of the  interview . We com pared  th is  trans la tion  w ith  the tra n sc rip t of 
the  English spoken pa rts  of the in te rv iew  and did  not find  incons is tenc ies  
betw een the tw o docum ents. Therefore, we used the tra n sc rip ts  of the English 
spoken  parts  of the in te rv iew s as the p rim ary  data sou rce  and referred to the 
K isw ahili spoken  parts  on ly  in case of doubt.
As S qu ires (2009) po in ts  out, in c ross-language  qua lita tive  research the 
in te rp re te r (research assistant) shou ld  be regarded as a soc ia l ac to r and not 
m ere ly as a tech n ica l trans la to r.17 The com p le x ity  of the ‘soc ia l in te rp lay ' in the 
in te rv iew s and the e ffec t on the genera tion  of da ta  was dw elled  on by the 
researcher and the research ass is tan t in the p repa ra to ry  phase. In particular, 
they to o k  note of the fac t tha t the ir d iffe ren t soc io e co n o m ic  and cu ltu ra l 
backg rounds m ight in fluence  the responses of pa rtic ip an ts .18 For exam ple, local 
norm s cou ld  make it d iff ic u lt fo r pa rtic ip an ts  to answ er open ly  and honestly  to a 
fo re ign  v is ito r or, m ore generally, to peop le  w hom  they assoc ia te  w ith  th e ir local 
hea lthcare  p rov iders .19 To reduce th is  risk, the researcher and research assistant 
regarded pa rtic ip an ts  as ‘experts  by experience '. The researcher and research 
assistant were not involved in the provis ion of healthcare to the pa rtic ipan ts  and 
presented them selves as ‘researchers who wanted to learn from  the partic ipant's
Part I -  Exploring the problem of non-adherence to TB treatment
#
#experiences '. In add ition , pa rtic ip an ts  were ap p roached  both as ‘ respondents ', 
w ho ta lk  abou t the ir own pe rcep tions  and experiences, and as ‘ in fo rm ants ', who 
base the ir answ ers on w hat they know  from  others. We expected tha t the latter 
s tra tegy w ou ld  he lp pa rtic ip an ts  to  ta lk  free ly  abou t w hat is gene ra lly  cons idered  
as deviant health behaviour.
We op tim ized  the accu racy  of da ta co llec tio n  and ana lys is  by an exp lo ra tion  of 
the key con cep ts  p rio r to the actua l da ta co llec tio n  to cap ture  the ir broad 
spec trum  of poss ib le  m eanings. We addressed  the v a lid ity  of da ta  co llec tio n  in 
in terim  in te rv iew  ana lyses by eva luating w he the r the in te rv iew er and the 
pa rtic ip an ts  appeared to have a s im ila r un de rs tand ing  of the m eaning of the key 
con cep ts .12 Furtherm ore, we eva luated the va lid ity  of the ana lyses of the 
pa rtic ip an ts ' acco un ts  by ve rifica tio n  of em erg ing  them es in consecu tive  
in te rv iew s and by an a fte rw a rds  brie f eva luation of the con s tru c ted  m odel w ith  
ind iv idua l pa rtic ip an ts  (responden t va lida tion ).1920
Ethical considerations
We obtained eth ical approval from  the Institutional Review Board of the K ilimanjaro 
C hris tian M edica l C entre (M oshi, Tanzania) and the Tanzanian N ational Institute 
fo r M edica l Research (Dar es Salaam , Tanzania). Prior to the interviews, 
pa rtic ip an ts  rece ived verbal and w ritten  in fo rm ation  abou t the purpose  and 
s truc tu re  of the in te rv iew  and s igned  an in fo rm ed consen t form . We in fo rm ed 
them  tha t c o n fid e n tia lity  w as guaranteed.
Results
Characteristics of study participants
We in te rv iew ed eleven patients, s ix  men and five w om en. Their m edian age was 
36 years (range 22-71). Five pa rtic ip an ts  were m arried, three were s ingle , two 
were w idow ed  and one w as d ivorced. The m a jo rity  (seven pa rtic ipan ts) had 
a ttended  p rim ary  educa tion  only. Three had com p le ted  se co nd a ry  schoo l and 
one had no fo rm a l educa tion  at all. Four pa rtic ip an ts  were co -in fec ted  w ith  HIV, 
tw o of w hom  were us ing an tire trov ira l m ed ica tion . The s tudy  sam ple  w as a fa ir
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rep resen ta tion  of the genera l TB pa tien t popu la tion  in the K ilim an ja ro Region 
w ith  respect to the m ale/fem ale d is tr ibu tion  (55% male in the s tud y  sam ple  versus 
63%  m ale in the genera l TB pa tien t popu la tion), m edian age (36 versus 37 years), 
and p ro po rtion  of H IV -in fected pa tien ts  (36% versus 37%).19 
A ll pa rtic ip an ts  were in the th ird  m onth of TB trea tm en t when they  were in terview ed 
and were on com m un ity -based  DOT. M ost pa rtic ip an ts  were adhering  w e ll to 
trea tm ent at the tim e of the  interview . Six pa rtic ip an ts  had not m issed a sing le 
dose du ring  the firs t 2 m onths of trea tm en t acco rd ing  to MEMS results. Four 
pa rtic ip an ts  had m issed less than five doses and one pa rtic ip an t had m issed ten 
doses sho rtly  a fte r the onset o f trea tm ent. By the tim e of p repa ring  th is  m anuscrip t, 
a ll pa rtic ip an ts  had succe ss fu lly  com p le ted  treatm ent.
Content analysis
Two ca tego ries  of them es were iden tified : (1) them es tha t re lated to the pa tien t's  
in ten tion  to adhere to TB treatm ent, and (2) them es tha t re flected perceived 
fa c ilita to rs  of and barrie rs to adherence once the in tention  to adhere is there. An 
overv iew  of the them es and sub them es inc lud ing  the num ber of pa rtic ip an ts  who 
referred to the ind iv idua l them es, is p rov ided  in Table 1. In the fo llow ing , them es 
are presen ted as separa te en tities  and in re la tion to one another. The quo ta tions 
in the  text do not a lw ays fo llow  the tech n ica l ru les of the English language; rather, 
they represent as accu ra te ly  as poss ib le  a litera l trans la tion  of w ha t pa rtic ip an ts  
said. In F igure 1, the the o re tica l adherence behav iou r m odel tha t we cons truc ted  
is presented. The con ne c tion s  betw een them es and sub them es are dep ic ted  
w ith  num bered arrow s in the F igure and they are referred to in the text below.
Category 1. Intention to adhere to TB treatment
The pa rtic ip an ts  all expressed a strong  de te rm ina tion  to adhere to TB trea tm ent. 
The main them es unde rly ing  th is  in tention  to adhere were know ledge  and be lie fs 
abou t TB trea tm en t and the m otiva tion  to get cured (F igure 1, a rrow s 1 and 3).
Theme 1. Knowledge and beliefs about TB treatment
This them e cons is ted  of th ree  in te rre la ted  sub them es: (1) genera l be lie fs  and 
pe rcep tions  of TB disease, (2) the be lie f tha t TB is curable, and (3) the be lie f that 
the  do c to r's  in s tru c tion s  need to be fo llow ed to get cured. The p a rtic ip a n ts ’
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Table 1 C onten t ana lys is : ove rv iew  of ca tego ries , them es and sub them es
Category Themes and subthemes n/11a
1. Intention to adhere to 1.1 Knowledge and beliefs about TB treatment 11
TB treatment
1.1.1 General beliefs and perceptions of TB 
disease
9
1.1.2 Belief that TB is curable 11
1.1.3 Belief that the doctor's instructions need 
to be followed to get cured
9
1.2 Motivation to get cured 10
1.2.1 Long history of suffering 5
1.2.2 Responsibility towards family / financial 
need to start working again
5
2.Perceived facilitators of 2.1 Social support 11
and barriers to adherence
to TB treatment 2.1.1 Financial support a
2.1.2 Emotional support 4
2.1.3 Social support as a reminder to take the 
medication
a
2.2 Cues: reminders to take the medication 6
2.3 Healthcare service factors 6
2.4 Socioeconomic factors 7
2.5 Substance abuse factors 11
a Theme/subtheme identified in the accounts of n (out of 11) participants. TB = tuberculosis.
con fidence  in b iom ed ica l healthcare, i.e. b iom ed ic ine  as opposed  to trad itiona l 
m ed ic ine  such as w itch c ra ft and herba l m ed ic ine  tha t are w ide ly  ava ilab le  in 
Tanzania,21 recurred w ith in  all sub them es. Five pa rtic ip an ts  con trasted 
b iom ed ic ine  d ire c tly  to  trad ition a l m ed icine. The o thers referred to the ir re liance 
on b iom ed ic ine  in a m ore sub tle  way, fo r exam ple by s ta ting  tha t: “The disease 
has com e to my body and the doctors in the hospita l have identified w hat it is. So I 
have to take the m ed ica tion .” (59-year-o ld  wom an)
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#W ith regard to the firs t subthem e, genera l be lie fs  and pe rcep tions  of TB disease, 
the  pa rtic ip an ts ' re liance on b iom ed ic ine  de term ined the ir hea lthcare  seeking 
behav iou r (F igure 1, a rrow  2). A 56 -yea r-o ld  man from  a rural area sta ted that 
un like him self, m any o lde r peop le  from  rural areas tend to s tay away from  
hosp ita ls  and use trad ition a l m ed ic ine  instead:
We have those  elders, to  date they s till have the ir m ed ica tion . They w o n 't go 
to the hosp ita l. Those people, even if they have a headache, they w ill ju s t go 
to the fie ld  and p ick  the ir m ed ica tion . Th is d isease [TB], esp ec ia lly  in th is  
rural area, is sa id  to be a d isease of long tim e [a ch ron ic  d isease], so people 
d o n 't bo ther to  go to the hosp ita l to check. They jus t take the trad itiona l 
m edicine. People in the village, they say th is  is a trad ition a l d isease, it never 
cures, it never ends. For myself, I w ent to the hosp ita l because I have been 
out of the v illage, in towns, I have been to the hosp ita l, I understand .
In the pe rcep tion  of others, trad ition a l m ed ic ine  and b iom ed ic ine  do not 
au tom atica lly  exclude one another. A 22-year-old fem ale com m unity-w orker said: 
“ I th in k  one m onth before com ing here [the hospita l], I was tak ing  one trad itional 
m edicine, Maasai m edicine. They said tha t th is  m ed icine cures TB, it cures every 
kind of che s t.”
O ther be lie fs  abou t TB also in fluenced  the pa rtic ip an ts ' hea lthcare  seeking 
behaviour. Som e pa rtic ip an ts  be lieved tha t all pa tien ts  w ith  TB have b lood -s ta ined  
spu tum . A 56 -yea r-o ld  man de layed to go to the hosp ita l to be d iagnosed  because 
his spu tum  w as not b loo d -s ta in ed  and he did  the re fo re  not th in k  he cou ld  have 
TB. A 22 -year-o ld  H IV-negative w om an be lieved tha t peop le  w ith  TB are always 
co -in fec ted  w ith  HIV. Because she feared to be d iagnosed  w ith  HIV, she delayed 
to seek hea lthcare  fo r several m onths:
First of all, I w as to ld  tha t the person w ho is having TB, m ust a lso have HIV/ 
AIDS. That was my pressure  [that m ade me fee l anxious]. One day I w ent to 
the hosp ita l. They checked me the X-ray and to ld  me tha t they  had to take a 
sam ple  of my spu tum . But I w as scared! I to ld  the doctor, jus t give me the 
m ed ic ine  tha t can make my chest okay, but d o n 't tes t tha t th ing . M ost of the 
tim e, I w as so concen tra ted  in my brain, I w as to ld  tha t if you have th is  th ing,
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Figure 1 A th e o re tic a l m ode l of trea tm e n t adhe rence  behav iou r
a nt
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you m ust a lso have som e th ing  like th is. That made me s ick  even more! But 
the day I dec ided  to go, I said, I'd be tte r go and che ck  everyth ing.
The be lie fs  of pa tien ts  and com m un itie s  abou t TB a lso resu lted in feared or 
perce ived s tigm a tiza tion . C om m un ity  be lie fs from  w h ich  TB s tigm a orig ina ted 
inc luded  the be lie f tha t all pa tien ts  w ith  TB a lso have HIV, the be lie f tha t pa tien ts 
w ith  TB are h igh ly  in fec tious  and shou ld  be iso lated, and the be lie f tha t TB is a
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“ b a d ” (trad itiona l) disease. Feared or perce ived s tigm a  d iscou raged  pa tien ts  to 
share the ir experience w ith  others.
A ll pa rtic ip an ts  be lieved tha t TB is curable, the second sub them e of the them e 
know ledge  and be lie fs  abou t TB treatm ent. P artic ipan ts  reported  on several 
sou rces  of in fo rm ation  tha t he lped them  to  be lieve tha t TB is curable. Som e 
pa rtic ip an ts  had read abou t TB trea tm ent on health educa tion  posters in 
hea lthcare  fac ilities . M ost pa rtic ip an ts  be lieved tha t TB is cu rab le  because they 
had heard from  o thers  w ho were cured a fte r us ing the m ed ica tion  as prescribed. 
In add ition , the pa rtic ip an ts  had experienced a subs tan tia l im provem ent in the ir 
health a fte r they had sta rted  TB trea tm ent and th is  s treng thened the ir be lie f tha t 
TB is cu rab le  (F igure 1, a rrow  6). W hereas our pa rtic ip an ts  un de rs tood  tha t they 
had to con tinue  trea tm ent desp ite  tha t they fe lt better, they a ttribu ted  
non-adherence  by o thers to a lack  of know ledge  abou t the necess ity  of con tinu ing  
trea tm ent: “ For those  peop le  w ho fee l im proved like me, they m ay s top  the 
m ed ica tion  because they d o n 't know .” (36-year-o ld  wom an)
The be lie f tha t to get cured the do c to r's  in s tru c tion s  shou ld  be fo llow ed  (the th ird  
subthem e of the them e know ledge and beliefs about TB treatm ent) was expressed 
by all pa rtic ipan ts . In s im p lified  term s, m ost pa rtic ip an ts  reasoned tha t (1) they 
were s ick, so (2) they had to get cured, and thus (3) they had to fo llow  the ir 
d o c to r's  ins tructions. The be lie f w as in fluenced  by exam ples from  others  who 
d id  not adhere to trea tm ent and had an un favourab le  trea tm ent outcom e. 
A 25-year-o ld  male referred to the exam ple of his brother:
I rem em ber my own brother, w ho w as w o rk ing  in the bush, he go t TB and he 
s tayed in the hosp ita l fo r a lm ost 2 years and the rea fte r he w as d ischarged . 
But he was not fo llow ing  the in s tru c tion s  [of the doc to r]. He was d rink ing  and 
som etim es sm oking , so the TB, again he go t it. So w hen he was returned to 
the hospita l, it w as in vain, he died. So I de c ided  to take it s tro n g ly  because I 
w as rem em bering my bro ther and I d id  not w ant the sam e to happen to me.
The pa rtic ip an ts  m entioned several in s tru c tion s  tha t they had rece ived and that 
they were fo llow ing  stric tly , inc lud ing  the necess ity  of con tinu ing  trea tm ent fo r 6
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m onths even tho ugh  c lin ica l im provem ent had a lready occu rred . They also 
referred to in s tru c tion s  tha t they  m ight have taken m ore lite ra lly  than m eant by 
the hea lthcare  provider, such as no a lcoh o l consum p tion , sm oking , heavy w o rk  
and sexual in te rcou rse du ring  TB treatm ent. A cco rd in g  to the  pa rtic ipan ts , m ost 
TB pa tien ts w ho fa il to adhere to the prescribed  trea tm ent, e ither do not know  or 
canno t com p ly  w ith  these instructions.
Theme 2. Motivation to get cured
To the question  w hy the pa rtic ip an ts  were m anag ing so well to take the ir 
m ed ica tion  every day, m any pa rtic ip an ts  responded tha t they w anted to  get 
cured (F igure 1, a rrow  3). The sub them es tha t were found  to underlie  th is 
m otiva tion  to get cured were a long h is to ry  of su ffe ring , resp on s ib ility  tow ards 
the fam ily  and the financ ia l need to s ta rt w o rk ing  again. A 28-year-o ld  wom an 
had a ttended several hea lthcare  fac ilit ie s  before it w as d iscove red  tha t her 
backache was caused by sp ina l TB. She sta ted: “ For sure, the pain tha t I had, the 
way it has been relieved, I need to con tinue  tak ing  the m ed ica tion .” O ther 
pa rtic ip an ts  fe lt a s trong  re sp on s ib ility  tow a rds  the ir fam ily  w h ich  m otiva ted them  
to get cured, as is illustra ted  by the fo llow ing  quo ta tion  of a 56-year-o ld  man:
There is one th ing  w h ich  is push ing me so m uch: my kids. Because the firs t 
ch ild ren, when I w as not having th is  d isease, I w as ab le to educa te  them  and 
th a t's  w hy they are now in un iversity. But the second range of ch ild ren, now I 
am sick, I canno t get the m oney w h ich  I used to get from  my job. Because I 
canno t do tha t jo b  due to my health. So there  is a push ing to me tha t I need 
to go back to tha t job. But how can I go? I need to ensure tha t I take my 
m ed ica tion  so tha t I can get to work.
Category 2. Perceived facilitators of and barriers to adherence to 
TB treatment
Several fac to rs  were m entioned tha t cou ld  fac ilita te  o r ham per adherence to TB 
treatm ent. The pa rtic ip an ts  perce ived the presence of sup po rt from  fam ily  
m em bers o r frie n d s  (herea fter referred to as soc ia l support), the use of rem inder 
cues and the presence of he lp fu l hea lthcare  s ta ff as fac ilita to rs  of adherence. 
S oc ioe cono m ic  d ifficu ltie s  and subs tance  abuse fac to rs  were regarded as the
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an op po s ite  e ffec t on adherence (e.g. the absence of soc ia l su p p o rt was regarded 
as a ba rrie r to adherence  by som e pa rtic ipan ts), the fa c ilita to rs  of and barrie rs to 
adherence  are g rouped  tog e the r in F igure 1 (arrow 4).
Theme 1. Social support
The presence of soc ia l s u p p o rt w as a recurren t them e in all in terviews. Partic ipants 
pe rce ived tha t soc ia l s u p p o rt is: (1) a m eans of financ ia l o r m ateria l assistance; 
(2) a m eans of em otiona l sup po rt; or (3) a m eans to rem ind them  to take the 
m ed ica tion . A 65 -yea r-o ld  man referred to m ateria l ass is tance  w hen he was 
asked how church m em bers he lped him to adhere to trea tm ent: “ It is on ly  one 
day, they  b rough t me a k ilog ram  of sugar.” A 33-year-o ld  male pa rtic ipan t 
co -in fec ted  w ith  HIV rece ived em otiona l sup po rt from  his relatives: “ So they help 
me in g iv ing  ideas tha t d o n 't fee l lonely, d o n 't fee l tha t you are the on ly  one 
because you are in fected. Just fee l like o ther pe op le .” The 56 -yea r-o ld  man who 
w as m otiva ted to get cured because of his re sp on s ib ility  tow ard  his ch ildren, was 
rem inded to take the m ed ica tion  by the ch ild ren: “ So they ac tu a lly  te ll me that, if 
I am tak in g  my m ed ica tion  at 8 am, they  com e and te ll me: ‘Dad, have you taken 
you r m ed ica tion? ' So they he lp me w ith  the tim e .”
A pa rt from  be ing a fa c ilita to r of adherence, soc ia l su p p o rt a lso served as an 
in itia to r of pe rce ived soc ia l pressure: the  expec ta tions  of the pa rtic ip an ts ' fam ily  
m em bers w ith  regard to adherence were im p o rtan t m otiva to rs  fo r som e 
pa rtic ip an ts  to adhere to trea tm ent. A 71-year-old man expressed th is  s trik ing ly : 
“ I need to make sure tha t I take the m ed ica tion  p rope rly  because if I w on 't 
con tinue  well, my fam ily  w ill see me as a m ean ing less pe rson .” Thus, socia l 
s u p p o rt d id  not on ly  fac ilita te  adherence by being a m eans of financ ia l, em otional, 
or practical help, it also influenced the partic ipants ' intention to adhere (Figure 1, 
a rrow  5).
A lm ost all pa rtic ip an ts  had in fo rm ed the ir c lose re la tives abou t the d isease and 
soc ia l s u p p o rt w as p rim arily  received from  fam ily  m em bers. Feared or perceived 
s tigm a w ith he ld  m ost pa tien ts  to in fo rm  frien ds  or co lleagues. A 35 -year-o ld  
w om an from  a rural area fo r exam ple, s ta ted : “ People are jus t po in ting  fingers.
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is now sick, is tak in g  the m ed ica tion .' They canno t he lp me anyth ing . Instead, 
they w ill po in t fing e rs  a long the road.”
Whereas two participants received social support from peer patients, others stated 
that TB patients are reluctant to share their experience w ith other patients. A 65-year-old 
man said: “You know, when we sit here, everyone with the bottle [medication container] 
just hides so that nobody can see and know that he is using.”
Theme 2. Reminder cues
The pa rtic ip an ts  m entioned several cues tha t he lped them  to rem em ber to take 
the ir m ed ica tion . Som e pa rtic ip an ts  used the a larm  of a m ob ile  phone to inform  
them  when the tim e to take the m ed ica tion  had reached. O thers p laced the ir 
m ed ica tion  bo ttle  som ew here w here  it is c learly  v is ib le , to rem ind them selves. In 
add ition , m ost pa rtic ip an ts  care fu lly  se lected  an ap p ro p ria te  tim e fo r m ed ica tion  
intake. A 25-year-o ld  man from  an urban area described:
I decided only in the m orning, because in the evening there is a lot. I m ight work 
there in the evening, figh ting w ith friends. So I m ight find myself com ing home 
and just set to sleep, so I w on 't take my m edication, or com e back from  work, 
tired, I forget to take my m edication. That's why I said, it is on ly in the morning. 
Because I wake up, I brush my teeth, take my m edication and go to work.
Theme 3. Healthcare service factors
Several issues cam e up w ith  regard to hea lthcare  serv ice  fac to rs  tha t were 
perce ived to  a ffec t trea tm ent adherence. The pa rtic ip an ts  agreed on the 
im portance  of be ing in fo rm ed adequate ly. A 28-year-o ld  w om an exp la ined how 
she knew tha t she had to com p le te  treatm ent:
From the sem ina r tha t I go t from  the doctor, he to ld  me, th is  d isease is not 
fin ished , so if you d o n 't fin ish  the m ed ica tion , it w ill com e back. So tha t is 
enough fo r me to see tha t I have to continue.
A part from  health educa tion , hea lthcare  s ta ff cou ld  fac ilita te  the pa tien ts ' 
adhe rence to trea tm ent by p rov id ing  rem inder cues, by ensuring  superv is ion  of
56 | Chapter 3
Part I -  Exploring the problem of non-adherence to TB treatment
#
#m ed ica tion  intake, and by p rov id ing  pa tien ts  w ith  financ ia l or m ateria l assistance, 
a cco rd ing  to the pa rtic ipan ts . The a ttitude  of hea lthcare  s ta ff tow a rds  patien ts 
w as a lso d iscussed. None of the pa rtic ip an ts  com p la ined  abou t th e ir own 
experience w ith  hea lthcare  s ta ff at the  c lin ics  they a ttended . G enerally, they 
s ta ted  tha t hea lthcare  p rov iders  shou ld  be po lite  and supportive .
Theme 4. Socioeconomic factors
The soc io e co n o m ic  cha llenges  tha t m ost pa rtic ip an ts  faced  were perce ived as a 
ba rrie r to fo llow ing  the in s tru c tion s  tha t they had received and that, they believed, 
had to be com p lied  w ith  s tric tly . For exam ple, pa rtic ip an ts  were to ld  not to take 
the  m ed ica tion  on an em p ty  s tom ach (doc to r's  ins truc tion ) and m ost pa rtic ipan ts  
experienced  tha t the  m ed ica tion  increased the ir ap pe tite  (e ffect of treatm ent; 
F igure 1, a rrow s 6 and 7). Som e had to s trugg le  to get enough foo d  and th is 
s trugg le  was aggravated by the ins truc tion  not to do a heavy jo b  du ring  TB 
treatm ent. A 25 -year-o ld  man, a porter, said:
W ith my job, I have a friend  w hom  I used to ca rry  his luggage. So w hen I got 
th is, he sa id  to me: “ I give you the a fte rnoon  food, but fo r the evening, you 
ju s t find  you rse lf.” So a fte r th is, because I w as p rov ided w ith  the a fte rnoon 
meal, I dec ided  to take the ligh t work. That one I can do tw o  or three jo b s  a 
day. I get 2500 o r 3000 sh illing s  and then I ju s t stop, because I w ill use the 
money. So I d id  tha t fo r a lm ost 2 m onths. But in the mean tim e, my health was 
im proving. So I decided, I can a lso increase the w ork load , but not tha t much 
because of the [doc to r's ] ins tructions.
O ther pa rtic ip an ts  reported  on the d iff ic u lty  of paying fo r the tra n sp o rt fee of 
trave lling  to the c lin ic  to co llec t the ir m ed ica tion  every 1 o r 2 weeks. A lthough  the 
soc io e co n o m ic  d ifficu ltie s  were pe rce ived as ba rrie rs  to adherence , these 
d ifficu ltie s  d id  not ac tua lly  lead to non-adherence  in our pa rtic ipan ts . It seem ed 
tha t the p a rtic ip an ts ' s trong  in ten tion  to adhere he lped them  to cope w ith  the 
pe rce ived soc io e co n o m ic  cha llenges. A 35-year-o ld  w om an w ho ind ica ted  that 
she cou ld  hard ly  find  enough m oney to pay the bus fee to the c lin ic , answ ered to 
the  question  how she neverthe less m anaged to com e every week: “ I have no 
cho ice . I have to com e, because I am s ick  and I w ant to  get be tte r.”
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Theme 5. Substance abuse factors
All pa rtic ip an ts  suggested  tha t a lcoho l abuse is the m ost im portan t barrie r to 
adherence to TB trea tm ent by others; e ither because these o thers know  tha t 
a lcoh o l and TB trea tm ent canno t be taken tog e the r (at least, tha t is w hat patien ts 
are to ld  in the c lin ic) and they fa il to s top  us ing a lcoho l, or because a lcoho l 
abuse m akes them  care less abou t th e ir health. O ther subs tance  abuse fac to rs  
tha t were m entioned by pa rtic ip an ts  as poss ib le  ba rrie rs  to trea tm ent adherence 
inc luded  sm ok ing  and drug abuse, fo r s im ila r reasons as a lcoh o l abuse.
Effects of TB treatment
As described  in the p resen ta tion  of the tw o  ca tegories  of them es, the e ffec ts  of 
m ed ica tion  intake in fluenced  the p a rtic ip an ts ' in tention  to adhere  and the 
perce ived barrie rs to adherence. For exam ple, the cura tive e ffec t of trea tm ent 
s treng thened the p a rtic ip an ts ' be lie f tha t TB is cu rab le  (F igure 1, a rrow  6), and 
adverse e ffec ts  of trea tm en t (such as fee ling  hungry) aggravated the perceived 
so c ioe cono m ic  d ifficu ltie s  tha t pa rtic ip an ts  had to cope w ith  (F igure 1, a rrow  7).
Discussion
In th is  study, we exp lo red pa tien t pe rcep tions  of adherence  to TB trea tm ent and 
con s tru c ted  a p re lim ina ry  theo re tica l m odel of trea tm ent adherence  behaviour 
based on con ten t ana lys is  of the pa tien ts ' accoun ts . The s tud y  pa rtic ip an ts  w ho 
were w e ll-adheren t to TB treatm ent, revealed tha t the in tention  to adhere is the 
m ost im portan t de te rm inan t of adherence behaviour. This in ten tion  is p receded 
by the dec is ion  to seek b iom ed ica l hea lthcare  (as opposed  to trad itiona l 
healthcare) and shaped by know ledge  and be lie fs  abou t TB trea tm en t and the 
m otiva tion  to get cured. The in tention  to adhere helps pa rtic ip an ts  to cope w ith  
the pe rce ived barrie rs to  adherence  and to create an adherence enab ling 
env ironm en t in w h ich  the presence of soc ia l s u p p o rt plays an im portan t role. 
Social suppo rt is perceived as a d irect fac ilita to r of adherence to TB treatm ent by 
being a m eans of em otional and financ ia l help and by rem inding patien ts to take 
the ir m ed ica tion . In add ition , soc ia l s u p p o rt s treng thens  the pa tien ts ' in ten tion  to 
adhere by con tribu ting  to pe rce ived soc ia l pressure.
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Our find ing that the patient's intention to adhere is a m ajor determ inant of adherence 
behaviour is in agreem ent w ith  tw o com m only  c ited cogn itive  health behaviour 
theories: the theo ry  of reasoned action (TRA)22 and the theo ry  of planned behaviour 
(TPB).23 A ccord ing to the TRA, the intention to behave in a certain way is determ ined 
by two independent variables that are also reflected in our study find ings: attitudes 
tow ards the behaviour and sub jective  norm s (i.e. perceived socia l pressure).22 In 
agreem ent w ith the TRA, we found that know ledge and beliefs abou t TB treatm ent 
(attitudes toward the behaviour) underlie the patien t's in tention to adhere and that 
socia l sup po rt induces perceived socia l pressure tow ards trea tm ent adherence 
(F igure 1, arrows 1 and 5, respectively). In the TPB, perceived behavioural contro l 
(i.e. se lf-e fficacy) is included as a th ird  variab le tha t de term ines behavioural 
in ten tion .23 C ontrary to this, we found that the in tention to adhere can help patients 
to overcom e the perceived barriers of adherence to TB treatm ent. However, not all 
barriers to adherence are under vo litiona l con tro l and therefore, it w ou ld  be too 
s im p le to conc lude  that all pa tien ts w ho do not m anage to overcom e the barriers 
to adherence lack the in tention to adhere to treatm ent. Nevertheless, our find ings 
suggest tha t when counse lling  non-adheren t patients, an assessm ent of the 
pa tien t's  in tention to adhere is a cruc ia l firs t step.
One of the lim ita tions  of the TRA, TPB and o the r health behav iou r theo ries  is that 
little  a tten tion  is pa id to the role of so c iocu ltu ra l fa c to rs .824 We found  tha t the 
know ledge  and be lie fs  abou t TB trea tm ent of Tanzanian pa tien ts  are co lou red  by 
b iom ed ica l and trad ition a l health be lie fs, and tha t con fide nce  in b iom ed ic ine  is 
an im p o rtan t firs t step tow a rds  the in tention  to adhere to trea tm ent. A cco rd in g  to 
our pa rtic ipan ts , m any TB pa tien ts  in rural se ttin gs  use trad ition a l m ed ic ines 
aga inst TB and refuse to seek b iom ed ica l healthcare. This cou ld  be regarded as 
a fo rm  of ‘p rim ary  non-adherence ', i.e. fa ilu re  (refusal) to take any m ed ica tion  at 
a ll,25 and ind ica tes tha t we m ust expand our eva luation of the p rocesses that 
resu lt in non-adherence  to the period  before pa tien ts  s ta rt v is iting  the healthcare 
facility .
The d is tinc t con fide nce  of our pa rtic ip an ts  in b iom ed ic ine , the ir be lie f tha t the 
do c to r's  in s tru c tion s  need to be fo llow ed, and the ir s trong  m otiva tion  to get 
cured re flec t e lem ents of P arsons's s ick  role m ode l.26 A cco rd in g  to the s ick  role
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m odel, pa tien ts are expected to w ant to get cured as soon as poss ib le  (i.e. return 
to the healthy, non-dev ian t sta te  again) and to com p ly  w ith  the ir do c to r's  advice. 
In return, they  are tem po ra rily  exem pted from  the ir norm al ac tiv ities  and have the 
right to rece ive adequate  hea lthca re .26 The p a rtic ip an ts ' m otiva tion  to get cured 
cou ld  be in te rpre ted as a desire  to return to the healthy state and to be ab le to 
perfo rm  norm al soc ia l roles again. P atients w ho s top  to adhere w hen they have 
sta rted  to fee l better, m ight perce ive tha t they have a lready re turned to the 
norm al, healthy state again. At th is  po int, the necess ity  to con tinue  tak ing  the 
m ed ica tion  cou ld  be pe rce ived as m ore d is rup ting  to one 's id en tity  than the 
illness itself, and cogn itive  fac to rs  such as know ledge  abou t the necess ity  of 
com p le ting  the fu ll trea tm ent course becom e pa rticu la rly  essentia l at th is  stage. 
It seem ed tha t our pa rtic ip an ts  had m isperce ived  or taken too  lite ra lly  som e of 
the in s tru c tion s  tha t they had rece ived from  hea lthcare  w orkers. Som e of the 
m isperce ived  in s tru c tion s  such as the p ro h ib itio n  to w o rk  hard o r have sexual 
in te rcou rse du ring  TB treatm ent, were ac tua lly  perce ived as barrie rs to adherence 
by the pa rtic ipan ts . A lthough  our pa rtic ip an ts  m anaged to cope  w ith  these 
perce ived barriers, o thers may not. It is the re fo re  im portan t tha t healthcare 
workers evaluate carefu lly how patients interpret the instructions that they have 
received w ith  respect to TB treatm ent.
A no ther so c iocu ltu ra l aspec t of adherence tha t w as raised by our pa rtic ip an ts  
was the role of s tigm a, in pa rticu la r s tigm a  re lated to the assoc ia tion  of TB w ith  
HIV. In Tanzania, 37% of TB pa tien ts  are co -in fec ted  w ith  HIV,1 w hereas the 
estim ated H IV -prevalence in the genera l adu lt popu la tion  is 5 .7% .27 Negative 
a ttitud es  tow a rds  peop le  liv ing w ith  HIV/AIDS are w ide ly  p resen t28 and can be 
p ro jected  on TB pa tien ts  as w e ll.29 O ther s tud ies  have ind ica ted  tha t the fear of 
s tigm a can even d iscou rage  TB pa tien ts  to seek hea lthcare  at a ll.30-32 Because of 
feared or perceived stigm a, m ost of our partic ipants were reluctant to ta lk  about 
the ir d isease w ith  com m u n ity -m em b ers  or peer patients. S u rp ris in g ly  though, 
they all knew  exam ple s to ries  of o ther TB pa tien ts  and had ga thered a large 
part of th e ir know ledge  abou t TB trea tm ent from  these stories. C ons idering  that 
in fo rm a tion -sha ring  between pa tien ts  and com m un ities  w ill im prove com m un ity  
know ledge  abou t TB treatm ent, reducing TB s tigm a  cou ld  eventua lly  have a 
subs tan tia l im pact on trea tm ent adherence.
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We in te rv iew ed a se lective  g roup  of eleven pa tien ts  on com m un ity -based  DOT 
only. We did  not in te rv iew  non-adheren t pa tien ts  (that is, pa tien ts  w ith  less than 
80% intake of p rescribed  doses) because we did  not encoun te r such levels of 
non-adherence  in the pool of pa tien ts  from  w h ich  our pa rtic ip an ts  were selected. 
Moreover, we in te rv iew ed pa tien ts  in a re la tive ly  early  phase of trea tm ent. Thus, 
the  m odel of trea tm ent adherence behav iou r tha t we present in th is  a rtic le , is 
based on the acco un ts  of a se lec tive  pa tien t popu la tion  only. It shou ld  be viewed 
as a p re lim ina ry  adherence  behav iou r m odel tha t w arran ts  fu rth e r s tud ies  to 
va lida te  the unde rly ing  theories, to con firm  its a p p lic a b ility  to o ther patien t 
po pu la tio ns  inc lud ing  non-adheren t patients, and to eva luate its re levance to the 
design of e ffec tive  adherence p rom oting  in te rven tions. N everthe less, we th ink  
tha t our fin d in g s  provide som e po tentia l avenues fo r s tra teg ies  tha t cou ld  help 
pa tien ts  to adhere to  TB trea tm ent.
Conclusions and avenues for adherence promoting strategies
The main find in g  in th is  s tud y  is tha t the pa tien t's  in tention to adhere to TB 
trea tm ent p lays a m ajor role in the estab lishm en t of adherence behaviour. This 
in ten tion  cou ld  be s treng thened by im proving  com m u n ity  know ledge  abou t TB 
treatm ent. S ocia l sup po rt is perce ived as a d irec t fa c ilita to r of adherence and in 
add ition , soc ia l su p p o rt s treng thens  the pa tien t's  in ten tion  to  adhere  by induc ing 
pe rce ived soc ia l pressure. Thus, invo lv ing  a c lose relative or spouse in the 
trea tm ent of TB pa tien ts  and m aking th is  person co -re spo ns ib le  fo r  adherence  to 
trea tm ent such as done in com m u n ity -b ased  DOT program m es, cou ld  have a 
positive  im pact on trea tm en t adherence. Finally, the in tention  to adhere seem s to 
he lp pa tien ts to cope w ith  the pe rce ived ba rrie rs  to adherence to TB treatm ent. 
Th is find in g  im p lies  tha t in te rven tions such as the prov is ion  of m oneta ry  or food 
incen tives cou ld  encourage  pa tien ts  w ho have the in tention  to adhere, but are 
un like ly  to make a d iffe rence  in pa tien ts  w ho lack th is  in tention.
By exp lo ring  pa tien t pe rcep tions  of adherence to TB trea tm en t and deve lop ing  a 
p re lim ina ry  the o re tica l m odel of adherence  behaviour, we have con tribu te d  to a 
genera l un de rs tand ing  of how adherence behav iou r is es tab lished . Further 
s tud ies  in larger, non-adheren t pa tien t po pu la tio ns  shou ld  con firm  the v a lid ity  of 
the  adherence behav iou r m odel tha t we presen ted in th is  artic le.
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#Abstract
O b je c tiv e : To assess adherence  to com m u n ity -b ased  D irectly  O bserved 
Treatm ent (DOT) am ong Tanzanian tub e rcu lo s is  pa tien ts  us ing the M ed ica tion  
Event M on ito ring  System  (MEMS) and to va lida te  a lte rna tive  adherence  m easures 
fo r resou rce -lim ited  se ttin gs  using MEMS as a go ld  standard .
M e th o d s : This was a lo ng itud ina l p ilo t s tudy  of 50 pa tien ts recru ited  consecu tive ly  
from  one rural hosp ita l, one urban hosp ita l and tw o urban health centres. 
Treatm ent adherence  was m on ito red  w ith  MEMS and the v a lid ity  of the fo llow ing  
adherence m easures was assessed: ison iaz id  urine test, urine co lou r test, 
M orisky  scale, Brief M ed ica tion  Q uestionna ire  (BMQ), adap ted AIDS C lin ica l 
Trials G roup (ACTG) adherence  questionna ire , pill coun ts  and m ed ica tion  refill 
v isits.
F in d in g s : The mean adherence  rate in the s tud y  popu la tion  w as 96.3%  (standard 
devia tion, SD: 7.7). Seventy percen t of pa tien ts were less than 100% adherent, 
21% less than 95% and 2% less than 80%. The ACTG adherence  questionna ire  
and urine co lou r test had the h ighest sen s itiv itie s  but lowest spe c ific itie s . The 
M orisky  sca le  and refill v is its  had the h ighest spe c ific itie s  but lowest sensitiv ities. 
The com b ina tion  used in routine p ractice  (pill coun ts  and refill v is its) y ie lded 
m oderate se n s itiv ity  and spec ific ity , but its se n s itiv ity  im proved w hen the ACTG 
adherence ques tionna ire  was added.
C o n c lu s io n : P atients on com m un ity -based  DOT show ed good  adherence  in th is  
study. The com b ina tion  of pill counts, refill v is its  and ACTG adherence 
questionna ire  cou ld  be used to m on ito r adherence  in se ttin gs  w here MEMS is 
not a ffo rdab le . The fin d in g s  w ith  regard to adherence and the va lid ity  of s im ple 
adherence m easures shou ld  be con firm ed in la rger po pu la tio ns  w ith  w ide r 
va ria b ility  in adherence rates.
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#Introduction
N on-adherence  to tub e rcu lo s is  (TB) trea tm ent is a m ajor barrie r to g loba l TB 
con tro l. To ensure adherence to trea tm en t by TB patien ts, the d irec t observa tion  
of trea tm ent (DOT) by a tra ined  sup e rv iso r is recom m ended .1 Initia lly, DOT was 
p rov ided  in hea lthcare  fac ilit ie s  only, but because of the high w o rk load  involved, 
several coun tries  have s ta rted  to involve com m u n ity  m em bers in the prov is ion  of 
DOT.2 S tud ies  have show n tha t com m un ity -based  DOT is a cos t-e ffec tive  s tra tegy 
tha t y ie lds  trea tm en t ou tcom es s im ila r to those  ob ta ined  w ith  fac ility -based  
DOT.3-6 However, com m un ity -based  DOT has been critic ized  fo r be ing beyond 
the con tro l of healthcare p rov iders  and hence conduc ive  to se lf-adm in is te red  
trea tm ent and non -adhe rence .67
The actua l degree of adherence  by pa tien ts  on com m un ity -based  DOT has not 
ye t been assessed. M easuring adherence  is d iff ic u lt because m ost ava ilable 
d irec t and ind irec t m easures have lim ita tions. D irect adherence m easures, such 
as tes ts  tha t de tect d rugs in p lasm a or urine, cover b rie f m ed ica tion  intake 
pe riods  only. Ind irect m easures, such as pill coun ts  and se lf-re po rt questionna ires, 
cover longer pe riods but assum e rather than prove the pa tien t's  actua l m ed ica tion  
in take .8
A sop h is tica ted  ind irec t adherence  m easure is the M ed ica tion  Event M on ito ring  
System  (MEMS). MEMS m ed ica tion  bo ttles  con ta in  a m ic ro e le c tro n ic  ch ip  that 
reg is te rs  date and tim e of every bo ttle  open ing . Assum ing  tha t bo ttle  open ings 
represent m ed ica tion  intake, MEMS prov ides a de ta iled  pro file  of the pa tien t's  
adherence  behaviour. MEMS is cu rre n tly  regarded as the go ld  s tandard  to 
m easure adhe rence .8 It has been used as such in a w ide  range of s tud ies  on 
adherence  to an tihypertens ive  and lip id -lo w ering  the ra py ,910 the ra py  for 
ne u ro log ic  and psych ia tric  d iso rd e rs ,11,12 po s t-transp lan ta tion  im m u nosu pp res­
sive the rapy,1314 and an tire trov ira l the rapy.15-17 Few s tud ies  report on the use of 
MEMS to m on ito r adherence  to TB trea tm en t.18-21 Because of the high cost 
involved, MEMS is not feas ib le  fo r use in rou tine  prac tice  in m ost se ttin gs  w ith  a 
high TB burden but cou ld  be used as a re ference s tandard  to va lida te  s im p le  and 
a ffo rd ab le  m easures tha t can be used in pa tien ts on com m un ity -based  DOT.821
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#In th is  p ilo t study, we used MEMS to: (1) describe  adherence rates am ong 
Tanzanian TB pa tien ts  on com m un ity -based  DOT, and (2) de term ine the va lid ity  
of several d irec t and ind irect adherence m easures of po ten tia l use in resource- 
lim ited settings.
Methods
Study setting
The study was conducted in Tanzania's Kilim anjaro Region, where the annual TB 
case notification rate is 178 per 100,000 popu lation.6 The national TB program m e 
em powers patients to choose between com m unity- and facility-based DOT. The 
m ajority of patients opt fo r com m unity-based DOT and those on facility-based DOT 
are m ostly inpatients.6 Patients on com m unity-based DOT have to select a treatm ent 
supporte r from  the ir com m unity  (usually a relative or spouse) who is instructed on 
how to provide da ily DOT in the home setting. Patients on com m unity-based DOT 
are supposed to co llect the ir m edication once a week in the first 2 m onths of 
treatm ent and once every 2 weeks in the rem aining 4 months. They should return 
m edication blisters fo r pill counts and the ir clin ic attendance is reg istered.22
Study design and procedures
This was a long itud ina l p ilo t s tudy  in w h ich  trea tm en t adherence  of 50 patien ts 
on com m un ity -based  DOT w as m on ito red  by MEMS th rou gh ou t trea tm ent. MEMS 
was used as a go ld  s tandard  to va lida te  several o ther adherence m easures 
(single and in com b ina tions) in th is  pa tien t g roup. The adherence  m easures were 
se lected fo r the ir a p p lic a b ility  in the Tanzanian se tting  and inc luded  an isoniazid  
(INH) urine test, a urine co lou r tes t fo r rifam p ic in , the Brief M ed ica tion  
Q uestionna ire  (BMQ), the M orisky scale, an adap ted  vers ion of the AIDS C lin ical 
Trials G roup (ACTG) adherence questionna ire , pill coun ts  and c lin ic  a ttendance 
fo r m ed ica tion  refills.
The pa rtic ip an ts  were recru ited  betw een February and May 2010 from  one rural 
hospita l, one urban hosp ita l and tw o  urban health centres. C ons ide ring  the pilo t 
nature of our study, we chose to enrol 50 pa tien ts  only. A du lt ou tpa tien ts  who 
con secu tive ly  presen ted at one of the s tudy  s ites w ith  new ly d iagnosed  TB and
70 | Chapter 4
Part II -  M easuring adherence
#
#MEMS to validate adherence measures | 71
w ho had chosen com m un ity -based  DOT were e lig ib le  to pa rtic ipa te . E lig ib le  
pa tien ts  were in fo rm ed abou t the s tud y  p rocedures  by tra ined  c lin ic  s ta ff and 
asked to s ign an in fo rm ed consen t form . They were to ld  tha t th e ir TB m ed ica tion  
w ou ld  be p rov ided  in a m ed ica tion  bo ttle  w ith  a m ic ro e le c tro n ic  ch ip  tha t reg is ters 
every bo ttle  open ing . They were asked not to use the MEMS bo ttle  fo r o ther 
m ed ica tion , to open it on ly  to  take out m ed ica tion , and to bring the bo ttle  to 
every m ed ica tion  refill v is it. Patients were in fo rm ed tha t they w ou ld  be under 
rou tine  trea tm en t and care.
Drug d ispens ing  nurses were respons ib le  fo r  p rov id ing  pa tien ts  w ith  m edica tion. 
M ed ica tion  refill v is its  were con du c te d  in acco rda nce  w ith  rou tine  practice, 
except tha t the m ed ica tion  b lis te rs  were cut into p ieces to make them  fit in the 
MEMS bottle . The nurses reg istered the dates of the pa tien ts ' c lin ic  v is its  for 
m ed ica tion  refills  and the num ber of tab le ts  rem a in ing  at each vis it. During the 
v is its  in w eeks 4, 8, 12 and 16, the p rocedures  devia ted from  routine practice. At 
these vis its, pa tien ts  sub m itte d  a sam p le  of urine and were asked to fill the BMQ 
and M orisky sca le  (in w eeks 4, 8, and 12) or the ACTG adherence  questionna ire  
(in w eek 16). At com p le tion  of trea tm ent, the pa tien ts  filled  ou t a questionna ire  
abou t the ir experience w ith  MEMS bo ttle  use.
Treatment adherence measures
Medication Event Monitoring System
MEMS m ed ica tion  bo ttles  (250cc con ta ine rs  w ith  a 38m m  MEMS 6 TrackCap, 
Aardex Ltd, Sw itze rland) were used by all pa rtic ip an ts  th ro u g h o u t treatm ent. 
MEMS data were used to ca lcu la te  adherence rates (by d iv id ing  the num ber of 
days on w h ich  at least one bo ttle  open ing  w as reg istered by the to ta l num ber of 
m on ito red  days and m u ltip lied  by 100) and to d iffe ren tia te  betw een adheren t and 
non-adheren t pa tien ts  fo r  va lida tion  of the o ther adherence m easures. For the 
la tte r purpose, s tandard  adherence rate cu t-o ff va lues of 100%, 95% and 80% 8 
were app lied .
Isoniazid urine test (IsoScreen)
The IsoScreen tes t (GFC D iagnostics  Ltd, B icester, England) is based on the 
A rkansas m ethod fo r the de tection  of INH in urine and supp lied  in a ready-to-use 
p las tic  tes ting  device. The test was pe rfo rm ed in acco rdance  w ith  the d irec tions
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#provided in the accom pany ing  m anual. The tes t resu lt was negative w hen no 
co lou r change w as observed a fte r five m inutes, positive  w hen the co lou r changed 
to da rk  purp le  and equ ivoca l w hen the  co lou r tu rned  green. P atients w ith  at least 
one negative tes t were regarded as non-adherent.
Urine co lour test
Prior to each INH urine test, the urine co lou r was checked fo r the  presence of 
rifam p ic in . O range urine w as scored  as positive ; ye llow  urine as negative. 
Patients w ith  at least one negative tes t were ca tegorized  as non-adherent.
M orisky scale
The M orisky scale is a se lf-re po rt adherence  m easure w ith  fou r ques tions  about 
com m on barrie rs to adhe rence .23 We c lass ified  as non-adheren t all pa tien ts who 
answ ered ‘yes' to at least one of the  fo u r ques tions  in at least one of the three 
repeated tests.
Brief Medication Questionnaire
The BMQ cons is ts  of three sec tions  (‘screens ') w ith  ques tions  abou t adherence 
behaviour, experienced e ffec ts  of trea tm ent and o ther fac to rs  tha t cou ld  a ffect 
adherence . The screens were scored  as described  e lsew here .24 Patients w ith  a 
to ta l score  of one o r m ore in at least one of the three repeated tes ts  were c lass ified  
as non-adheren t.
Adapted AIDS C linical Trials Group adherence questionnaire 
The ACTG adherence  questionna ire  w as deve loped fo r pa tien ts in fected w ith  the 
hum an im m u nod e fic ien cy  v irus  (HIV) w ho pa rtic ipa te  in c lin ica l tr ia ls 25 and is 
ava ilab le at:
w w w .g h d o n lin e .o rg /u p lo a d s /A C T G _ A d h e re n c e _ B a s e lin e _ Q u e s tio n n a ire .p d f 
(Date last accessed : May 12th, 2011). O ur adap ted  vers ion  cons is ted  of three 
m u ltip le  cho ice  item s co rre spo nd ing  to sec tio ns  B (social support), C (poss ib le  
reasons fo r non-adherence) and D (adherence behaviour) of the o rig ina l baseline 
questionna ire . We scored  any answ er o the r than ‘never' to the ques tions  in 
sec tions  C and D or less than ‘som ew hat sa tis fied ' to the ques tions  in section  B 
as positive. A positive  score  w as regarded as ind ica tive  of non-adherence.
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Refill visits and p ill counts
The pa tien ts ' c lin ic  a ttendance  fo r m ed ica tion  refills w as reg istered and rem aining 
tab le ts  were coun ted  at every refill v is it. Patients w ho de layed at least once fo r a 
m ed ica tion  refill v is it and those  w ho had at least once an in co rrec t num ber of 
tab le ts  rem a in ing were c lass ified  as non-adherent.
Data analysis
MEMS data were ana lyzed by us ing Pow erview  so ftw are  (Aardex Ltd, S w itzerland). 
Periods of ‘pocke t do s in g ' (i.e. tak ing  out m ed ica tion  fo r later use) tha t were 
iden tified  by the MEMS use questionna ire  were excluded from  the ana lys is  as 
non -m on ito red  periods. S ta tis tica l ana lys is  was pe rfo rm ed in SPSS vers ion  16.0 
(SPSS Inc., C h icago, USA). M eans are presen ted w ith  s tandard  devia tion  (SD) 
and m edians w ith  in te rquartile  range (IQR). M eans were com pared  by using the 
S tuden t t-test. The sensitiv ity , spec ific ity , positive and negative pred ic tive  values 
and accu racy  (de fin itions p rov ided in Table 3) of s ing le  and com b ined  adherence 
m easures were ca lcu la ted  by using MEMS as the go ld  standard . For com b ined  
m easures, non-adheren t pa tien ts  were pa tien ts  w ho were c lass ified  as 
non-adheren t by at least one of the s ing le  m easures in the com b ina tion .
Ethical approval
The s tud y  w as approved  by the  Ins titu tiona l Review Board of the K ilim an jaro 
C hris tian  M edica l Centre (M oshi, Tanzania) and the N ational Institu te  fo r M edica l 
Research (Dar es Salaam , Tanzania).
Results
Patient characteristics and treatment outcomes
We enro lled  31 m ale and 19 fem ale patien ts. The cha rac te ris tics  are sum m arized 
in Table 1. Six of the 22 pa tien ts w ho were co -in fec ted  w ith  HIV used an tire trov ira l 
m ed ica tion  and 14 were on co-trim oxazo le  p rophy lax is . A lthough  all pa tien ts 
were on com m u n ity -b ased  DOT, seven had no fo rm a l trea tm ent supporter. 
T h irty-seven pa tien ts  su cce ss fu lly  com p le ted  trea tm ent. Six pa tien ts d ied; all 
were H IV-positive. Three pa tien ts  de fau lted  and fou r pa tien ts  d ropped  out of the
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s tud y  (three were transfe rred  to ano the r reg ion and one deve loped jaun d ice  fo r 
w h ich  his trea tm en t had to be in terrup ted).
Treatment adherence according to M E M S
No MEMS data w as ava ilab le  fo r three pa tien ts  (one de fau lte r and tw o  w ho died) 
because the m ed ica tion  bo ttle  was not returned. For the o ther 47 patien ts, a tota l 
of 6871 trea tm en t days were m on ito red  by MEMS. On 194 m on ito red  days, the 
MEMS bo ttle  was not opened; a m edian of 2 days per pa tien t (IQR: 0-5). The 
mean adherence rate was 96.3%  (SD: 7.7) and did  not d iffe r s ig n ifica n tly  between 
pa tien ts w ith  and w ith o u t a trea tm ent suppo rte r: 96.2%  (SD: 8.2) and 97.1% (SD: 
3.1), respec tive ly  (p=0.79).
Of all pa tien ts, 70% were less than 100% adherent, 21% less than 95%, and 2% 
less than 80% (Table 2). A m ong the pa tien ts  w ho com p le ted  the 6 -m onths 
trea tm ent course, 73%, 19%, and 0% of pa tien ts  were less than 100%, 95%, and 
80% adherent, respective ly.
M onth ly  adherence rates were fa irly  constant. In the g roup  of pa tien ts  who 
com p le ted  trea tm ent, the m edian m on th ly  adherence rate was 100% and the 
mean m on th ly  adherence rate varied betw een 95.4%  (SD: 7.3) in m onth 6 and 
98.5%  (SD: 2.7) in m onth 3.
Validation of adherence measures
For the va lida tion  of the a lte rna tive  adherence  m easures on ly  pa tien ts  who 
com p le ted  the 6 -m on ths  trea tm en t course (n=37) were inc luded . As show n in 
F igure 1, the p ro p o rtio n s  of non-adheren t pa tien ts  iden tified  by the d iffe rent 
m easures varied  w idely. Table 3 show s the sensitiv ity , spec ific ity , pos itive  and 
negative pred ic tive  values, and accu racy  of the adherence  m easures in te rm s of 
the ir a b ility  to d iffe ren tia te  betw een adheren t and non-adheren t pa tien ts. The 
ACTG adherence  questionna ire  and urine co lou r tes t had the h ighest sens itiv ities  
but lowest spec ific itie s . The M orisky  sca le  and refill v is its  had the highest 
spe c ific itie s  but lowest sens itiv ities . The sens itiv itie s  of m ost m easures im proved 
when the cu t-o ff value to d iffe ren tia te  betw een adheren t and non-adheren t 
pa tien ts w as lowered from  100% to 95% adherence, but the spe c ific itie s  dropped. 
The positive  and negative pred ic tive  va lues a lm ost reversed by chang ing  the 
cu t-o ff value from  100% to 95%, re flec ting  the large d iffe rence  in p ro p o rtio n s  of
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Table 1 C h a ra c te ris tics  & trea tm e n t o u tcom es  of s tu d y  p a rtic ip a n ts  (N =  50)
Characteristic n (%)a
Gender Male sex 31 (62)
Age (years) Mean (SD) 41.6 (14.0)
Educational level No education 2 (4)
Primary education 38 (76)
Secondary education 9 (18)
Advanced secondary education 1 (2)
Marital status Single 14 (28)
Married 23 (46)
Divorced 9 (18)
Widow 4 (8)
TB diagnosis Smear positive pTB 16 (32)
Smear negative pTB 25 (50)
EPTB 9 (18)
Clinic for treatment Urban 44 (88)
Rural 6 (12)
Mode of transport to clinic By foot 30 (60)
Public transport 17 (34)
Private transport 3 (6)
Treatment supporter None 7 (14)
Spouse 13 (26)
Relative 27 (54)
Friend 3 (6)
HIV status HIV-positive 22 (44)
HIV-negative 28 (56)
Favourable Cured 12 (24)
treatment outcome Treatment completed 25 (50)b
Unfavourable Died 6 (12)
treatment outcome Defaulted 3 (6)
Study drop-out 4 (8)
a Except for age, which is expressed in mean and standard deviation; b All of whom had smear-negative 
pulmonary or extrapulmonary TB; SD = standard deviation; pTB = pulmonary tuberculosis; EPTB = 
extrapulmonary tuberculosis.
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pa tien ts ca tegorized  as non-adheren t by us ing the  fo rm e r versus the la tte r cu t-o ff 
value. A cu t-o ff value of 80% cou ld  not be app lied  because none of the patien ts 
w ho com p le ted  trea tm ent w as less than 80% adherent.
The com b ina tion  of pill coun ts  and refill v is its  tha t is used in rou tine  prac tice  had
Table 2 M edian m on ito re d  trea tm e n t days and adhe rence  rates,
and p ro p o rtio n s  of pa tien ts  w ho were less than 100%, 95%  and 
80%  adhe ren t as assessed  by MEMS
Patientsa Monitored days 
median (IQR)
Adherence rate
(%)
median (IQR)
<100%
adherent,
n (%)
<95%
adherent,
n (%)
<80%
adherent,
n (%)
All patients 
(n=47)
168 (138-172) 98.4 (95.7-100) 33 (70) 10 (21) 1 (2)
Treatment completed 
(n=37)
169 (168-180.5) 98.4 (95.7-100) 27 (73) 7 (19) 0
Defaulters
(n=2)
40/113b 50.0/100c 1 (50) 1 (50) 1 (50)
Deaths
(n=4)
63 (29.5-104) 98.4 (95.6-99.6) 3 (75) 1 (25) 0
Study drop outs 
(n=4)
33 (21-73) 98.3 (88.4-100) 2 (50) 1 (25) 0
a Only patients of whom MEMS data was available are included; b Number of monitored days of defaulter 
1/ defaulter 2; c Adherence rate of defaulter 1/ defaulter 2; MEMS = medication event monitoring system; 
IQR = interquartile range.
a m odera te se n s itiv ity  and spec ific ity . Its se n s itiv ity  and negative pred ic tive  value 
fo r the iden tifica tion  of pa tien ts w ho were less than 95% adheren t im proved by 
adding any of the other adherence m easures except the M orisky scale (Table 3).
Patients’ experience with M EM S use
The questionna ire  abou t the use of MEMS, w h ich  w as filled  ou t by the 37 patien ts 
w ho com p le ted  trea tm ent, revealed tha t on ly  one pa tien t had co rre c tly  unders tood  
the pu rpose of MEMS desp ite  verba l and w ritten  in fo rm ation  at the onset of the 
study. Twenty-five pa tien ts (68%) sta ted  tha t the white, bu lky  appearance  of the
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Table 3 S ensitiv ity, spec ific ity , positive  and negative pred ic tive  values, 
and accu racy  of the ind iv idua l adherence  test m easures and in 
com b ina tions
Sensitivitya
(%)
Specificity13
(%)
PPVc
(%)
NPVd
(%)
Accuracye
(%)
MEMS cut-off rate' ^  
4-Test measure
<100 <95 <100 <95 <100 <95 <100 <95 <100 <95
INH urine test 33 43 40 60 60 20 18 82 35 57
Urine colour test 74 86 20 27 71 21 22 89 59 38
ACTG questionnaire 70 100 30 37 27 27 73 100 60 49
BMQ 54 57 70 55 82 24 37 84 58 56
Morisky scale 15 14 100 90 100 25 30 82 38 76
Pill counts 33 29 60 63 69 15 25 79 41 57
Refill visits 22 14 100 83 100 17 32 81 43 70
Refill visits + pill counts 41 29 60 57 73 13 27 77 46 51
Refill visits + pill counts 
+ ACTG questionnaire
79 100 0 20 68 23 0 100 57 35
Refill visits + pill counts 
+ urine colour
78 86 20 23 72 21 25 88 62 35
Refill visits + pill counts 
+ BMQ
69 71 50 38 78 22 39 85 64 44
Refill visits + pill counts 
+ INH urine test
63 71 30 37 71 21 23 85 54 43
Refill visits + pill counts 
+ Morisky scale
41 29 60 57 73 13 27 77 46 51
a Sensitivity = the proportion of non-adherent individuals who were correctly identified as non-adherent 
by the test measure; b Specificity = the proportion of adherent individuals who were correctly identified 
as adherent by the test measure; c PPV = positive predictive value: the proportion of non-adherent 
individuals according to the test measure who were non-adherent according to MEMS; d NPV = negative 
predictive value: the proportion of adherent individuals according to the test measure who were 
adherent according to MEMS; e Accuracy = the proportion of individuals who were correctly identified 
as either adherent or non-adherent by the test measure; f Non-adherence defined as an adherence rate 
of <100% (27 patients) or <95% (7 patients) assessed by MEMS.
MEMS = medication event monitoring system; INH = isoniazid; BMQ = brief medication questionnaire; 
ACTG = AIDS clinical trials group.
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MEMS bo ttle  rem inded them  to take the m ed ica tion . However, the  o ther patien ts 
said tha t the use of MEMS had not in fluenced the ir adherence  behaviour. The 
mean adherence  rates d id  not d iffe r be tw een these tw o  groups: 97.5% (SD: 3.0) 
and 97.3% (SD: 3.2) respec tive ly  (p=0.86).
E ight pa tien ts occa s io na lly  opened the MEMS bo ttle  to take out m ed ica tion  for 
la ter use (resu lting in a to ta l of 42 non-m on ito red  trea tm en t days). This occurred 
when pa tien ts  d id  not w ant to take the MEMS bo ttle  a long on travel occasions.
Figure 1 Non-adherence to TB treatm ent of patients who com pleted treatment 
(n=37), as assessed by the difference adherence measures
Refill v isits 
Pill coun ts  
M orisky  scale 
BMQ
ACTG  questionna ire  
Urine  co lo u r test 
IN H  urine test 
M EM S (< 9 5 %  adherent) 
M EM S (< 1 0 0 %  adherent)
35
47
41
70
76
73
0%  10% 20%  30%  40%  50%  60%  70%  80%  90%  100% 
% assessed as non -adheren t
BMQ = brief medication questionnaire; ACTG = AIDS clinical trials group; INH = isoniazid; MEMS 
= medication event monitoring system.
Discussion
This is the firs t s tud y  in w h ich  MEMS w as used to assess trea tm ent adherence 
rates in pa tien ts  on com m un ity -based  DOT over the fu ll 6 -m o n ths  TB trea tm ent 
course. We observed  high adherence rates in our p ilo t s tudy  of 50 Tanzanian 
patients. A lm ost 80% of pa tien ts  were m ore than 95% adheren t and on ly  one
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#patien t w as less than 80% adherent. These find in gs  do not con firm  the concern  
tha t pa tien ts  on com m un ity -based  DOT are prone to becom e non-adheren t, even 
tho ugh  the s tudy  did  reveal tha t som e pa tien ts (i.e. those  w ith ou t a form al 
trea tm ent suppo rte r) turn com m un ity -based  DOT into se lf-adm in is te red  
trea tm ent.
The p a rtic ip an ts ' de m og raph ic  cha racte ris tics , such as the ratio of m ales to 
fem a les and th e ir trea tm ent ou tcom es, were com parab le  to those  of the general 
TB pa tien t popu la tion  in the K ilim an ja ro R eg ion,6 sug ge sting  tha t we s tud ied  a 
reg iona lly  representa tive  pa tien t sam ple. However, the adherence  rates of our 
pa tien ts  cou ld  have been biased by the ir pa rtic ip a tion  in the study. A lthough  we 
tried  to devia te as little  as poss ib le  from  routine practice, the repeated adherence 
ques tionna ires  and urine tes ts  ce rta in ly  m ade pa rtic ip an ts  aware of our interest 
in th e ir adherence  behaviour. Tw o-th ird of the pa tien ts  tho ugh t tha t the ir 
adherence  behav iou r had been in fluenced by the use of MEMS, but the ir average 
adherence  rate d id  not d iffe r from  those  observed am ong pa tien ts  w ho stated 
tha t MEMS had not in fluenced th e ir behaviour. F ind ings from  o ther stud ies 
suggest tha t w hen MEMS is used over long periods, its ‘ in te rven tiona l e ffe c t’ 
d isap pea rs .2627 Since our sam ple  size w as sm all, la rger popu la tion  stud ies 
shou ld  be conducted  to assess the real im pact of com m u n ity -b ased  DOT w ith  
and w ith ou t fo rm a l trea tm ent s u p p o rte r on adherence rates. We did  not aim  to 
va lida te  the con cep t of com m un ity -based  DOT; s tud ies  fo r th is  pu rpose should 
have a d iffe ren t design.
The main ob jective  of our s tu d y  w as to use MEMS as a reference s tandard  to 
ca lcu la te  the v a lid ity  of several adherence m easures tha t are feas ib le  fo r use in 
pa tien ts  on com m un ity -based  DOT in resource -lim ited  se ttings. The high 
adherence  rates in the s tudy  popu la tion  fo rced  us to ap p ly  high adherence rate 
cu t-o ff va lues to  ca lcu la te  the v a lid ity  and re liab ility  of the adherence  m easures. 
Th is resu lted in w ide  gaps between the sens itiv itie s  and spe c ific itie s  of the 
m easures.8 C om b ina tions  of m easures were found  to be m ore accura te  than 
s ing le  m easures in id en tify ing  as m any true non-adheren t pa tien ts  as possib le  
(reflected in high sens itiv itie s  and negative pred ic tive  values). The se n s itiv ity  and 
negative pred ic tive  value of the rou tine ly  used com b ina tion  of pill coun ts  and
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#clinic attendance for medication refills improved substantially by adding a simple 
and cheap measure such as the ACTG adherence questionnaire, particularly at 
an adherence rate cut-off value of 95%.
A few remarks with respect to the different test measures should be made. The 
rifampicin urine colour test classified more patients as non-adherent than the 
INH urine test. Since the orange urine colouration caused by rifampicin is of 
short duration and may be absent all together,28 it is likely that the urine colour 
test m isclassified a number of patients with yellow urine as non-adherent. Such 
m isclassifications are difficu lt to confirm in a study population with high adherence 
rates.
The adapted ACTG adherence questionnaire yielded more favourable results 
than the other self-report measures. Differences in wording in the questionnaires 
may account for th is.8 While patients had to answer either ‘yes' or ‘no' to the 
questions in the Morisky scale, they could answer ‘often', ‘sometimes', ‘rarely', or 
‘never' to comparable questions in the ACTG adherence questionnaire. This 
w ider range of choice options may have evoked more honest replies. The ACTG 
adherence questionnaire (and to a lesser extent the BMQ) has the added 
advantage of d isclosing factors that cause non-adherence in the individual 
patient. These factors could be used to design tailored interventions for promoting 
adherence among non-adherent patients on community-based DOT. We therefore 
suggest using the triple combination consisting of the ACTG adherence 
questionnaire, refill visits and pill counts to monitor treatment adherence by 
Tanzanian patients on comm unity-based DOT. If the results are interpreted 
carefully, the combination seems valid and its use in routine practice appears 
feasible.
In conclusion, this study revealed high levels of treatment adherence by Tanzanian 
TB patients on comm unity-based DOT. A lthough caution should be exercised in 
interpreting the results because it is a pilot study, the findings support the 
recommendation of using community-based DOT as an alternative to 
facility-based DOT in settings with overburdened healthcare facilities. To monitor 
adherence of patients on comm unity-based DOT in resource-lim ited settings 
where electronic monitoring is not feasible, combinations of simple and affordable
80 | Chapter 4
Part II -  Measuring adherence
#
#adherence measures can be used. Supplementing pill counts and clinic 
attendance with a self-report measure such as the ACTG adherence questionnaire 
will help to identify potentially non-adherent patients who could benefit from 
tailored adherence-prom oting interventions. Further studies in larger patient 
populations are needed to assess the adherence rates of patients on community- 
based DOT and to confirm the valid ity of simple and affordable adherence 
measures.
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#Abstract
Background: An often used tool to measure adherence to antiretroviral therapy 
(ART) is the Medication Event Monitoring System (MEMS), a medication bottle 
with an electronic chip in its cap that registers date and time of bottle openings. 
Despite its strengths, MEMS data can be compromised by inaccurate bottle use 
and acceptability  problems due to its design. These barriers remain to be 
investigated in resource-lim ited settings. We evaluated the feasib ility and 
acceptability of using MEMS bottles to monitor adherence among patients 
infected with the human im m unodeficiency virus (HIV), attending a rural clin ic in 
Tanzania's Kilimanjaro Region.
M ethods: Eligible patients were approached and asked to use the MEMS bottle 
for 3 consecutive months. Thereafter, qualitative sem i-structured interviews 
about the use of MEMS were conducted with the patients. MEMS data were used 
to corroborate the interview results.
Results: Twenty-three of the 24 patients approached agreed to participate. Apart 
from MEMS use on travel occasions, patients reported no barriers regarding 
MEMS use. Unexpectedly, the MEMS bottle design reduced the patients' fear for 
HIV-status disclosure. Patients indicated that having their behaviour monitored 
motivated them to adhere better. MEMS data showed that most patients had high 
levels of adherence and there were no bottle-openings that could not be 
accounted for by medication intake. Non-adherence in the days prior to clinic 
visits was common and due to the clinic dispensing too few pills.
Conclusion: MEMS bottle use was readily accepted by patients. Although the 
MEMS bottle was used accurately by most patients, patients need to be more 
explicitly instructed to continue MEMS use when travelling. Even HIV-clinics with 
sufficient staff and free medication may impose structural adherence barriers by 
supplying an insufficient amount of pills.
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#Introduction
According to estimates of the Joint United Nations Programme on HIV/AIDS 
(UNAIDS), 33.4 million people were living with HIV/AIDS in 2009, of whom 67% 
on the African continent. Two million people died of AIDS in 2008 and 70% of 
these deaths occurred in Sub-Saharan African countries.1 According to the World 
Health Organization (WHO), the antiretroviral therapy (ART) coverage was 44% 
in Sub-Saharan Africa by the end of 2008.2 In Tanzania, the estimated adult HIV 
prevalence was 5.7% in 2009 (equivalent to 1.4 million people), and 96,000 
people died of AIDS in 2008.3 By March 2009, 55.2% of the 425,725 Tanzanian 
children and adults in need of ART were actually receiving it.4 
Scaling up the availability of ART is crucial for reducing m ortality and HIV-trans- 
m ission.5 ART offers an opportunity to prolong lives of people living with HIV/ 
AIDS (PLWHA) and revive societies that have been affected by the epidemic. 
While access to ART is vital, it is equally important to ensure that patients adhere 
to the prescribed regimen. High levels of adherence (>90-95%) are required for 
long-term viral suppression to delay progression to AIDS.6 Suboptimal adherence 
to ART increases the risk of drug resistance development. The emergence of 
drug resistance is a serious concern, especially in settings where the options for 
second-line treatment are lim ited.7 Therefore, monitoring the patients' adherence 
to ART is a requirement for adequate HIV care provision and research.
Accurate measurement of adherence is a challenge and at present there is no 
gold standard.89 A tool that has been used extensively in developed countries is 
the Medication Event Monitoring System (MEMS), a pill bottle that contains an 
electronic m icrochip that records date and time of each bottle opening. In 
contrast to other adherence measurement tools (such as self-reports, pill counts, 
pharmacy refill data, and therapeutic drug monitoring), MEMS combines objective 
data collection with detailed day-to-day information about medication intake 
over long time periods. MEMS data have been found to accurately predict clinical 
outcom es in the treatment of HIV in a range of studies, and its use has been 
described in over 500 peer-reviewed publications.1011
Sim ilar to other adherence measurement tools, MEMS data need to be evaluated 
fo r possible bias. Some suggest that MEMS data may underestimate adherence
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due to suboptimal bottle use (such as ‘pocket dosing', i.e. removing multiple pills 
at once for later use) or overestimate adherence because of bottle openings 
unrelated to medication intake.10 Moreover, HIV-infected patients who fear 
disclosure of their HIV-status have expressed concerns regarding the bulky 
design of the MEMS bottle. This could affect consistent use of MEMS and the 
patients' w illingness to participate in MEMS research, especially in Sub-Saharan 
Africa where HIV-related stigma is highly prevalent.12 Results from other studies 
suggest that monitoring ART adherence by using MEMS may improve medication 
intake, although the only study testing th is experimentally revealed no such 
patterns.1314 In sum, electronic monitoring provides uniquely detailed and 
objective adherence data over long time periods, but the data quality can be 
affected by the patients' acceptance and use of the device.
Although the importance of studying adherence to ART in developing countries 
is w idely acknowledged, only a few studies report using MEMS bottles to monitor 
ART adherence in Sub-Saharan Africa.1516 This may be explained by the 
perception that MEMS measurement is not feasible in these settings, or that 
MEMS bottles are too expensive to use in resource-lim ited settings. However, the 
costs of MEMS bottles seem modest (30 USD per 100 MEMS bottles for one year 
of data, 22 USD per 5,000 MEMS bottles for one year of data) when compared 
with the costs of clinical measures (e.g., 50 USD for a viral load measure and 25 
USD for one CD4 cell count).13 Hence, with non-adherence preceding viral 
replication and thereby CD4 cell count decline as well as manifestation of clinical 
symptoms, electronic measurement of adherence could be a useful and 
affordable option in research and clinic practice in resource-lim ited settings. 
Considering its potential usefulness for measuring adherence to ART, studies 
are needed that evaluate the feasib ility of MEMS monitoring in resource-lim ited 
settings. The aim of this study was to explore the patients' perceptions of and 
experiences with using MEMS bottles to monitor adherence in northern 
Tanzania.
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Study site
The study was conducted in a rural ART clin ic in the Kilimanjaro Region in 
northern Tanzania. The clinic provides services to about 700 PLWHA (of whom 
70% are on ART) and is attended by 50 PLWHA on an average clin ic day. There 
are 2 clinic days per week. Once in every 2 weeks on a clinic day, a health 
education session is conducted with all patients who are attending the clinic that 
day. The session takes about 15 minutes and is conducted by the clinician and a 
nurse at the clinic who provide practical information about adherence such as 
the importance of adherence and how to stay healthy in general. This health 
education session is usually followed by a discussion during which ART users 
ask questions and share their experiences in using ART.
Inclusion criteria and study procedures
This study covered a 3-m onths period during which participants were using their 
ART from MEMS bottles, after which sem i-structured interviews with the 
participants were conducted about their experiences with using MEMS bottles. 
Ethical clearance was obtained from the Tanzanian National Institute for Medical 
Research (NIMR) prior to commencement of the study (reference number: NIMR/ 
HQ/R.8a/Vol.IX/812). Financial support for this study was obtained from the 
‘ Innovation Foundation Healthcare Insurers' (RVVZ, The Netherlands) and from 
the ‘AIDS Foundation' (The Netherlands).
The elig ib ility criteria for participation in the study were: (1) aged 18 years or 
above; (2) being on ART for at least 6 months; (3) being a regular client to the 
clin ic and not a tem porary visitor; and (4) being w illing to participate in the study. 
All eligible patients who presented on one random clinic day were approached 
fo r participation. The researcher (author RL) was introduced to eligible patients 
by the ART clinician and explained that the aim of the study was to explore how 
patients perceive the use of a MEMS bottle for their antiretroviral medication. 
Patients were informed that participation in the study was voluntary, that refusal 
would not affect their relationship with the healthcare provider, and that they 
were free to w ithdraw from the study at any time. Interested patients signed a 
consent form.
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Study participants were informed that the MEMS bottle monitors pill intake 
behaviour. The researcher instructed the patients as follows: (1) open the MEMS 
bottle only when taking medication and close it properly afterwards; (2) always 
take medication directly from the MEMS bottle; (3) keep the MEMS bottle in a 
secured place out of reach of children or other people who may open the bottle; 
and (4) take the MEMS bottle along on clinic visits.
The study participants were followed for a period of 3 months (from mid-June to 
m id-September 2009). During this period, participants used their medication 
from the MEMS bottle and took the bottle along for medication refill during their 
monthly routine clinic visits. Only antiretroviral drugs were put in the MEMS 
bottles (no concom itant medication). At the clinic, patients handed over the 
MEMS bottle to the data clerk who downloaded the data while the patients visited 
the clinician. Patients then picked up the MEMS bottle and proceeded to the 
dispensing nurse who filled the bottle with medication, after which patients 
returned home. Downloaded MEMS data were not shared with study participants 
to avoid influencing their medication taking behaviour, neither were they viewed 
by clinicians to avoid them acting upon the findings.
After 3 months, the patients were approached for sem i-structured interviews. 
Patients were provided with a small compensation for the inconvenience of 
spending extra time at the clinic and to cover their transport costs.
Data collection and analysis
A pre-tested interview guide with open-ended questions was used. The guide 
consisted of three major themes: (1) the MEMS design (opinions about colour, 
shape and size); (2) the feasib ility of using MEMS (ease of use, storage of the 
MEMS bottle, portab ility  of the bottle on travel occasions, opinions about the 
guidelines for correct use); and (3) the impact of MEMS use on adherence 
behaviour and disclosure concerns.
All interviews were conducted in a private room at the ART clinic by three trained 
nterviewers (authors RL, EM, and DM). Interviews lasted approximately one hour 
and were conducted in Kiswahili. All interviews were audio recorded and 
transcribed. Tape recordings and transcripts were used for data analysis, after 
which the tape recordings were destroyed as per ethical requirements. 
Transcribed data were coded independently by two researchers (RL and DM)
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into clusters.
Since self-reports on proper use of the MEMS bottle may be biased by social 
desirability, m isinterpretation of questions and responses, or memory retrieval 
problems, following the interviews we also examined the MEMS data of all 
patients for: (1) patterns of overdosing (more openings on a day than prescribed) 
w ithout MEMS reports showing that patients ran out of medication before their 
next clinic visit (which should be the case if the overdoses are actual medication 
intakes and not curiosity openings); and (2) periods of >3 days during which the 
MEMS bottle registered no medication intake events, which could, apart from 
non-adherence, also indicate non-MEMS use. To distinguish between 
non-adherence and non-MEMS use, we first examined the interviews of patients 
reporting periods of non-MEMS use. If patients had missing data but did not 
report inaccurate MEMS use, we retrieved information on whether patients had 
collected their medication on time. If patients collected their medication too late 
in that period, the MEMS data were considered accurate and the patient as 
non-adherent. If patients did not report inaccurate MEMS use in the interview 
and were always on time to collect their medication, they were approached again 
and asked what happened in that period.
Results
Patient characteristics
All patients who attended the clin ic on June 6th 2009 and met the e lig ib ility  criteria 
(n=24), were approached for participation in the study and all agreed. However, 
one patient, a long-distance truck driver, w ithdrew from the study immediately 
after consenting because he judged the use of the MEMS bottle to be incompatible 
with his travelling schedule. Hence, 23 ART users completed the 3-m onths study 
period and were interviewed.
Fourteen (61%) participants were married, three (13%) were single, one (4%) was 
divorced, and five (22%) were widowed. All married participants had disclosed 
their HIV-status to their spouses. The median age was 44 years (interquartile
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range (IQR): 39-48). The period of ART use by the time of enrolment ranged from 
6 to 48 months. At enrolment, the CD4 cell count was less than 200 cells/uL in 
one patient (4%), between 201 and 300 cells/uL in six patients (26%), between 
301 and 500 cells/uL in ten patients (44%), and above 500 cells/uL in six patients 
(26%). The patient characteristics are summarized in Table 1.
A cceptability of M EM S design
The first indicator of the acceptability  of the MEMS bottle was the patients’ 
w illingness to participate in this study and use the MEMS bottle. As reported, all 
eligible patients accepted study participation, but one w ithdrew from the study 
immediately after consenting. The majority of participants (21/23) indicated to 
have no problem with the colour and size of the MEMS bottle. A female participant 
(36 years) narrated: “ The shape is good; it looks like a make-up bottle.” Another 
woman (41 years) stated: “This container looks like a body lotion; it is not easy 
for people to know that I am carrying the pills.” A man of 52 years remarked: 
“This medication bottle is better than ordinary pill bottles, its shape and size are 
OK.” Another man (30 years) said: “ If you put this bottle on the table, no one will 
know what it is for. Its size has no problem, and its colour- no problem .” 
Common feedback was that the MEMS bottles, contrary to the regular medication 
bottles, do not have labels that reveal its content. This was perceived as highly 
beneficial. For example, a woman of 39 years remarked: “This bottle is very good. 
No one would immediately know what it is for. The normal pill bottles are labelled 
so when someone sees it, it is recognized quickly.” Another woman (41 years) 
said: “This one is cool. With the other type, people read it and start bombarding 
you with questions.”
Upon inquiring about what patients th ink the ideal shape of a MEMS bottle would 
be, two participants proposed that a flat-shaped container would be easier to 
carry in one’s pocket. A long-distance truck driver (man, 50 years) said: “ I would 
prefer a container with a flat shape like a small mobile phone because it will be 
easy to put in the pocket.”
Feasibility of using M EM S according to guidelines
None of the patients reported to have had difficulties with follow ing the guidelines 
for accurate MEMS use: (1) to put the cap on the MEMS bottle after use and close
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Table 1 Demographic & disease characteristics of participants who com ple­
ted the study (N=23)
Characteristic n (%)
Sex Male 9 (39)
Female 14 (61)
Marital status Single 3 (13)
Married 14 (61)
Divorced 1 (4)
Widowed 5 (22)
Months on ART 6-12 2 (9)
12-24 12 (52)
24-48 9 (39)
Education level No formal education 1 (4)
Uncompleted primary education 4 (17)
Completed primary education 15 (65)
Secondary education 3 (13)
Occupation Small scale farming 10 (44)
Monthly salaried work 4 (17)
Occasional work 5 (22)
Distance to the clinic < 3 km 16 (70)
> 3 km 7 (30)
CD4 count at baseline (cells/uL) < 200 6 (26)
201-300 10 (43)
301-500 6 (26)
> 501 1 (4)
ART = antiretroviral therapy.
it properly; (2) always take all pills from the MEMS bottle; and (3) avoid that the 
bottle is opened by a fam ily member. Moreover, no one complained about the 
condition not to open the bottle between medication intakes. A widower 
(44 years) said “ I keep it on my table, it’s easy. I have my time for medication 
intake, so I open it during that time. On travel occasions, I move with it.” When 
asked if a fam ily member or child might have opened the MEMS bottle, most
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patients reported to have kept the MEMS bottle out of reach from others. 
A woman (41 years) remarked: “ I did not have any problem. I keep it in my 
bedroom and put it in a drawer to avoid it being opened by children. I have no 
problem with it, the instruction is not d ifficu lt.” One participant (man, 50 years) 
said: “ I hide my container in my suitcase. I don ’t want children or any other 
person to open it or ask me about it, this is my secret.”
Four participants talked about the challenges of always using all their medication 
from the MEMS bottle. These challenges were mainly related to travelling. The 
patients considered it unsafe to travel with the bottle as they feared that it could 
be stolen or lost. For example, a long-distance truck driver (man, 50 years) 
indicated: “When I was travelling, I left it at home and took the medication along.
I was afraid the device could be stolen.” A woman (39 years) confessed: “ I left my 
MEMS bottle at home during my travel away from home and I transferred my pills 
nto an ordinary medication bottle.” A mason (man, 50 years) said: “ I had to travel 
to Arusha for construction work for one and a half month. I left my MEMS bottle 
at home and instead transferred my pills into another bottle. I feared my MEMS 
bottle could be stolen or m isplaced at the construction site.”
Im pact of M EM S use on patient behaviour
Nearly 75% of patients (17/23) had informed other fam ily members that they had 
a new medication container. As one of the respondents said: “ I have informed my 
fam ily and children that this bottle records pill taking behaviour every time you 
open, so I strictly forbid them to touch it because it will be revealed when false 
openings are done to the pill bottle.” All participants who had told their fam ily 
members about the MEMS bottle said that their fam ily members became more 
supportive in rem inding them to take the medication. One participant (woman, 
45 years) said: “ Because my fam ily members don’t want me to have a bad record 
on my medication, they are very supportive in reminding me about the time to 
take pills.”
On the question about how patients felt that their behaviour was being monitored 
by the MEMS bottle, a typ ica l response was: “ I have no problem with that.” A 
woman (45 years) answered: “That is very good because it motivates me to 
remember to take pills.” A man (30 years) remarked: “ I have become more 
conscious in taking medication. I am now more systematic and I don ’t forget to
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take my pills because I know that I am being monitored. With other containers I 
could take pills any time and skip taking pills at w ill.” Similarly, another man (45 
years) said: “ Because I know that I am being recorded, I make every effort to take 
my medication as prescribed.” A women (45 years) stated: “ In the past I used to 
skip pills even for about 20 days, sometimes I found myself with two containers 
full of pills, but with th is new container, I don ’t skip a day.”
Corroborating interview responses with M EM S data
Examination of the MEMS reports revealed that there was no evidence of 
systematic overdosing by any of the patients. Bottles were typ ica lly opened twice 
a day at regular intervals. Sporadically, MEMS bottles were opened 3 times a day 
instead of 2. This was usually on clinic visit days when the bottle was refilled. 
Hence, these data confirm  patients’ reports that they only opened the bottle for 
medication intake.
There were six patients whose MEMS data showed periods of more than 3 days 
of missed medication (observed range was 12 to 71 days). Two of these patients 
reported during the initial interview that they had left the MEMS bottle at home 
when travelling, fearing that it might be stolen. Hence, they were not considered 
as non-adherent, but as not using the MEMS bottle. Two of the four remaining 
patients who reported in the initial interview to have always used the MEMS bottle 
as prescribed, showed up too late for collecting their medication in that period. 
Their missing MEMS data was therefore considered to accurately describe their 
medication intake (i.e., non-adherence). Of the two remaining patients who did 
not self-report inaccurate MEMS use and were on time fo r collecting their 
medication, one could be re-contacted to explain the data. This patient reported 
to have left the MEMS bottle at home when travelling for a period of 6 weeks. The 
non-m onitored period was indeed 6 weeks, and this was thus considered to be 
non-MEMS use rather than non-adherence. Hence, the MEMS bottles seemed to 
have been used accurately by all patients, except by three patients who did not 
use it during long-distance travels.
M EM S adherence scores
The interviews suggest that patients were on average highly adherent. Moreover, 
they suggest that patients changed their medication intake behaviour because
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they were being monitored, an effect that has also been recognized in the 
Western literature. However, this monitoring effect is expected to reduce over 
time.16 As a final step, we therefore explored the patients’ monthly adherence 
scores, namely the percentage of doses taken (taking adherence) and the 
percentage of doses taken within a 9-15 h interval (timing adherence), and 
explored whether adherence decreased over time also in th is study. For the three 
patients who travelled and used their medication from another bottle, their period 
of non-MEMS use was set to ‘m issing’. Monthly adherence scores were only 
computed for these three patients if they provided at least 2 weeks of continuous 
MEMS data.
The adherence scores are summarized in Table 2 and reveal that adherence 
levels were fairly high and declined somewhat over time. Seventy-four percent 
(17/23) of the patients took more than 95% of their medication during the first 
month, 63% (14/22) in month 2 and 62% (13/21) in month 3. W ilcoxon’s Signed 
Rank tests revealed that for taking and tim ing adherence there was a statistically 
significant decrease in adherence between month 1 and 3 (both p < 0.05), but 
not between month 1 and 2, or 2 and 3.
Table 2 Adherence scores per month
Month 1 (n=23) Month 2 (n=22) Month 3 (n=21)
Taking adherence® Mean (SD) 97.4 (4.7) 95.9 (5.78) 85.0 (26.8)
Median (IQR) 98.2 (4.6) 96.4 (5.4) 98.2 (18.8)
Timing adherenceb Mean (SD) 94.2 (6.8) 92.6 (6.1) 82.1 (26.4)
Median (IQR) 96.4 (4.6) 92.9 (6.3) 96.7 (20.5)
a Percentage of prescribed doses taken; b Percentage of doses taken within 12 ± 3 hours; SD = 
standard deviation; IQR = interquartile range.
One additional finding was that MEMS data frequently revealed 3 to 5 days of 
non-adherence before a clinic visit. Upon exploring the cause of this pattern, it 
became clear that whereas the time between two consecutive visits in th is clinic 
ranges from 30 to 35 days, patients were only provided with medication for 30
Part II -  Measuring adherence
#
#days. Hence, even the most motivated patients could not always be fully adherent 
due to m ismanagement at the clinic level.
Discussion
This study explored the feasib ility and acceptability  of using MEMS bottles to 
monitor adherence to ART in Tanzania’s Kilimanjaro Region. Twenty-three 
patients on ART used a MEMS bottle during 3 consecutive months. After this 
period, sem i-structured interviews were conducted with the participants. Overall, 
patients perceived MEMS bottles as simple and acceptable for use. The absence 
of a label on the bottle was perceived as an advantage to the ordinary pill bottles 
and, unexpectedly, reduced fear for HIV-status disclosure. The majority of 
patients stated that the use of MEMS bottles had improved their adherence 
because of increased fam ily support and the knowledge that the MEMS bottle 
was monitoring their behaviour. This is in line with findings by Wendel et al.17
Whereas we found that the MEMS bottle was readily accepted by patients on 
ART, others found that some patients, especially those who prefer not to disclose 
their HIV-status, do not like the white, bulky appearance of the MEMS bottle 
because of privacy concerns.18-20 The high acceptability  of MEMS use by patients 
in the present study is particularly remarkable because fears of disclosure of 
one’s HIV-status and consecutive stigmatization are w idely present in Tanzania 
and patients prefer to carry their medication as discretely as possible.2122 It 
turned out that the MEMS bottle design facilitated just that, with the absence of 
a medication label and the perception that the MEMS bottle looks like a package 
of common products in this region, such as lotion or shampoo bottles.
The main barrier to using MEMS were travel occasions. Three patients indicated 
to have left the MEMS bottle at home during travelling because of fears that it 
might be lost or stolen. This fear of losing the MEMS bottle on travel occasions 
was because patients perceived the MEMS bottle as a valuable device that could 
be stolen. The finding indicates the need of stressing to patients that using the 
medication from the MEMS bottle when travelling is important and that the risk of
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especially important because adhering to treatment may be more challenging 
when travelling.
It has been suggested that adherence monitoring with MEMS can be perceived 
as intrusive or patronizing.20 Patients in the present study perceived the monitoring 
of their adherence behaviour as an advantage; they reported that their adherence 
had improved due to MEMS monitoring. Most participants explicitly said that 
they paid more attention to taking their medication on the correct time because 
they were aware that their adherence behaviour was being monitored. Some 
patients adm itted that they had been skipping medication intake for weeks in a 
row prior to starting to use the MEMS bottle, but not anymore since MEMS use. 
Adherence rates were indeed high, especially during the first month of monitoring. 
However, the levels of adherence tended to decrease after the first month of the 
study and then stabilized, suggesting that patients returned to their usual 
adherence behaviour. This pattern has also been observed in other studies.2324
Examining the MEMS data in order to determine periods of non-adherence or 
non-MEMS use, patterns of missed doses were found prior to clinic visits because 
too few pills were being given to patients to bridge time between consecutive 
visits. Upon discussing the potential health consequences of this malpractice, 
the healthcare providers and dispensing nurses acknow ledged what went wrong. 
They now provide patients with enough medication (including a buffer supply in 
case the patient is not able to visit the clinic on the appointed day).
This study showed that MEMS devices have a potential application in adherence 
research and monitoring of adherence in clinical practice in resource-limited settings. 
Although attention has to be paid to accurate MEMS use, both at the time of 
instruction and at the moment of data interpretation, we did not observe the typical 
hurdles related to MEMS use in resource-rich settings. For example, patients did not 
experience problems with the MEMS bottle design. In the absence of financial 
resources for regular viral load or CD4 testing, (intermittent) monitoring of adherence 
with MEMS may be possible and provide clinicians with valuable information to 
support the patients’ medical treatment and medication adherence.
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was conducted in a single clinic, which limits external va lid ity of the findings. 
However, the aim of the study was to explore the feasib ility and acceptability  of 
MEMS through qualitative procedures. Second, patients may not have understood 
well enough that their adherence data would not be shared with their doctor. The 
expectation that the doctor would act upon detection of non-adherence, might 
explain part of the intervention effect of MEMS use, as described above. Third, 
adherence of patients with long periods of non-MEMS use should be interpreted 
with caution, since it cannot be verified whether medication was taken as 
prescribed in non-monitored periods.
Conclusions
This study suggests that the use of MEMS in a resource-lim ited, rural setting is 
feasible and acceptable to patients, and that MEMS is a potentially reliable 
source of information on adherence in settings where viral loads are not readily 
available. Special attention should be paid to instructing patients about using the 
MEMS bottle while travelling. Moreover, researchers and clinicians are advised 
to develop procedures to verify whether missing MEMS data was due to 
non-adherence or non-MEMS use. Finally, although beneficial in clinical practice 
or adherence supporting interventions, the reported effects of MEMS use on 
adherence could result in bias and thus distort outcomes in research. 
Guaranteeing the patients’ anonym ity in data processing and analysis, and 
incorporating a period during which patients can get used to the MEMS bottle 
are advised.
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Abstract
At the University Centre for Chronic Diseases Dekkerswald, a tertiary tuberculosis 
(TB) referral hospital in The Netherlands, therapeutic drug monitoring (TDM) is 
used in a selected group of patients with delayed response to TB treatment and 
possibly low TB drug concentrations in plasma. In th is article, a case series is 
presented to illustrate the value of individualized TB drug dosing in four relapse 
patients with low TB drug concentrations. Increased doses of the TB drugs, 
especially of rifampicin, resulted in adequate peak plasma concentrations and 
improved clinical response to treatment in these patients, while no adverse 
events occurred.
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First-line treatment of drug-susceptible tuberculosis (TB) is highly effective. 
Nevertheless, a number of patients fail to respond to treatment, have relapse TB, 
or develop drug-resistant TB.1 Inadequate response to TB treatment results from 
a complex and poorly understood combination of factors that vary from patient to 
patient.2 Suboptimal plasma concentrations of first-line TB drugs, in particular of 
rifampicin and isoniazid, are among these factors.34 Low plasma concentrations 
can result from malabsorption in patients with human im m unodeficiency virus 
(HIV) infection or gastrointestinal tract anomalies, diabetes mellitus (DM) as a 
concom itant disease, or interindividual variability in pharm acokinetics.5-10 
Therapeutic drug monitoring (TDM), i.e. individualized drug dosing guided by 
drug plasma concentrations,11 could be of help in improving response to drug 
treatment. So far, TDM has been applied to TB treatment in a limited number 
of centres only.2'7'812 In our setting, TDM was introduced to a selected group 
of patients in 2006. Here, we present our TDM practice and a case series that 
illustrates the value of using TDM in patients with drug-susceptib le TB who are 
suspected to have low TB drug plasma concentrations.
Methods
Setting
The University Centre for Chronic Diseases Dekkerswald is one of two tertiary 
TB referral hospitals in The Netherlands for patients with severe or complex TB 
disease, co-m orbidities such as HIV-infection, and drug-resistant TB.
TB treatment in th is centre is in accordance with guidelines of the Dutch 
Association of Physicians for Lung Disease and Tuberculosis (NVALT) and the 
standard, first-line treatment regimen consists of 2 months daily isoniazid (H; 5 
mg/kg bodyweight, maximum 300 mg), rifampicin (R; 450 mg in patients with 
bodyweight < 50 kg; 600 mg in patients with bodyweight > 50 kg), pyrazinamide 
(Z; 30 mg/kg bodyweight, maximum 2000 mg), and ethambutol (E; 15-20 mg/ 
kg bodyweight, maximum 1600 mg), followed by 4 months of daily H and R, in 
separate form ulations.13
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TDM practice
In our centre, TDM is used in patients with drug-susceptible TB when abnormal 
TB drug concentrations are suspected (e.g. in case of HIV-infection, DM, 
gastrointestinal anomalies, malnutrition, or renal or hepatic dysfunction), in case 
of delayed sputum culture conversion (i.e. after more than 8 weeks of treatment), 
and in case of relapse TB.
Pharmacokinetic sampling is performed after a minimum of 2 weeks of treatment, 
when steady state concentrations of the first-line TB drugs have been achieved. 
Samples are taken pre-dose (C0), and at 2 h (C2) after drug intake on an empty 
stomach to estimate the peak plasma concentration.8 After initial experiences 
we currently take samples at 4 (C4) and 6 h (C6) post-dose as well, to be able 
to determine peak plasma concentrations more accurately and to differentiate 
between delayed absorption and malabsorption.
After sampling, plasma is separated immediately, frozen to -80 °C, and transported 
on dry ice to the laboratory for bioanalysis of TB drugs by validated high­
performance liquid chrom atographic (HPLC) methods. Plasma concentrations 
of rifampicin are routinely measured, considering its known concentration- 
effect relationship.814 To limit the cost, isoniazid, pyrazinamide and ethambutol 
concentrations are only determined if the rifampicin concentration is below the 
lower limit of the target range.
The follow ing target ranges of peak plasma concentrations are used for first-line 
TB drugs that are taken in daily, oral doses: 3-5 mg/L for isoniazid; 8-24 mg/L for 
rifampicin, 20-50 mg/L for pyrazinamide, and 2-6 mg/L for etham butol.8 Hospital 
pharmacists interpret the TDM results and respiratory physicians decide on 
adjusting drug doses.
Results -  Case Series
Patient 1 -  relapse TB after previously delayed sputum culture conversion
A 57-year-old Caucasian man with a body mass index (BMI) of 18.6 kg/m2 and a 
history of alcohol abuse and smoking, was treated with the standard 2HRZE/4HR 
for susceptible pulmonary TB from January to July 2008. He was on Directly 
Observed Treatment (DOT) during the first 2 months. Sputum culture conversion
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occurred late; after 11.5 weeks of treatment. In April 2009, he presented with 
relapse pulmonary TB (the Mycobacterium tuberculosis (MTB) strain was 
identical to that of the first episode) which was still susceptible to HRZE. High 
Resolution Computed Tomography (HRCT) showed large pulmonary cavities. 
Treatment with HRZE was started. There was no clinical improvement in the 
first 4 weeks. Considering the slow culture conversion in the first TB episode 
and the fact that it concerned a relapse case, TB drug plasma concentrations 
were measured. A rifampicin peak concentration of 5.6 mg/L at C2 was found. 
The isoniazid peak plasma concentration was undetectable (< 0.025 mg/L) at 
C2 and the pyrazinamide peak plasma concentration was 8.3 mg/L. After dose 
adjustment of rifampicin from 600 to 1200 mg, its peak plasma concentration 
increased to 15.2 mg/L. Dose adjustments of isoniazid and pyrazinamide did not 
lead to peak plasma concentrations within the target ranges (0.04 mg/L and 12.2 
mg/L, respectively). Nevertheless, w ithin 2 weeks after increasing the drug doses, 
the patient's productive cough dim inished and his appetite approved. Sputum 
culture conversion occurred 6 weeks after dose adjustments. The patient did 
not experience adverse events to the higher doses of rifampicin, isoniazid and 
pyrazinamide. His clinical condition was excellent at completion of treatment in 
March 2010 and remained well during a follow-up period that lasted until October 
2010.
Patient 2 -  treatment failure in a patient with relapse TB and DM
A 59-year-old Indian man with a history of type II DM and alcohol abuse, was 
diagnosed with pulmonary TB in India in November 2006. He was treated until 
April 2007 and said to have been well-adherent to treatment. Within 8 months 
after completing treatment, he was diagnosed with active TB in The Netherlands. 
The HRCT of the chest showed bilateral cavernous and endobronchial lesions. 
Standard treatment with HRZE under DOT was started. The MTB strain was 
susceptible to HRZE. One month after start of treatment, pyrazinamide was 
stopped because of gastro-intestinal intolerance. There were no signs of 
hepatotoxicity at that time. Sputum remained culture positive for more than 4 
months (indicating treatment failure according to the Dutch NVALT guidelines).13 
Drug susceptib ility testing showed that the MTB strain was still susceptible to 
all first-line TB drugs. Rifampicin plasma concentrations were determined and
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revealed a peak concentration of 4.1 mg/L at C2. Dose adjustment took place 
(from 600 to 1200 mg), upon which the C2 plasma concentration increased to 
22.4 mg/L, reflecting the nonlinear pharm acokinetics of rifam picin.15 Sputum 
culture conversion occurred 1 month later. The patient gained weight and his 
cough disappeared. Despite gastrointestinal problems at the onset of treatment, 
the patient completed treatment w ithout any further adverse events. The total 
treatment duration was 11 months. After more than 1.5 years of follow-up, there 
were no signs of relapse.
Patient 3 -  second relapse TB after gastric surgery in the past
A 66-year-old Caucasian man with a history of Billroth II gastrectomy (1980), 
ischemic heart failure and chronic obstructive pulmonary disease (COPD, gold 
III), was successfully treated with self-adm inistered 2HRZE/4HR for pulmonary 
TB in 2004. In December 2007, he developed relapse TB caused by an 
identical, drug-susceptible MTB strain. He was treated with 2HRZE/4HR again 
(unsupervised). In December 2008, the patient returned with a second relapse 
of pulmonary TB. He presented with weight loss of 10 kg (BMI 13.7 kg/m2). This 
second relapse was confirmed by identical MTB genotypic fingerprints to those 
of the previous episodes. Treatment with HRZE was started and the patient was 
admitted to our centre. Plasma concentrations of rifampicin and pyrazinamide 
were obtained considering the possibility of drug absorption problems in this 
patient as a consequence of gastric surgery in the past. Peak concentrations were 
low (4.0 and 10 mg/L, respectively) and occurred delayed (at C4) for rifampicin. 
Because of the low BMI of the patient, protein-unbound (free) concentrations of 
rifampicin and pyrazinamide were measured as well, since a change in unbound 
concentrations (i.e. free fraction) may affect the interpretation of the total (bound 
plus unbound) concentration.16 However, both unbound fractions and plasma 
albumin levels were normal. Therefore, the doses of isoniazid, rifampicin and 
pyrazinamide were adjusted (H from 200 to 250 mg, R from 450 to 600 mg, Z 
from 1250 to 2000 mg). The pyrazinamide peak plasma concentration reached 
the target range (43 mg/L) with this dose adjustment, and the rifampicin peak 
plasma concentration did so after another dose adjustment (to 900 mg; C6: 8.5 
mg/L). Sputum culture conversion occurred within 8 weeks after the second 
dose adjustment of rifampicin. The higher doses were tolerated well. The patient
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progressive heart failure a few months later.
Patient 4 -  relapse TB with DM and extensive cavitary disease
A 42-year-old Caucasian man with a history of type II DM and schizophrenia, 
completed treatment with 2HRZE/4HR under DOT for susceptible pulmonary TB in 
July 2007. In April 2008, he presented with relapse pulmonary TB that was susceptible 
to HRZE. The HRCT showed bilateral multiple small consolidations, large cavities 
in the left upper lobe and partial collapse of the right lung, together with traction 
bronchiectasis. Treatment with HRZE was started again. Sputum culture conversion 
occurred within 6 weeks after start of treatment, but clinical and radiologic response 
were slow. Rifampicin plasma concentrations were measured after 12 weeks of 
treatment and the peak plasma concentration was 2.3 mg/L at C2. Dose adjustment 
of rifampicin from 600 to 900 mg took place and resulted in an improved peak 
plasma concentration of 8.2 mg/L. The C4 en C6 plasma concentrations however, 
were 3.6 and 1.6 mg/L respectively, and it was decided to increase the dose to 
1200 mg in order to achieve higher exposure. Clinically, the patient improved from 
the time of the final dose adjustment. A control CT scan 3 months later showed 
slight improvement, but the large cavities in the left upper lobe were unchanged. 
Positron Emission Tomography (PET) showed little fluorodeoxy-glucose uptake in 
the lesions and therefore, we decided to refrain from surgery. Supervised treatment 
was continued for 9 months. No adverse events occurred. After more than 1.5 years 
of follow-up, the patient did not show signs of relapse TB.
Discussion
In our setting, TDM proved to be of help in detecting low TB drug plasma 
concentrations as one of the possible causes of slow treatment response, treatment 
failure or relapse TB, and in monitoring the effects of step-wise increases in drug 
doses. We presented four patients with relapse TB, all of whom appeared to have 
peak plasma concentrations of TB drugs below the target range. In most cases, 
increased drug doses resulted in peak plasma concentrations w ithin the target 
range and clinical response to treatment, while no adverse events occurred.
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Generally, the applicab ility  of TDM depends on the fulfilm ent of a number of 
criteria.1112 First, there should be a large interindividual variation in drug plasma 
concentrations, which is the case in TB treatm ent.8
Second, there should be a clear relationship between drug plasma concentrations 
and response (which can be therapeutic or toxic). The association between TB 
drug plasma concentrations and treatment response is incom pletely understood. 
A limited number of in vitro and murine studies have shown that the ratio between 
the area under the plasma concentration curve (AUC) and the minimum inhibitory 
concentration (MIC) is the pharm acodynam ic index that best explains the effects 
of isoniazid, rifampicin, pyrazinamide and ethambutol.17-22 Findings from a 
number of studies in humans pointed towards an association between low TB 
drug concentrations and poor treatment outcom e,3A2324 but the association has 
been questioned by findings from other studies.625
As a third criterion for TDM, the drug concentration range in which a drug is 
effective and tolerated well, should be known and narrow. Little is known about 
which TB drug concentrations should be targeted to achieve adequate treatment 
response. Data from in vitro and murine studies cannot be extrapolated directly 
to humans, and validated targets for peak plasma concentrations (that generally 
correlate with AUC values) are not available from human studies. The target 
ranges that are currently used, were derived from studies in healthy volunteers 
who took standard doses that are effective in most patients, under controlled 
phase I study conditions.8
The fourth criterion for the applicab ility  of TDM is that there should be no 
alternative, easier measurable indicator of treatment response available. Although 
clinical response and sputum smear or culture conversion are markers of TB 
treatment response,26 they are typ ica lly assessed after weeks of treatment, when 
the emergence of resistance or treatment failure may already have occurred.2 
Obviously, TB treatment does not fulfil all requirements for TDM, mainly 
because of gaps in knowledge and understanding of the pharm acokinetics and 
-dynam ics of TB drugs. Sharing clinical experience of using TDM to individualize 
TB treatment could help to fill parts of those gaps.
We have presented a series of four cases only. The results are therefore not 
generalizable. Nevertheless, we th ink that th is case-series illustrates the value
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of TDM as a tool to assess whether inadequate response to TB treatment can be 
attributed to suboptimal exposure to TB drugs in patients with drug-susceptible 
TB. More research is needed to evaluate the TB drug plasma concentration -  
response relationship as a basis for TDM in TB treatment.
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#Abstract
Setting: Kilimanjaro Region, northern Tanzania.
O bjectives: To assess the effect of the introduction of the patient centred 
tuberculosis treatment (PCT) approach -which allows tuberculosis (TB) patients 
to choose between com m unity and facility-based directly observed treatment 
(DOT)- on treatment outcomes, and to analyse factors that contribute to opting 
for community-based DOT.
Design: Retrospective analysis of treatment outcomes of TB patients registered 
in the Kilimanjaro Region in 2007, differentiating between patients on community 
vs. facility-based DOT and taking into account dem ographic factors, disease 
classification, TB-diagnosis and human im m unodeficiency virus (HIV) status. 
Results: Data of 2769 TB patients were analysed. Treatment success rates were 
81% and 70% in patients on com m unity vs. facility-based DOT, respectively 
(p<0.001). Cure rates were respectively 73% and 72% in smear-positive 
pulmonary TB patients on com m unity vs. facility-based DOT (p=0.62). Women, 
children, patients residing in other d istricts than Hai, patients with newly 
diagnosed TB and patients with smear-negative pulmonary TB were most likely 
to be on comm unity-based DOT.
Conclusions: The PCT approach was shown to be effective in terms of treatment 
outcomes. Treatment success rates were higher in patients who opted for 
community-based DOT than in patients who chose facility-based DOT (all cases), 
and sim ilar in smear-positive pulmonary TB patients on com m unity or 
facility-based DOT.
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Directly Observed Treatment (DOT), promoted by the World Health Organization 
(WHO) as one of the elements of the DOTS strategy, is considered to be an important 
strategy to improve adherence to tuberculosis (TB) treatment.1 In Tanzania, one of 
the 22 countries with the highest burden of TB,2 patients used to receive daily DOT 
at the healthcare facility (facility-based DOT) during the first 2 months of treatment, 
and were then moved to self-administered treatment in the continuation phase of 
treatment. In 2006, a 6-months regimen containing rifampicin throughout treatment 
was introduced. The use of rifampicin, one of the cornerstones of current TB 
treatment,3 required daily DOT during the full course of treatment. This, coupled with 
an increasing TB incidence and insufficient human resources for healthcare, made 
facility-based DOT unmanageable.4 Randomized controlled trials were conducted in 
rural and urban Tanzanian districts to evaluate the efficacy of community-based 
DOT (DOT provided by a community member) compared to facility-based DOT.45 
Results showed that, at least in an experimental setting, community-based DOT is 
as effective as facility-based DOT, and that sputum conversion rates and treatment 
outcomes were similar. Moreover, community-based DOT was found to be readily 
accepted by the community.6 Results from these studies encouraged the Tanzanian 
Ministry of Health and Social Welfare to implement community-based DOT in the 
National TB and Leprosy Programme (NTLP).
In 2007, the so-called patient centred TB treatment (PCT) approach was introduced 
in Tanzania. The PCT approach allows TB patients to choose where their daily 
treatment is supervised and by whom; i.e. to choose between facility-based and 
community-based DOT.7 Community-based DOT in the PCT approach involves the 
selection of a treatment supporter who is usually a family member or spouse. The 
treatment supporter is oriented in how to provide DOT and how to support the 
patient. The patient and the treatment supporter are supposed to visit the healthcare 
facility once a week during the intensive phase of treatment and once every 2 weeks 
during the continuation phase, to collect drugs and report problems.7 The PCT 
approach has been used in Tanzania for over 2 years now. Facility-based DOT has 
become less popular among patients, and is mainly used by in-patients (personal 
communication with TB and leprosy coordinators).
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The present study aimed to evaluate the effect of the PCT approach on treatment 
outcomes in TB patients from the Kilimanjaro Region in 2007. Treatment outcomes 
were compared between patients who opted for community-based DOT and 
patients who chose facility-based DOT. An analysis was made of the entire cohort 
of TB patients, and of the subgroup of patients with newly diagnosed sputum 
smear-positive TB.
Methods
Setting
The Kilimanjaro Region is situated in northern Tanzania. It covers an area of 
13,309 km2 and has a population of over 1.3 m illion.8 The region is divided into 
six districts, one urban (Moshi Urban) and five rural (Moshi Rural, Mwanga, 
Same, Rombo, Hai). The region hosts one of the four national referral hospitals, 
in Moshi Urban, and the national TB referral hospital, in Hai. The region also has 
one governmental regional hospital, in Moshi Urban, and several hospitals and 
health centres in the districts. The NTLP is integrated into the existing primary 
healthcare system.7 One regional and six district TB and Leprosy Coordinators 
(RTLC and DTLCs) are responsible for managing the NTLP at the regional and 
d istrict levels of the Kilimanjaro Region.
Methods
The 2007 TB registers from all d istricts of the Kilimanjaro Region were used as 
data sources. Apart from demographic data (sex, age and district of residence), 
data were collected on TB classification (new case, relapse, failure, transfer in, 
return after default, other, as defined by the WHO)1 and diagnosis (smear-positive 
pulmonary, smear-negative pulmonary or extrapulm onary TB), human immuno­
deficiency virus (HIV) status, type of DOT (community or facility-based) and 
treatment outcome. Treatment outcomes were described in terms of treatment 
success (cured and completed treatment) and unfavourable treatment outcomes 
(failure, defaulter, death, transferred out and lost to follow-up), in line with WHO 
definitions.1
The study was approved by the Institutional Review Board of the Kilimanjaro
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Christian Medical Centre, Moshi, Tanzania. Informed consent was not obtained 
from participants as it was a retrospective study in which no individual patient 
details were used.
Data analysis was performed using SPSS version 16.0.1 (Statistical Package for 
the Social Sciences, Chicago, IL, USA) for W indows 2007 (MicroSoft, Redmond, 
WA, USA).
Chi square tests were used to compare proportions. Univariate and multivariate 
logistic regression analyses were performed to analyse factors that contributed 
to the choice of com m unity vs. facility-based DOT, and to analyse the effect of 
the chosen type of DOT on treatment outcomes. Finally, unfavourable treatment 
outcom es were analysed for association with type of DOT (univariate analysis). 
Odds ratios (OR), defined as the probability of occurrence over non-occurrence, 
with values greater than one indicating a greater probability of occurrence as 
compared to the reference group (indicated by 1 in the tables), and 95% 
confidence intervals (95% CI) were calculated and are provided in the tables.
Results
Patient characteristics
A total of 2769 TB patients were registered. The case notification rate of new and 
retreatment cases (n=2449) was 178 per 100,000 population; 63% (n=1749) of 
the patients were male, and 11% (n=308) were children aged <15 years (Table 1). 
The median age of the adults was 35 years (interquartile range [IQR] 26-47). 
Moshi Urban, Moshi Rural and Hai D istricts covered 76% of the patient load. 
Eighty-three percent (n=2312) of the patients were new TB cases, 4% (n=115) 
were relapse cases, 1% (n=22) treatment failures or returning after default and 
12% (n=320) were transferred in or not otherwise defined. Forty-one percent 
(n=1126) of patients were diagnosed with smear-positive pulmonary TB, 75% of 
whom (n = 840) were new cases; 39% (n=1075) had smear-negative pulmonary 
TB and 21% (n=568) extra-pulmonary TB (smear results not known). HIV status 
was not known in 36% (n=994) of patients; 31% (n = 847) were HIV-positive and 
34% (n=928) HIV-negative. S ignificantly more female than male patients were 
HIV-positive (39% vs. 26%, OR 1.8, 95% CI 1.5-2.2).
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The characteristics of patients on com m unity vs. facility-based DOT are 
summarised in Table 1. A total of 1646 patients (59%) opted for community-based 
DOT. Compared to patients on facility-based DOT, patients on community-based 
DOT were more likely to be female, aged <15 years or HIV-positive, and were 
less likely to be registered in Hai District, to be diagnosed with smear-positive 
pulmonary TB or to be a retreatment case (univariate analysis). Multivariate 
logistic regression analysis showed an independent association of female sex, 
being a child, residing in any district other than Hai, having newly diagnosed TB 
and having smear-negative pulmonary TB with opting for comm unity-based DOT 
(Table 1).
Patient factors that contributed to treatm ent success
The overall treatment success rate was 77% (n/N=2128/2769); 30% (n = 835) of 
patients were cured and 47% (n=1293) completed treatment.
As shown in Table 2, treatment success was more likely in patients on com m uni­
ty-based DOT than in those on facility-based DOT (81% vs. 70%), in patients with 
smear-positive pulmonary TB, and in patients who were HIV-negative (univariate 
analysis). These factors were also independently associated with treatment 
success in a multivariate regression model (Table 2). In Same and Moshi Rural 
districts, treatment success rates were high in comparison to Hai district, but the 
difference disappeared in the multivariate regression model. Sex, age and 
treatment classification (new or retreatment) were not s ignificantly associated 
with treatment outcome.
Effect of type of DOT on treatm ent success in sm ear-positive  
pulm onary TB  cases
Of 1126 patients with smear-positive pulmonary TB, 815 (72%) were cured and 97 
(9%) completed treatment. Cure rates did not differ s ignificantly between patients 
who opted for community-based DOT and those who opted for facility-based 
DOT (73% and 72%, respectively; OR 1.1, 95% CI 0.8-1.4). In smear-positive 
pulmonary TB patients for whom sputum smear results after 2 and 5 months of 
treatment were documented (66% and 63%, respectively), no significant 
differences in smear conversion rates between patients on community-based
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Table 1 Characteristics of the total cohort of patients and of patients on 
com m unity versus facility-based DOT
Total
cohort
(N=2769)
n
Patients on 
community- 
based DOT 
(n=1646) 
n (row %)
Patients 
on facility- 
based DOT 
(n=1123) 
n (row %)
Unadjusted OR 
(95% CI)a
Adjusted OR 
(95% CI)b
Sex
Male 1749 990 (57) 759 (43) 1 1
Female 1020 656 (64) 364 (36) 1.4 (1.2-1.6) 1.3 (1.1-1.6)
Age, years
>14 2461 1442 (59) 1019 (41) 1 1
0-14 308 204 (66) 104 (34) 1.4 (1.1-1.8) 1.4 (1.0-1.9)
Districts
Hai 681 146 (21) 535 (79) 1 1
Moshi Urban 893 465 (52) 428 (48) 4.0 (3.2-5.0) 3.7 (2.9-4.7)
Moshi Rural 535 477 (89) 58 (11) 30.1 (21.7-41.9) 33.9 (23.9-48.1)
Rombo 256 222 (87) 34 (13) 23.9 (16.0-35.9) 30.2 (19.6-46 .7)
Same 238 198 (83) 40 (17) 18.1 (12.3-26.8) 20.5 (13.7-30 .7)
Mwanga 166 138 (83) 28 (17) 18.1 (11.6 -28 .2) 20.2 (12.6-32 .5)
TB classification
New 2312 1426 (62) 886 (38) 1 1
Retreatment 137 25 (18) 112 (82) 0.1 (0.1-0.2) 0.1 (0.1-0.2)
Other/ 320 195 (61) 125 (39) 1.0 (0 .8 -1.2) 0.7 (0.5-0.8)
transferred in 
TB diagnosis
Smear-pos. PTB 1126 589 (52) 537 (48) 1 1
Smear-neg. PTB 1075 719 (67) 356 (33) 1.8 (1.6-2.2) 1.3 (1.0-1.6)
EPTB 568 338 (60) 230 (40) 1.3 (1.1-1.6) 0.9 (0.7-1.1)
HIV status
Negative 928 534 (58) 394 (42) 1 1
Positive 847 531 (63) 316 (37) 1.2 (1.0-1.5) 1.1 (0.9-1.4)
Unknown 994 581 (58) 413 (42) 1.0 (0 .9-1.2) 1.1 (0.9-1.4)
a Univariate (unadjusted) ORs and 95% CIs were calculated for patients on community-based DOT vs. 
those on facility-based DOT; the reference category was community-based DOT. 
b Multivariate (adjusted) ORs and 95% CIs were calculated for patients on community-based DOT vs. 
those on facility-based DOT; the reference category was community-based DOT.
DOT = directly observed treatment; OR = odds ratio; CI = confidence interval; TB = tuberculosis; PTB 
= pulmonary TB; EPTB = extra-pulmonary TB; HIV = human immunodeficiency virus.
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Table 2 Characteristics of patients with successful and unfavourable 
treatment outcomes
Treatment 
successa 
(n=2128) 
n (row %)
Unfavourable 
outcomeb 
(n=641) 
n (row %)
Unadjusted OR 
(95% CI)c
Adjusted OR 
(95% CI)d
DOT type
Facility-based 791 (70) 332 (30) 1 1
Community-based 1337 (81) 309 (l9) 1.8 (1.5-2.2) 1.8 (1.5-2.3)
Sex
Male 1343 (77) 406 (23) 1
Female 785 (77) 235 (23) 1.0 (0.8-1.2) ns
Age, years
>14 1883 (77) 578 (23) 1
0-14 245 (79) 63 (21) 1.2 (0.9-1.6) ns
District
Hai 505 (74) 176 (26) 1 1
Moshi Urban 654 (73) 239 (27) 1.0 (0.8-1.2) 1.0 (0.8-1.3)
Moshi Rural 440 (82) 95 (18) 1.6 (1.2-2.1) 1.3 (0.9-1.8)
Rombo 194 (76) 62 (24) 1.1 (0.8-1.5) 0.8 (0.5-1.1)
Same 202 (85) 36 (15) 2.0 (1.3-2.9) 1.3 (0.9-2.0)
Mwanga 133 (8o) 33 (20) 1.4 (0.9-2.1) 1.1 (0.7-1.8)
TB classification
New 1779 (77) 533 (23) 1
Retreatment 104 (76) 33 (24) 0.9 (0.6-1.4)
Other/transferred in 245 (76) 75 (23) 1.0 (0.7-1.3) ns
TB diagnosis
Smear-pos. PTB 912 (81) 214 (19) 1 1
Smear-neg. PTB 813 (76) 262 (24) 0.7 (0.6-0.9) 0.7 (0.6-0.9)
EPTB 403 (71) 165 (29) 0.6 (0.5-0.7) 0.6 (0.5-0.7)
HIV status
Negative 753 (81) 175 (19) 1 1
Positive 626 (74) 221 (26) 0.7 (0.5-0.8) 0.7 (0.5-0.9)
Unknown 749 (75) 245 (25) 0.7 (0.6-0.9) 0.7 (0.6-0.9)
a Cured or treatment completed (definitions WHO1).
b Treatment failures, defaulters, deaths, transferred out, or lost to follow-up (definitions WHO1). 
c Univariate (unadjusted) ORs and 95% CIs were calculated for patients with successful treatment 
outcome vs. those with unfavourable treatment outcome; the reference category was successful treatment 
outcome.
e Multivariate (adjusted) ORs and 95% CIs were calculated for patients with successful treatment outcome 
vs. those with unfavourable treatment outcome; the reference category was successful treatment 
outcome. Only variables that were significant in univariate analysis have been included in the multivariate 
logistic regression analysis.
OR = odds ratio; CI = confidence interval; DOT = directly observed treatment; ns = not significant; TB = 
tuberculosis; PTB = pulmonary TB; EPTB = extra-pulmonary TB; HIV = human immunodeficiency virus.
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DOT and those on facility-based DOT were found (respectively 95% and 97% 
after 2 months, and 99.5% and 99.5% after 5 months).
Evaluation of unfavourable treatm ent outcom es
A total of 256 (9%) patients died. In 0.2% (n=5) treatment failed, 0.4% (n=11) 
defaulted, 10% (n=273) were transferred out, and 3% (n=96) were lost to 
follow-up. Nine percent (148/1646) of the patients on comm unity-based DOT and 
10% (108/1123) of the patients on facility-based DOT died during treatment (OR 
0.9; 95% CI 0.7-1.2). Thirteen percent of HIV-positive patients (111/847) and 8% of 
HIV-negative patients and patients with an unknown HIV-status (145/1922) died 
(OR 1.9; 95% CI 1.4-2.4). Six percent of patients with smear-positive pulmonary 
TB (65/1126) and 12% of patients with smear-negative pulmonary TB or 
extrapulm onary TB (191/1643) died (OR 0.5; 95% CI 0.3-0.6). All of the five 
patients who failed to respond to treatment had smear-positive pulmonary TB; 
two received comm unity-based DOT and three facility-based DOT. Four had an 
unknown HIV status and one was HIV-positive. Eight of the 11 defaulters were on 
comm unity-based DOT. Forty-two percent (n=115) of the 273 patients who were 
transferred out of the region chose community-based DOT and the remaining 
58% (n=158) chose facility-based DOT. Thirty-six (38%) patients who were lost to 
fo llow-up but did not com ply with the definition of defaulter (n=96) received 
comm unity-based DOT and 63% (n=60) facility-based DOT.
Discussion
In this study, higher treatment success rates were observed in patients who 
opted for comm unity-based DOT than in patients who opted for facility-based 
DOT; sim ilar cure rates were found in smear-positive pulmonary TB patients on 
com m unity or facility-based DOT. The results from this observational, non-exper­
imental study confirm findings from earlier studies that were conducted in 
experimental settings in Tanzania,45 other Sub-Saharan countries9-11 and 
non-African countries,12-14 in which community-based DOT provided by comm unity 
health workers,1314 com m unity volunteers4912 or fam ily members51011 proved at 
least as effective as facility-based DOT. Such results encourage the involvement
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of the com m unity in the delivery of supervised TB treatment, a strategy that is 
readily accepted by patients691315 and has been shown to be cost-effective.16-21 In 
Tanzania, comm unity-based DOT reduced the total cost of treating a TB patient 
by 35% compared to facility-based DOT.16
The fact that more patients on facility-based DOT were lost to fo llow-up than 
patients who chose comm unity-based DOT suggests that community-based 
DOT does not increase the risk of patients being lost to NTLP control. This, 
however, will need to be reassessed in the years to come. Concerns have been 
raised that community-based DOT as prescribed by the PCT approach is applied 
increasingly less rigorously: patients are sent home w ithout identification of a 
treatment supporter, opting for self-adm inistered therapy instead (personal 
communication with RTLC and DTLCs). The gradual shift from community-based 
DOT to self-adm inistered therapy is not desirable in settings with insufficient 
resources to monitor treatment adherence.22
The present study revealed some factors that influence the choice for community or 
facility-based DOT. The most important of these was district of residence: 
facility-based DOT was more common in Hai District than in the other districts. This 
could be explained by the presence of the national TB referral hospital in Hai District, 
where it is the policy to admit patients during the first 2 months of TB treatment. 
Women and children were more likely than men to opt for community-based DOT. In 
the Kilimanjaro Region, women are the main caregivers for their children and families, 
and are occupied with looking after the home. Community-based DOT may therefore 
be perceived as interfering less with daily activities than facility-based DOT. 
Retreatment cases and patients with smear-positive TB were less likely to receive 
community-based DOT. As these cases are regarded as significant threats to public 
health, the policy for such patients may tend towards hospital admission and 
facility-based DOT rather than community-based DOT. Although the cornerstone of 
the PCT approach is the empowerment of patients to choose between community 
and facility-based DOT, external factors, such as district of residence, disease 
classification and physician's advice, also contribute to the decision. Except for 
smear-positivity, none of the factors that contributed to the choice of type of DOT 
were independently associated with treatment outcome.
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The data presented here should be interpreted with caution. A lthough the TB 
registers provided nearly complete data for most outcome parameters of this 
study, TB cases in the Kilimanjaro Region are still registered manually, and the 
data are therefore sensitive to errors in documentation and interpretation. The 
TB registers did not provide information about whether patients on facility-based 
DOT were in- or out-patients, and it was not documented whether in-patients 
continued to be on facility-based DOT throughout treatment or whether they 
shifted to comm unity-based DOT at a later stage of treatment. Some in-patients 
may have been lost to follow-up after discharge, which could explain the relatively 
large proportion of patients on facility-based DOT who were lost to fo llow-up as 
compared to patients on comm unity-based DOT. Finally, uncertainties about the 
correctness of TB diagnosis in cases of smear-negative TB, and the true value of 
‘completed treatment' as an internationally used indicator for treatment success, 
raise doubts about the usefulness of treatment outcom es in studies that evaluate 
com m unity and facility-based DOT.
In conclusion, th is study showed that, in terms of treatment outcomes, com m u­
nity-based DOT is at least as effective as facility-based DOT in a PCT strategy 
that allows patients to choose between the two.
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#Introduction
One-third of the world population is infected with Mycobacterium tuberculosis 
(MTB) and hence at risk of developing active tuberculosis (TB). Each year 8.8 
million patients are newly diagnosed with active TB and 1.6 million patients die of 
TB. The rapid spread of the human im m unodeficiency virus (HIV) has fuelled the 
TB epidemic, especially in Sub-Saharan Africa, where 28% of TB patients are 
HIV-positive.1 The current first-line treatment for TB is a multidrug regimen 
consisting of rifampicin, isoniazid, pyrazinamide and ethambutol (RHZE). It must 
be taken for at least 6 months to achieve high cure rates (more than 95% in 
experimental settings).
Problem s with current tuberculosis treatm ent
There are several major problems associated with the currently available TB 
treatment. First, the duration and com plexity of treatment result in non-adherence 
to treatment. This leads to suboptimal response (failure and relapse), the 
emergence of resistance, and continuous spread of the disease.2 Second, 
adverse events in response to TB drugs are common and contribute to the 
problem of non-adherence.23 Third, the increasing incidence of multidrug- 
resistant (MDR; resistance to at least rifampicin and isoniazid) and extensively 
drug-resistant (XDR; MDR resistance plus resistance to a fluoroquinolone and an 
aminoglycoside) TB is a serious concern. Resistant TB occurs in the presence of 
partially suppressive drug concentrations that enable replication of bacteria, the 
formation of mutants, and overgrowth of w ild-type strains by mutants (selective 
pressure).4 The prevalence of MDR TB in new TB cases ranged from 0% in some 
Western European countries to more than 22% in Azerbaijan (2002-2007 survey); 
14 of 72 participating countries reported an MDR TB prevalence of more than 
5%.5 Second-line drugs for drug-resistant TB are not available everywhere and 
are less effective, more toxic, and require longer use than first-line drugs.6 Fourth, 
coinfection of TB and HIV is a problem by itself. Combined treatment of TB and 
HIV involves a high pill count with associated adherence problems, overlapping 
toxicity profiles of the antiretroviral and TB drugs, drug interactions between 
rifampicin and the antiretroviral protease inhibitors, and the risk on the immune 
reconstitution syndrom e.7 Fifth, prophylactic therapy of latent TB (TB infection
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w ithout symptoms) with isoniazid is also associated with problems of non­
adherence.8 Attempts to shorten treatment with alternative drugs resulted in 
severe adverse events.9-11
The World Health Organization (WHO) has developed the directly observed 
therapy short course (DOTS) strategy to optimize response and adherence to TB 
treatment. However, DOTS is labour-intensive and expensive. It causes a high 
burden on public health programmes, especially in developing countries with 
limited human resources.12 In addition, TB diagnosis in the DOTS strategy is 
based on sputum microscopy, rather than sputum culture.13 Only advanced 
pulmonary TB is detected by sputum m icroscopy and it requires qualified 
m icroscopists.14 Consequently, TB detection rates are suboptimal and resistant 
MTB strains are not detected.1415
Clearly, there is an urgent need to improve treatment by either enhancing the 
application of existing agents or introducing new drugs. Potential new agents 
should reduce treatment duration, have an acceptable to lerability profile, be 
active against MDR/XDR TB, be of use in HIV-infected patients with TB, and be 
active against latent TB (Table 1). The aim of this article is to review the challenges 
of developing new TB drugs, to present an up-to-date and critical evaluation of 
new agents in the phase of clinical testing, and to suggest ways forward to 
improve TB treatment.
Challenges of developing new TB drugs
The rapid development of new TB drugs has been hampered by several obstacles. 
First of all, the TB drug market is associated with insufficient profit opportun ity or 
investment return to instigate pharmaceutical industries to develop new drugs. 
The cost of developing a new drug is estimated at $115 to $240 m illion.16 To be 
profitable, market prices of new drugs should be relatively high, whereas the 
cost of the standard regimen is only about $11 per patient.14 In response to the 
reluctance of pharmaceutical industries, governments and nongovernmental 
organizations have started to invest in TB drug research and development. In the 
1990s, the United States Centers fo r Disease Control and Prevention (CDC) 
established the Tuberculosis Trials Consortium (TBTC). In 2000, private and
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Table 1 Required properties of new TB drugs
What a new drug should do Characteristic(s) required
Simplify treatment or reduce Strong (early) bactericidal and sterilizing
treatment duration activity
Low pill count, fixed-dose combinations 
Allow for intermittent therapy
Have an acceptable toxicity profile Low incidence of treatment-limiting adverse 
events
No overlapping toxicity profile with other TB 
drugs
Be active against MDR/XDR TB No cross-resistance with first-line drugs
Be useful in HIV-infected Minimal interactions with antiretroviral drugs
patients with TB No overlapping toxicity profile with 
antiretroviral drugs
Be active against latent TB Activity against dormant bacilli 
Favourable toxicity profile
TB = tuberculosis; MDR = multidrug-resistant; XDR = extensively drug-resistant; HIV = human 
immunodeficiency virus.
public sector partnerships formed the Global Alliance for TB Drug Development 
(GATB), a non-profit venture that supports the discovery and development of 
cost-effective new drugs.12 Various other research consortia are testing new 
drugs in preclinical and clinical trials. Large funding agencies, such as the 
European & Developing countries Clinical Trials Partnership (EDCTP) and the Bill 
& Melinda Gates foundation are supporting these initiatives.
A second challenge in TB drug development is the d ifficu lty to identify new 
com pounds with activ ity against MTB. Regimens against TB should kill both the 
rapidly growing mycobacteria (bactericidal activity) and the persisting 
mycobacteria in lesions (sterilizing activity).17 The molecular mechanisms 
responsible for mycobacterial dorm ancy (i.e., mycobacteria in a state of low 
metabolic activity and not form ing colonies), persistence (i.e., drug-susceptible
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and drug resistance are not yet fu lly understood.8 The deciphering of the 
mycobacterial genome in 1998 has been of help in elucidating regulatory 
mechanisms of metabolic pathways and thereby revealing new drug targets.1819 
A next challenge rises with the evaluation of new compounds, as there are 
currently no animal models available that predict with accuracy the required 
treatment duration with newly identified com pounds.20 The guinea pig model is 
being explored as an alternative for the mouse model since it resembles TB 
pathology in humans more closely.21
The phase of clinical testing of new TB drugs is tim e-consum ing, as the current 
‘gold standard' to assess efficacy of TB regimens in phase III clinical trials is the 
relapse rate 2 years after completing treatment. In phase II clinical trials, the 
sputum culture conversion rate after 2 months of treatment is used as a surrogate 
marker for relapse rate, but the value of th is surrogate marker is controversial.2223 
Several other surrogate markers are under evaluation.23 Large sample sizes are 
needed in phase III clinical trials to compare the effective standard regimen to a 
new regimen, even in trials that use a noninferiority design. This contributes to 
the length of the TB drug development process.24
Another challenge is the scarcity of trial sites with sufficient research capacity to 
conduct clinical trials with large sample sizes. Trials should be performed in 
countries where the TB burden is highest, but the human and infrastructural 
capacity for perform ing large, h igh-quality phase III clinical tria ls is usually limited 
in these settings.24 Despite the challenges of TB drug development, studies are 
being conducted with higher doses of the rifamycins and several new drug 
candidates have reached the phase of clinical testing.
Old drugs revised: higher doses of rifamycins
Rifam picin
Rifampicin is considered to be the cornerstone in the current treatment of TB.25 
Its standard dose in TB treatment is 10 mg/kg of body weight, corresponding to 
600 mg in most populations. Results from studies with mice and early bactericidal 
activ ity (EBA) studies in which the fall in colony form ing units (CFU) during the
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first 2 days of treatment is studied suggest that the standard dose of rifampicin 
in TB treatment is at the lower end of the concentration-response curve.26-28
Mechanism of action
Rifampicin inhibits the p-subunit of the RNA polymerase, a multisubunit enzyme 
that transcribes bacterial RNA.25 Mycobacterial resistance to the rifamycins 
results from mutations in the rpoB  gene that codes for the p-subunit of the RNA 
polymerase.29 About 95% of mutations occur in a region of less than 100 bp of 
the rpoB  gene.30 The increasing prevalence of resistance to rifampicin and 
isoniazid (MDR TB) is a serious concern.5
Pharmacokinetics
The pharm acokinetics of rifampicin in adults treated with the licensed dose (10 
mg/kg of body weight) are shown in Table 2 and have been reviewed elsewhere.25 
In the 1960s and 1970s, the pharm acokinetics of higher single doses (up to 30 
mg/kg) and repeated doses (up to 16 mg/kg) of rifampicin in adults were 
assessed, showing nonlinear increases in exposure.3132 More recently, the phar­
m acokinetics of daily rifampicin at 13 mg/kg have been compared with 10 mg/kg 
in 50 Indonesian patients with pulmonary TB who were treated with the standard 
regimen (2 months of RHZE followed by 4 months of RH [2RHZE/4RH]).33 
Increasing the dose by 30% increased the peak concentration of rifampicin in 
plasma (Cmax) by 49%; the area under the plasma concentration-tim e curve (AUC) 
increased by 65%. AUC is an important parameter fo r concentration-dependent 
killers such as the rifamycins. It indicates total exposure to the drug over a certain 
time period. In a recent EBA study, a 71% increase in AUC was seen with a 67% 
increase in rifampicin dose from 12 to 20 mg/kg after 5 days of monotherapy.26 A 
higher dose of rifampicin is not likely to affect the pharm acokinetics of other TB 
drugs and antiretroviral drugs more strongly than the standard dose, as 
rifampicin's inductive effect on the cytochrome P450 (CYP450) enzyme system 
appears to be maximal at a daily dose of 300 mg.34
Pharmacodynamics and efficacy
The minimal inhibitory concentration (MIC) of rifampicin is 0.15 mg/L in broth 
culture.2535 Rifampicin exhibits concentration-dependent activ ity that correlates
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best with the AUC/MIC ratio, as was shown in the mouse m odel.2536 
Results from an efficacy study in mice predicted a one-third reduction in TB 
treatment duration when the rifampicin dose was increased by 50%.27 Only a few 
data are available on the efficacy of regimens based on a higher dose of rifampicin 
in humans. A short regimen of a high dose of rifampicin (1200 mg daily or every 
other day) with a high dose of isoniazid (900 mg) and streptomycin (1000 mg) 
daily yielded almost 100% sputum culture conversion after 3 months.37 All 
patients remained culture-negative fo r up to 1 year. Sixteen percent of patients 
relapsed after 12 to 24 months. If pyrazinamide was included in the regimen, 
treatment response might have improved, as pyrazinamide accelerates sputum 
culture conversion rates significantly.38 Another study in TB patients did not show 
a difference in efficacy between 600 mg or 750 mg rifampicin daily combined 
with 300 mg isoniazid for 20 weeks.39 Recently, the EBA of 1200 mg rifampicin 
daily was studied in 14 patients with pulmonary TB. The mean 2-day EBA was 
almost tw ice as high as that of 600 mg rifam picin.26
Safety and to lerability
Little is known about the to lerability  of higher than standard doses of rifampicin. 
Past attempts to use large interm ittent rather than daily doses of rifampicin were 
met with a high incidence of the flu-like syndrome. This was ascribed to the 
interm ittency of dosing rather than the size of the dose.25 Daily rifampicin at 13 
mg/kg was tolerated well by Indonesian patients.33 Grade 1 and 2 hepatotoxicity 
was more common in the higher-dose group (46% versus 20%, p=0.054), but 
none of the patients developed serious hepatotoxicity. Five days of rifampicin 
monotherapy of 1200 mg was tolerated well by patients in the EBA study.26 Higher 
doses of rifampicin did not cause to lerab ility  problems in patients with brucellosis 
(900 mg, 45 days) or cutaneous leishmaniasis (1200 mg, divided in two doses, 
28 days).4041 The to lerability of rifampicin in other diseases was reviewed in 650 
patients; it was good with doses up to 1200 mg, but less favourable with doses 
of 1800 mg.42
Discussion
Available data suggest that higher daily doses of rifampicin can shorten TB 
treatment. The maximum tolerable dose of rifampicin should be assessed when
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administered alone and in combination with currently available drugs. The EBA 
of a range of higher doses of rifampicin given alone and in combination should 
be investigated more extensively, and phase II and III clinical trials with higher 
than standard doses of rifampicin in different multidrug regimens should be 
performed. Rifampicin is cheap and w idely available, and physicians have 
experience with this drug. If increasing the dose of rifampicin proves to be safe 
and effective, th is intervention could be implemented broadly and quickly. 
Drawbacks of rifampicin are its inductive effect on the CYP450 enzyme system, 
which is involved in the metabolism of many other drugs, and the increasing rate 
of mycobacterial resistance to rifampicin.
Rifapentine
Rifapentine (10 mg/kg) was approved for the treatment of pulmonary TB by the 
U.S. Food and Drug Administration (FDA) in 1998.43 It allows for interm ittent 
dosing at w ider intervals, which facilitates observed treatm ent.44 However, 
regimens with rifapentine and isoniazid once weekly in the continuation phase of 
treatment are slightly inferior to regimens with rifampicin and isoniazid twice 
weekly, especially in patients with cavitary TB.434546 A high rate of mycobacterial 
monoresistance to rifamycins was seen in HIV-infected patients treated with 
rifapentine and isoniazid.47 The use of rifapentine once weekly has therefore 
been restricted to HIV-negative pulmonary TB patients w ithout cavitation and 
with a negative sputum culture after the intensive phase of treatm ent.48 Higher 
than standard doses of rifapentine have shown the potency to shorten TB 
treatment in mice, especially when combined with moxifloxacin.49
Mechanism of action
Rifapentine is a cyclopentyl rifamycin that, like other rifamycins, inhibits 
mycobacterial RNA synthesis by binding to the p-subunit of DNA-dependent 
RNA polymerase.4448 Mutations in the gene coding for the p-subunit (rpoB) of the 
mycobacterial RNA polymerase lead to complete resistance to all rifam ycins.5051
Pharmacokinetics
The pharm acokinetic properties of rifapentine in standard dose in adults are 
summarized in Table 2 and described elsewhere.25'43'4452-58 When the dose of
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rifapentine was increased from 600 to 900 or 1200 mg in 35 TB patients, the AUC 
ncreased by 39% or 61%, respectively.59 Rifapentine induces the CYP450 enzyme 
system to a lesser extent than rifam picin.25 Rifapentine autoinduction -the 
phenomenon that induction of the CYP450 enzyme system also increases 
metabolism of the drug itself- was recently shown in a phase I study: rifapentine 
AUC decreased by 20% after 7 days of thrice-weekly rifapentine at 900 mg in 13 
healthy volunteers.60 Rifapentine (900 mg thrice-weekly) reduced the AUC of 
moxifloxacin (400 mg daily) by 17% in the same study.
Pharmacodynamics and efficacy
The MIC of rifapentine ranges from 0.02 to 0.125 mg/L, i.e., two to four times 
lower than that of rifam pin.5461-64 When adjusted for protein binding, the AUC/MIC 
ratio for rifapentine in standard dose is 76.6 (AUC/MIC ratio for rifampicin, 
70.8).36
Rifapentine is being evaluated with moxifloxacin as a companion drug. A higher 
dose of rifapentine (15 mg/kg) with moxifloxacin (100 mg/kg tw ice per day) in a 
once-weekly continuation-phase regimen in mice showed better sterilizing 
activ ity than once-weekly rifapentine (15 mg/kg) and isoniazid (75 mg/kg) or 
tw ice-weekly rifampicin (10 mg/kg) and isoniazid (75 mg/kg).65 A tw ice-weekly 
regimen in mice containing rifapentine (15 or 20 mg/kg), pyrazinamide (300 mg/ 
kg), and moxifloxacin (100 mg/kg), preceded by 2 weeks of daily rifampicin (10 
mg/kg), pyrazinamide (150 mg/kg), and moxifloxacin (100 mg/kg), resulted in 
stable cure after 4 months of treatm ent.49 Substitutions of rifampicin (10 mg/kg) 
by rifapentine (10 mg/kg) and of isoniazid (25 mg/kg) by moxifloxacin (100 mg/kg 
tw ice per day) in a daily standard regimen in mice lead to bacillus eradication 
rates tw ice as fast as the standard regimen.66 A recent study in mice showed that 
the main sterilizing com ponent in regimens containing rifapentine, moxifloxacin, 
and pyrazinamide is rifapentine, rather than moxifloxacin.67 An experiment in 
mice revealed a dramatic increase of bactericidal activ ity with increased 
rifapentine dose up to 80 mg/kg in a regimen of rifapentine, moxifloxacin (100 or 
400 mg/kg), and pyrazinamide (150 or 600 mg/kg), indicating the potential of 
higher doses of rifapentine to shorten TB treatm ent.68
The International Consortium for Trials of Chemotherapeutic Agents in 
Tuberculosis (INTERTB) is currently conducting the RIFAQUIN trial with
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moxifloxacin (400 mg) instead of isoniazid (300 mg) in the standard regimen and 
with rifapentine once weekly (20 mg/kg for 4 months) or tw ice-weekly (15 mg/kg 
for 2 months) in the continuation phase.
Rifapentine is also a candidate drug for latent TB. A once-weekly, 3-months 
regimen of rifapentine (15 mg/kg) plus either moxifloxacin (100 mg/kg) or 
isoniazid (75 mg/kg) was as active as 6 months daily isoniazid (25 mg/kg) in 
monotherapy in a mouse model for latent TB.55 A regimen of rifapentine (900 mg) 
plus isoniazid (900 mg) once weekly for 12 weeks was tolerated better than daily 
rifampicin (450 to 600 mg) plus pyrazinamide (750 to 1500 mg) fo r 8 weeks by 
patients with latent TB. The regimen protected well against active TB.69
Safety and tolerability
A study in 150 HIV-negative TB patients treated with either 600, 900 or 1200 mg 
rifapentine plus isoniazid at 15 mg/kg once weekly in the continuation phase, 
showed good to lerability  of the 900 mg dose and an insignificant trend towards 
more adverse events in the 1200 mg arm.70 In another study (35 patients), no 
association between the occurrence of adverse events and a higher dose of 
rifapentine (up to 1200 mg) was found.59 Two of 14 healthy volunteers developed 
adverse events (grade 2 hepatitis and a flu-like syndrome with rash) after treatment 
with daily moxifloxacin (400 mg) and thrice-weekly rifapentine (900 mg).60
Discussion
Increasing the dose of rifapentine could shorten TB treatment, especially in 
combination with moxifloxacin, and may be useful against latent TB as well. 
Rifapentine will cause fewer problems of drug-drug interactions than rifampicin. 
The optimum higher dose of rifapentine has not yet been defined. The start of 
renewed rifapentine registration trials with higher doses has been announced by 
Sanofi-Aventis (presentation D. Leboulleux at TBTC meeting, 16-17 May 2008, 
Toronto, Canada).
Rifabutin
Rifabutin is mainly used for the prevention and treatment of disseminated 
Mycobacterium avium  complex disease in patients with advanced HIV infection.71 
The MIC of rifabutin against rifabutin-susceptible MTB strains is <0.08 mg/L, 8
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times less than the MIC of rifampicin against the same strains.637273 In TB patients, 
the activity of rifabutin was not greater than that of rifam picin.7475 Furthermore, 
the occurrence of dose-related (> 450 mg) adverse events, such as polyarthralgia, 
uveitis, flu-like syndrome and hepatitis,7677 is likely to deter any investigation into 
the efficacy of higher than standard doses of rifabutin in TB treatment.
New drugs for TB treatment
Fluoroquinolones
The fluoroquinolones are a prom ising class of drugs for the treatment of TB.78 In 
particular, they are distributed broadly throughout the body, including within 
cells, which explains their efficacy against intracellular m ycobacteria.79-82 The 
fluoroquinolones are registered as second-line TB drugs.83-85 Moxifloxacin and 
gatifloxacin are candidates for shortening TB treatment, since they have the 
lowest MICs,3686-89 and greatest bactericidal activity, as expressed in the rate of 
fall in CFU count.89-92 The approved dose for moxifloxacin and gatifloxacin is 400 
mg/day.93 While the potential of moxifloxacin and gatifloxacin to shorten TB 
treatment is being investigated in clinical trials, a new generation quinolones, 
including the promising TBK 613, is being developed in preclinical research (M. 
Spigelman, presented at the 1st International Workshop on Clinical Pharmacology 
of Tuberculosis Drugs, Toronto, Canada, 2008).
Moxifloxacin
Mechanism of action
Moxifloxacin is a broad-spectrum 8-methoxy fluoroquinolone with activ ity against 
both gram-positive and gram-negative bacteria, including anaerobes.9495 It 
inhibits bacterial DNA gyrase, an enzyme that is essential for the maintenance of 
DNA supercoils, which are necessary for chromosomal replication.96-99 The 
development of mycobacterial resistance to fluoroquinolones has been described 
in MDR strains,100-102 and in strains from HIV-infected TB patients with a low CD4 
count.80103 Fluoroquinolone resistance is due to stepwise mutations in the 
quinolone resistance-determ ining region of the mycobacterial gyrA and gyrB 
genes.80 No cross-resistance with the first-line TB drugs has been shown,8090104
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but cross-resistance w ithin the group of fluoroquinolones was proved.80'105106 
A study in newly diagnosed TB patients showed higher rates of MTB resistance 
to fluoroquinolones in patients with prior exposure to fluoroquinolones than in 
patients who were fluoroquinolone naïve.104 Other studies did not find such an 
association.100101
Table 2 Pharm acokinetics of rifam picin, rifapentine, moxifloxacin & 
gatifloxacin
Drug (dose) Bio­
availability
(%)
AUC
(mg-h/L)
Cmax
(mg/L)
tmax (h) t1/2 (h) Plasma 
protein 
binding (%)
References
Rifampicin 
(10 mg/kg)
68 21.5 8-20 1.5-2.0 2-5 85 25, 31
Rifapentine 
(600 mg)
Unknown 319-394 10-18 4.8-9 13-20 97 43, 44, 48, 52, 
53, 58
Moxifloxacin 
(400 mg)
86 26.9-39.3 2.5-4.3
(5.9)b
1-2
(0.7)b
9.2-15.6 50 
(6.5)b
94, 108, 114
Gatifloxacin 
(400 mg)
96 30-51.3a 3.4
(3.7)b
1.5
(2.4)b
6.5-7.8
(5.0)b
20 108, 111, 114, 
133
AUC = Area Under the plasma concentration-time Curve; Cmax = peak plasma concentration; tmax = time 
to Cmax; t1/2 = half life; a In steady state; b Multiple doses in patients with pulmonary tuberculosis.
Pharmacokinetics
The pharm acokinetic properties of moxifloxacin in humans are summarized in 
Table 2. Moxifloxacin is metabolized by glucuronidation and sulfation (phase II 
metabolism) rather than by CYP450-mediated (phase I) metabolism.107 Up to 20% 
of moxifloxacin is excreted unaltered in urine and 25% in feces.94108 The AUC 
from 0 to 24 h (AUC0-24) of moxifloxacin decreased by 27 to 31% when co-adm in­
istered with rifam picin.107109 This could be due to induction of phase II metabolic 
enzymes (uridine diphosphatase, glucuronosyltransferase and sulfotransferase) 
by rifampicin.107 The clinical relevance of th is interaction is unknown.
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Pharmacodynamics and efficacy
In vitro studies with moxifloxacin show MICs of 0.25 to 0.50 mg/L.88'91'92110 The 
bactericidal activity of fluoroquinolones is generally considered to be concentra- 
tion-dependent,79111 although a recent report showed tim e-dependent killing as 
w ell.92 The ratio of AUC to MIC is thought to be the best predictor of fluoroqui­
nolone efficacy in gram-negative, fast-m ultip lying bacteria.8092111 It was shown in 
vitro and in vivo that the greatest bactericidal activity occurs at AUC/MIC ratios of 
100 to 125 or more.111 While it is unclear whether this also applies to the slowly 
m ultiplying MTB, this observation would suggest that moxifloxacin is the fluoro­
quinolone with greatest efficacy, followed by gatifloxacin (AUC/MIC ratios of 96 
and 68, respectively, derived from in vitro and in vivo work).80 Aside from the 
AUC/MIC ratio, the other important indicator of efficacy of concentration- 
dependent killers is the C /MIC ratio, which should be more than 8 to 12 for~ max' ’
effective killing of gram-negative bacteria.36111-113 Data adapted from a single- 
oral-dose study in healthy volunteers showed that the Cmax/M IC90 ratio of 
moxifloxacin (400 mg) is 8.6.36,114
In vitro studies and studies in mice showed enhanced bactericidal activ ity of 
moxifloxacin and isoniazid when co-adm inistered.8891115-117 Ethambutol adversely 
affected the activ ity of moxifloxacin in vitro: it reduced moxifloxacin efficacy by 
80%.115 Moxifloxacin (100 mg/kg) was able to reduce the time to culture conversion 
in mice by 2 months when replacing isoniazid in the standard 6-months 
regimen.118,119 This reduction was not found when moxifloxacin was either added 
to the standard regimen or when it replaced any of the other drugs. It is 
hypothesized that the superior activ ity of 2 months of rifampicin plus moxifloxacin 
plus pyrazinamide followed by 4 months of rifampicin plus moxifloxacin 
(2RMZ/4RM) to 2RHZ/4RH is caused by a synergistic activ ity of rifampicin, 
moxifloxacin and pyrazinamide or antagonistic activity of rifampicin, isoniazid 
and pyrazinamide.118
Moxifloxacin efficacy has also been shown in humans. EBA studies in newly 
diagnosed pulmonary TB patients showed comparable activity of moxifloxacin 
(400 mg) and isoniazid (300 mg or 6 mg/kg).120121 The VT50 (the time needed to kill 
50% of viable bacteria) of isoniazid was lower than that of both rifampicin and 
moxifloxacin. The EBA and VT50 of combined moxifloxacin and isoniazid did not
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differ significantly from the two drugs in monotherapy. Based on these results, 
no antagonistic effect of adding moxifloxacin to the standard, isoniazid-contain- 
ing regimen is expected, nor will it enhance the bactericidal activ ity of the 
regimen.122 The effect of replacing ethambutol with moxifloxacin in the standard 
regimen on the 2-months sputum culture conversion rate was analyzed in 277 
patients with pulmonary TB from African and North American sites.123 No 
difference in percentage of negative cultures after 2 months of treatment (71% 
and 71%) was found. However, more patients treated with moxifloxacin had 
negative cultures after 4 weeks of treatment than patients treated with ethambutol 
(37% versus 26%; p=0.05). A comparable study is ongoing in Brazil.124 The 
Gatifloxacin for TB Study Team (OFLOTUB) performed a phase II clinical trial in 
which ethambutol in the standard regimen was replaced by gatifloxacin, 
moxifloxacin, or ofloxacin.125 The regimen with moxifloxacin caused the fastest 
decrease in CFU during the early phase of a biexponential fall (in a nonlinear 
model that differentiates between quickly and slowly eliminated bacilli).125126 Both 
moxifloxacin and gatifloxacin accelerated bacillary elim ination significantly in the 
late phase. The percentage of negative sputum cultures after 2 months of 
treatment did not differ s ignificantly between the treatment groups (82% versus 
77% on solid medium and 40% versus 44% on liquid medium [in MGIT] for 
moxifloxacin versus gatifloxacin, respectively).125 Two-months sputum culture 
conversion rates have also been evaluated in a double-blind randomized 
controlled trial in which isoniazid in the standard regimen was replaced with 
moxifloxacin (TBTC study 28). Culture conversion after 8 weeks of treatment was 
achieved in 60% of patients treated with the moxifloxacin-containing regimen 
and in 55% of patients using isoniazid (J. Grosset, presented at the 1st International 
Workshop on Clinical Pharmacology of Tuberculosis Drugs, Toronto, Canada, 
2008). A multicentre three-armed REMoxTB trial in which the standard regimen is 
compared to (i) a regimen of 2RHZM/2RHM and (ii) a regimen of 2RMZE/2RM 
has recently started. The possib ility of com bining moxifloxacin with rifapentine, 
two agents with a long half-life, is explored in the RIFAQUIN trial (see section 
about rifapentine).49'65'115127 Finally, moxifloxacin could be of use in the treatment 
of latent TB. The combination of 3 months of once-weekly moxifloxacin and 
rifapentine was as effective as 6 months of isoniazid monotherapy in a mouse 
model for latent TB.128
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A single dose of moxifloxacin up to 800 mg was tolerated w ell.94’95114 Little is 
known about the long-term to lerability in TB patients. Moxifloxacin (400 mg, 
administered for an average of 6.3 months) was w ithdrawn in 4 of 38 TB patients 
because of a major adverse event (including nausea, vomiting, muscle pain, 
tremors, insomnia and dizziness), but no irreversible or fatal events occurred.129 
In another study, no toxic ity was experienced by patients who were treated with 
moxifloxacin, rifampicin, and isoniazid for 6 months.130 Prolongation of QT time 
has been seen in patients using moxifloxacin for a variety of other bacterial 
infections.93 In February 2008, Bayer distributed a ‘Dear Doctor' letter warning 
physicians about rare but severe hepatological and derm atological adverse 
events associated with moxifloxacin. In July 2008, the European Medicines 
Agency (EMEA) sent out a review on the association of moxifloxacin and 
hepatological problems. It was concluded that the benefits of moxifloxacin in 
treatment of respiratory tract infections outweigh the risks, but its use should be 
restricted.131
Discussion
Moxifloxacin is a prom ising drug that could shorten TB treatment. However, the 
optimal dose of moxifloxacin in TB treatment must be evaluated with respect to 
the recently observed decrease of AUC0-24 when coadministered with rifampicin. 
Furthermore, concerns have been raised about the development of mycobacterial 
resistance against fluoroquinolones and the association between resistance and 
the w idespread use of fluoroquinolones for other infections.132 The efficacy 
studies in mice and humans revealed am biguous results. While culture conversion 
rates increased in mice when isoniazid was replaced by moxifloxacin in the 
standard regimen, this was not shown in humans, nor did moxifloxacin show 
better early bactericidal activ ity than isoniazid in humans. Replacing ethambutol 
by moxifloxacin in the standard regimen in humans also did not improve culture 
conversion rates convincingly. The optimal m oxifloxacin-including regimen has 
yet to be found. Finally, the adverse events of moxifloxacin require extended 
evaluation.
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Mechanism of action
Like the other fluoroquinolones, gatifloxacin blocks the bacterial DNA gyrase, 
thereby preventing chromosomal replication.96-99 Gatifloxacin and moxifloxacin 
show cross-resistance.80'105'106 The mechanism of resistance is described in the 
section on moxifloxacin.
Pharmacokinetics
Table 2 shows the pharm acokinetic properties of gatifloxacin. The elimination 
route of gatifloxacin is predom inantly renal; 77% of the oral dose is excreted in 
urine.114 The elim ination time of gatifloxacin was prolonged in 22 healthy 
volunteers who received a single dose of a fixed dose combination of rifampicin, 
isoniazid, pyrazinamide, and gatifloxacin (600, 300, 1600, and 400 mg, 
respectively). It led to a 14% increase in AUC of gatifloxacin (and a 19% reduction 
of rifampicin AUC).134
Pharmacodynamics and efficacy
The MICs of gatifloxacin ranges from 0.2 to 0.5 m g/L,36'87'110'135'136 resulting in AUC/ 
MIC90 ratios of 60 to 68 and Cmax/M IC90 ratios of 6.8 to 8.4 (adapted from results 
of studies in mice and healthy volunteers).3680 In vitro studies and studies in mice 
showed improved activity of rifampicin and isoniazid when gatifloxacin was 
added and even more when the regimen also included pyrazinamide.137-139 
Ethambutol interfered with gatifloxacin in vitro as it did with moxifloxacin: it 
caused a remarkable increase in the MIC90 of gatifloxacin.139 When gatifloxacin 
(100 mg/kg) was combined with ethionamide (75 mg/kg) and ethambutol (100 
mg/kg) in mice, greater bactericidal activ ity was achieved than with a 20 mg/kg 
rifampicin plus 25 mg/kg isoniazid regimen.86 The addition of pyrazinamide (150 
mg/kg) to gatifloxacin/ethionam ide/etham butol did not improve activity, but 
yielded stable cure after 12 weeks of treatment and 8 weeks of observation, 
whereas the regimen w ithout pyrazinamide did not.140
A multicentre trial of the OFLOTUB consortium  is enrolling patients at five African 
sites. It compares the efficacy and tolerability of a 4-months regimen of 2 months 
of rifampicin plus isoniazid plus pyrazinamide plus gatifloxacin followed by 2 
months of rifampicin plus isoniazid plus gatifloxacin (2RHZG/2RHG) to the
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standard 2RHZE/4RH regimen.124 The OFLOTUB consortium  also evaluated the 
fall in CFU count in patients enrolled in the same trial (see section on 
moxifloxacin).125
Safety and to lerability
A single dose of gatifloxacin (400 mg) was tolerated well.114 Only mild adverse events 
were reported in patients with respiratory tract infections who were treated with 
gatifloxacin at 100 to 400 mg/day for 5 to 12 days.141 An increased risk of dysglycaemia 
was described in elderly patients using gatifloxacin for a variety of bacterial 
infections.142 Elderly patients with hypoglycaemia or hyperglycaemia were 4 or 17 
times more likely to have used gatifloxacin than controls. The results of this study 
forced the OFLOTUB study group to tighten their exclusion criteria and to strengthen 
their monitoring on dysglycaemic events.124 No dysglycaemic events related to 
gatifloxacin use were reported in an earlier study that focused on the fall in CFU.125
Discussion
Gatifloxacin has many of the favourable features of moxifloxacin. However, the 
risk of mycobacterial resistance development and the recently found association 
between gatifloxacin and dysglycaem ic events are concerns. In vitro studies and 
studies in mice revealed contradictory results. While ethambutol reduced 
gatifloxacin activ ity in vitro, the combination of ethambutol, ethionamide, and 
gatifloxacin was highly effective in mice.
Diarylquinolines
Diarylquinolines have been identified in a process of screening various 
com pounds for potential anti-TB activity.143 The most active diarylquinoline 
(TMC207, also called R 207910 or Compound J) is currently being evaluated in 
phase II clinical trials at a dose of 400 mg/day.124
TM C 207
Mechanism of action
TMC207 inhibits the mycobacterial ATP synthase enzyme.143-144 TMC207 has 
shown equal activ ity in susceptible and MDR strains. No cross-resistance with 
available drugs is expected since the target of the diarylquinolines differs from
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that of the currently available TB drugs.143-145 Mycobacteria that are resistant to 
TMC207 in vitro show mutations in the atpE  gene, which encodes subunit c of 
ATP synthase.146
Pharmacokinetics
Oral administration with a meal results in a twofold increase of serum TMC207 
concentrations.124 The C is reached after 5 h; the half life is long: about 24 h inmax
humans. The pharm acokinetics of TMC207 show linearity with dose.143 TMC207 
is metabolized by the CYP450 3A4 enzyme to an active W-monodesmethyl 
metabolite (M2).147 Rifampicin reduces TMC207 plasma concentrations by 50%; 
however, a recent study in mice showed significant activ ity of TMC207 even with 
a 50% reduction in exposure, indicating that the relevance of th is interaction is 
questionable.124148 No drug-drug interactions were observed between TMC207 
and isoniazid plus pyrazinamide (K. de Beule and R. van Heeswijk, presented at 
the 1st International Workshop on Clinical Pharmacology of Tuberculosis Drugs, 
Toronto, Canada, 2008). Steady-state concentrations in humans take more than 
7 days to establish due to the extensive tissue d istribution of TMC207.124
Pharmacodynamics and efficacy
In vitro studies show MICs ranging from 0.030 to 0.120 ug/ml in both fully susceptible 
and MDR strains.143149 The in vitro activity of TMC207 did not increase with increasing 
drug concentration, suggesting tim e-dependent rather than concentration- 
dependent killing. The activity of TMC207 is limited to mycobacterial species only.143 
Treatment with TMC207 (25 mg/kg), isoniazid (25 mg/kg), and pyrazinamide (150 
mg/kg), and with TMC207, rifampicin (10 mg/kg), and pyrazinamide yielded 100% 
negative lung cultures in mice after only 2 months of treatment. When any of the 
drugs in the standard regimen was replaced with TMC207 (25 mg/kg), the 
bactericidal activ ity improved.143 Regimens based on the standard TB drugs and/ 
or moxifloxacin that contained both pyrazinamide and TMC207 were more active 
than regimens w ithout these two drugs. A 2-months regimen of once-weekly 
TMC207 (125 mg/kg), pyrazinamide (300 mg/kg) and rifapentine (15 mg/kg) was 
more active than rifampicin (10 mg/kg), isoniazid (25 mg/kg), and pyrazinamide 
(150 mg/kg) five times per week.150 These results suggest synergistic activ ity of 
TMC207 and pyrazinamide in mice.151
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The guinea pig model was used to demonstrate sterilizing activ ity of TMC207. 
Almost complete eradication of primary and secondary lung lesions was achieved 
after 6 weeks of TMC207 monotherapy (15 mg/kg), whereas the standard regimen 
had limited effect.152
An EBA study was done in which patients with pulmonary TB received various 
doses of TMC207, rifampicin, or isoniazid in monotherapy fo r 7 days. The EBA 
of both rifampicin and isoniazid was better than of TMC207. Only a dose of 400 
mg TMC207 showed an EBA between days 4 and 7 of the same magnitude as 
that of rifampicin and isoniazid in the same period.147 Because of the pharma­
cokinetic interaction between rifampicin and TMC207, the primary focus in the 
development of TMC207 is now on regimens w ithout rifampicin. Recently, a 
multicentre phase II study in 200 patients with MDR TB was started in which a 
standard second-line, rifampicin-free regimen is compared with the same 
regimen plus TMC207.124
Safety and tolerability
No serious adverse events were reported in single-dose (up to 700 mg) and 
multiple-dose (up to 400 mg) studies in healthy, male volunteers.153 In the EBA 
study, no adverse events related to the study drugs were encountered.124147
Discussion
TMC207 is a new, promising compound that has greater bactericidal activ ity than 
the standard first-line regimen in mice. It is active in susceptible and MDR strains. 
However, the EBA of TMC207 in humans is not as good as that of rifampicin and 
isoniazid. The variability of serum TMC207 concentrations with food intake is a 
disadvantage. TMC207 could be of use in rifampicin-free regimens against MDR 
and XDR TB. Interactions between TMC207 and rifapentine, another agent with a 
long half life, should be investigated.
Nitroimidazopyrans
The nitroim idazopyrans have been derived from the bicyclic nitroim idazofurans 
that were orig inally developed for cancer chemotherapy but also exhibited 
activ ity against actively growing and dorm ant MTB.154155 The com pounds are 
structurally related to metronidazole.155156 PA-824 (a nitroim idazo-oxazine) and
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OPC-67683 (a dihydroim idazo-oxazole) are currently being investigated in 
clinical trials.157
PA-824
Mechanism of action
PA-824 is a prodrug that needs the mycobacterial glucose-6-phosphate 
dehydrogenase (FDG1) or its cofactor, coenzyme F420, to be transform ed into an 
active form .155158 Activated PA-824 inhibits the synthesis of proteins and cell wall 
lipids. PA-824 activity is limited to MTB complex.155159 PA-824 is active in 
susceptible and resistant MTB strains. No cross-resistance with standard TB 
drugs has been observed.155 Mutations in the mycobacterial genes fbiA, fbiB, and 
fbiC  lead to impaired coenzyme F420 synthesis and therefore resistance to 
PA-824.160161 Mutations in the Rv3547 gene, encoding a protein with unknown 
function, have been described in PA-824 resistant strains. Complementing these 
mutants with intact Rv3547 fully restored the ability of the mutants to metabolize 
PA-824. This suggests mediation of a highly specific protein, next to FGD1 and 
coenzyme F420, in PA-824 activity.158
Pharmacokinetics
Serum PA-824 concentrations in mice are not influenced by coadministration of 
rifampicin, isoniazid, and pyrazinamide in various combinations, and PA-824 
does not influence concentrations of the latter drugs in serum.162 PA-824 is 
currently being investigated in phase I clinical trials under the auspices of the 
GATB. Studies in healthy volunteers showed a half-life of about 18 h and a time 
to reach C of 4 to 5 h. About 65% of PA-824 is excreted in urine and 26% inmax
feces.124
Pharmacodynamics and efficacy
In vitro studies showed MICs of PA-824 against fu lly susceptible and MDR strains 
ranging from 0.015 to 0.25 jug/ml. PA-824 activ ity is concentration-depend-
ent.155,163,164
The bactericidal activ ity of PA-824 (25 to 50 mg/kg) was comparable to that of 
isoniazid (25 mg/kg) in mice and guinea pigs,155163-165 and to those of rifampicin 
(20 mg/kg) and moxifloxacin (100 mg/kg) in mice.163 PA-824 showed greater
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activity than isoniazid and moxifloxacin in vitro and in mice, and comparable 
activ ity to combination therapy with rifampicin and isoniazid.163-164-166 PA-824 (100 
mg/kg) has been incorporated in the standard regimen in mice to evaluate its 
potential to shorten treatment duration. Only the regimen in which isoniazid was 
replaced with PA-824 achieved faster lung culture conversion and a lower CFU 
count after 2 months of treatment than the standard regimen. However, relapse 
rates were the same in these regimens.162 The sterilizing activ ity of a regimen 
containing PA-824 (100 mg/kg), moxifloxacin (100 mg/kg), and pyrazinamide 
(150 mg/kg) was recently found to be better than that of rifampicin (10 mg/kg), 
isoniazid (25 mg/kg), and pyrazinamide (150 mg/kg) in mice, indicating that 
PA-824 could be incorporated in rifampicin-free regimens to treat MDR TB.167 
PA-824 (100 mg/kg) was highly active in a mouse model for latent TB when 
combined with moxifloxacin (100 mg/kg).128 An extended EBA study in humans 
with daily PA-824 doses of 200 to 1200 mg over 14 days is ongoing in South 
Africa. Results are expected soon (M. Spigelman, presented at the 1st International 
Workshop on Clinical Pharmacology of Tuberculosis Drugs, Toronto, Canada, 2008).
Safety and tolerability
Single PA-824 doses ranging from 50 to 1500 mg were tolerated well by healthy 
volunteers, but multiple doses of 1000 mg were associated with a moderate, 
reversible increase in creatinine. This renal effect of PA-824 was found to be of 
insignificant clinical relevance in consecutive studies (M. Spigelman, presented 
at the 1st International Workshop on Clinical Pharmacology of Tuberculosis 
Drugs, Toronto, Canada, 2008).
Discussion
In mice, PA-824 seems most prom ising in regimens w ithout isoniazid. However, 
no regimen in which PA-824 was combined with the standard, first-line TB drugs 
in mice has convincingly shown the potential of shortening treatment duration. 
No additive or synergistic activ ity of PA-824 with the first-line drugs has been 
shown. PA-824 could be developed for the treatment of latent TB together with 
moxifloxacin, since the combination was highly active in a mouse model for latent 
TB. Its activity against drug-susceptible and drug-resistant MTB strains must be 
evaluated in regimens with second-line (or new) TB drugs.
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Mechanism of action
OPC-67683 is a mycolic acid biosynthesis inhibitor.168 While isoniazid inhibits the 
synthesis of all mycolic acid subclasses, OPC-67683 inhibits methoxy and 
ketomycolic acid synthesis only.169 OPC-67683 has to be activated by MTB to 
exert its activity. Mutations in the mycobacterial Rv3547 gene found in OPC-67683 
resistant MTB strains suggest that this gene codes for the key enzyme in 
activating OPC-67683 (as well as PA-824).169-170
Pharmacokinetics
Studies in healthy volunteers showed a more than dose-proportional increase in 
systemic exposure to OPC-67683 with a stepwise increase of the dose from 5 to 
400 mg.124 Absorption rates were higher when OPC-67683 was administered with 
a high fat meal. OPC-67683 was consecutively analyzed in a different 
administration formula. This improved system ic absorption.124 The newer formula 
is used in ongoing evaluations of OPC-67683. OPC-67683 does not affect the 
activity of liver microsome enzymes, nor is it affected by activated liver enzymes.169 
Interactions with drugs that are metabolized by these enzymes are therefore not 
expected.
Pharmacodynamics and efficacy
The MICs of OPC-67683 are equal in drug-susceptib le and -resistant MTB strains, 
and range from 0.006 to 0.024 ug/m l.168169 OPC-67683 exhibits concentration-de­
pendent activ ity also against intracellular MTB.169171
The in vitro intracellular activ ity of OPC-67683 was better than that of isoniazid 
and PA-824 and was as good as that of rifam picin.169 OPC-67683 showed 
sterilizing activity that was superior to isoniazid and equal to rifampicin in an in 
vitro model of drug-tolerant MTB, representing sem idormant bacilli.171 No 
antagonism of OPC-67683 with rifampicin, isoniazid, ethambutol, and 
streptomycin was shown in vitro .169
In mice, a regimen of OPC-67683 (2.5 mg/kg), rifampicin (5 mg/kg) and 
pyrazinamide (100 mg/kg) achieved faster eradication of bacilli than the standard 
RHZE regimen (5, 10, 100, and 100 mg/kg, respectively). Whereas no 
mycobacterial colonies were detected after 4 months of treatment with the OPC-
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67683-containing regimen, colonies were still detected after 6 months of 
treatment with the standard regimen.169
The EBA of 400 mg OPC-67683 in patients with pulmonary TB was low during the 
first 4 days. From day 4 onwards, a significant decrease in CFU was seen. This 
activ ity is currently explored in an extended (14 days) EBA study.124
Safety and to lerability
OPC-67683 in multiple doses up to 400 mg was tolerated well by healthy 
volunteers. No serious adverse events were reported.124
Discussion
OPC-67683 is a promising new TB drug with bactericidal and sterilizing activity 
in vitro and in mice. It could be useful in treatment of MDR and XDR TB. Its optimal 
formulation and its role in TB treatment in humans still need to be established. 
The low EBA is not favourable.
Diamines
A library of more than 60,000 com pounds was generated by synthesizing 
ethambutol analogues with 1,2-diamine pharm acophore.172-174 So far, the most 
prom ising diamine candidate from this library for TB treatment is SQ109.174
SQ109
Mechanism of action
SQ109 inhibits mycobacterial cell wall synthesis; the exact target is not yet 
known.172 Since resistance rates to SQ109 are low, it is thought that two 
mycobacterial gene changes are needed to result in resistance. Therefore, 
SQ109 may have more than one than one target in MTB.124
Pharmacokinetics
SQ109 undergoes a first-pass step in the liver before it enters the systemic 
circulation. Liver m icrosomes convert SQ109 in four predom inant metabolites. 
CYP2D6 and CYP2C19 enzymes are involved in SQ109 metabolism; CYP3A4 has 
little effect on SQ109.175 It has been suggested that SQ109 is a prodrug that 
needs activation by mycobacterial CYP enzymes.172 Results from a recent
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drug-drug interaction study in rats suggest that SQ109 induces its own 
metabolism.176 SQ109 binding to plasma proteins ranges from 6 to 23% in 
humans, mice, rats and dogs.175 Binding to tissue proteins is higher than that to 
plasma proteins.172 SQ109 has a long half-life (61 h) in humans.177
Pharmacodynamics and efficacy
The MICs of SQ109 ranged from 0.16 to 0.64 mg/L in susceptible and drug-resistant 
MTB isolates, including etham butol-resistant strains.124172 SQ109 also exhibits 
bactericidal activity w ithin macrophages.173'174178 Its activ ity is concentration- 
dependent.178
Synergistic activity was shown in vitro between SQ109 and isoniazid and 
especially rifampicin. Synergy was even present in rifam picin-resistant strains. 
Streptomycin had an additive effect on SQ109 activity; ethambutol and 
pyrazinamide had no effect on the activity of SQ109.172 Four weeks of monotherapy 
with SQ109 (0.1 to 25 mg/kg) in mice resulted in a reduction of mycobacterial 
load in spleen and lungs that was comparable to the effect of treatment with 
ethambutol (100 mg/kg) but less than that of treatment with isoniazid (25 mg/ 
kg).178 When ethambutol (100 mg/kg) was substituted for by SQ109 (10 mg/kg) in 
an 8-weeks regimen of rifampicin (20 mg/kg) and isoniazid (25 mg/kg), with or 
w ithout pyrazinamide (150 mg/kg), in mice with chronic TB, the mycobacterial 
load was 1.5 log10 lower than with the standard RHZE regimen.179 
Safety and tolerability
No adverse events were reported in a phase I single-dose study.124 Multiple doses 
of SQ109 (up to 300 mg) were tolerated well by healthy volunteers.180
Discussion
SQ109 is a potential TB drug that has entered phase I/II clinical trials. It has low 
MICs against both susceptible and resistant MTB strains. SQ109 has different 
and more favourable properties than ethambutol, suggesting that it should be 
regarded as a tru ly new diamine, and not just as an ethambutol analogue. SQ109 
could be included in regimens containing rifampicin and isoniazid, since 
synergism with both drugs has been shown. Clinical trials are ongoing to 
establish its future role in TB treatment.
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In the search for com pounds with activ ity against mycobacteria and fungi, several 
pyrrole derivatives have been developed. LL3858 is being investigated in phase 
I clinical trials.124180 A fixed-dose combination called LL3848, containing LL3858 
and the standard, first-line TB drugs, is also being developed.181
LL3858
Mechanism of action
The mycobacterial target of LL3858 is not yet known. Since LL3858 is active 
against MTB strains that are resistant to available TB drugs, the target probably 
differs from the targets of the currently used drugs.182
Pharmacokinetics
No data about the pharm acokinetics of LL3858 in humans are available yet.182 
Pharmacodynamics and efficacy
The MIC90 of LL3858 for MTB is 0.25 jug/ml. LL3858 exhibits concentration- 
dependent activity.180 LL3858 (12.5 mg/kg) reduced the mycobacterial load in 
mice to a greater extent than isoniazid. Regimens of 8 weeks of LL3858, isoniazid 
and rifampicin with or w ithout pyrazinamide sterilized lungs and spleens of 3 
of 6 and 4 of 6 mice, respectively. When the treatment period was extended to 
12 weeks, complete sterilization of the target organs was achieved in 6 of 6 
mice.180,182
Tolerability
The to lerability of LL3858 is currently being investigated in phase I clinical 
trials.182
Discussion
The pyrroles are a new class of com pounds with prom ising activ ity against MTB, 
atypical mycobacteria, and fungi. The pyrrole derivative LL3858 has reached 
phase I clinical trials.
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Several new drugs for TB treatment are being evaluated in clinical trials. Available 
data reveal different properties of the agents (Table 3) and provoke speculation 
about future directions. Higher doses of the rifamycins are prom ising and may be 
the first to be implemented in a regimen of shorter duration. Moxifloxacin and 
gatifloxacin might shorten TB treatment, possibly in combination with rifapentine. 
Coadministration of moxifloxacin and PA-824 could be active against latent TB. 
PA-824 and TMC 207 are candidates for a rifampicin-free regimen for treatment 
of MDR and XDR TB. SQ109, on the other hand, could enhance the activity of ri- 
fam picin-containing regimens.
Unfortunately, shorter treatment regimens based on the new agents discussed 
here are likely to take at least another decade to be fully developed and 
implemented in clinical practice. Since not all new agents will succeed in clinically 
useful regimens, and since only a few drugs are currently in preclinical 
development, more new agents are needed. Therefore, urgent attention should 
be paid to the development of new drugs; th is requires more involvement of large 
pharmaceutical industries. The development of new drugs should get a 
programmatic approach in which a series of consecutive studies are properly 
planned, while keeping the desired end product in mind (J. Gheuens, presented 
at the TBTC meeting, Toronto, Canada, 2008). Moreover, the development of 
various agents must be coordinated, since a single new drug might not be very 
promising in a regimen with the standard TB drugs, but could be highly active in 
combination with other new drugs. The potential of bifunctional molecules with 
more than one target in MTB is currently being explored (M. Spigelman, presented 
at the 1st International Workshop on Clinical Pharmacology of Tuberculosis 
Drugs, Toronto, Canada, 2008). Initiatives such as the GATB have an important 
role in facilitating cooperation in drug development.
Ways to shorten clinical trials with new TB drugs should be explored. The 
evaluation of surrogate biomarkers that predict the likelihood of relapse, such as 
serial sputum colony counts and molecular markers, should be incorporated into 
clinical trials as much as possible. Validated surrogate markers will reduce the 
time it takes to assess the efficacy of new agents.
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Special groups of patients should be addressed in clinical trials. Since TB is a 
major problem in patients with HIV, these patients should be included in clinical 
research on new TB drugs as early as possible. Likewise, the development of 
improved TB treatment regimens for children should get high priority.183 Effective 
treatment regimens against MDR and XDR TB should be developed urgently.
To facilitate clinical trials, research capacity should be strengthened in developing 
countries, where the TB burden is highest.
Finally, control of the TB epidem ic implies more than developing new drugs. The 
d iagnostic and therapeutic facilities of healthcare centres in developing countries 
should be improved and the socioeconom ic status and general welfare of 
patients (including nutritional and HIV status) should be addressed to help 
eradicating TB.
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Addendum in proof
The potential of PA-824 to shorten TB treatment duration when combined with 
the standard, first-line TB drugs was recently reassessed in the mouse model.184 
Mice treated with rifampicin (10 mg/kg), PA-824 (100 mg/kg), and pyrazinamide 
(150 mg/kg) remained free of relapse after 4 months of treatment, while 15% of 
mice treated with a 4-m onths regimen of rifampicin, isoniazid (25 mg/kg), and 
pyrazinamide relapsed. The combination of PA-824 and pyrazinamide and of 
PA-824 and rifampicin displayed synergistic activ ity in the same study. Results 
from this study hold promise for PA-824 to shorten TB treatment duration in 
combination with first-line drugs.
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Table 3 Overview of TB drugs in the clinical pipeline
Drug Trial
phase
Potential to 
shorten treatment
Acceptable toxicity 
profile
High dose rifampicin II Yes To be established
High dose rifapentine II Yesb To be established
Moxifloxacin III Yes Yes
Gatifloxacin III Yes Yes; caution: 
dysglycaemia in elderly
TMC207 II Yesb To be established
PA-824 II Doubtful Yes; medium increase in 
creatinine observed
OPC67683 I/II Yesb To be established
SQ109 I/II Yesb To be established
LL3858 I Yesb Unknown
a Latent TB is the situation in which a host is infected with Mycobacterium tuberculosis but has 
not developed symptoms; b Results from preclinical data; TB = tuberculosis; HIV = human 
immunodeficiency virus; MDR TB = multidrug-resistant TB; NA = not applicable; AUC = Area Under 
the plasma concentration-time Curve.
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Active against 
MDR TB
Useful in HIV- 
infected patients 
with TB
Active 
against 
latent TBa
Interaction
with
rifampicin
Limited Yes, but not coadministered 
with protease inhibitors
Yes, but not first 
choice
NA
Limited To be established Yes NA
Yes Yes Yesb Yes; decrease in 
AUC of moxifloxacin 
by 30%
Yes Yes Unknown Possible
Yes Unknown Unknown Yes: decrease 
in TMC207 
concentration 
by 50%
Yes Unknown Yesb No
Yes Unknown Unknown No
Yes Unknown Unknown Synergism in vitro
Yes Unknown Unknown Synergism in vitro
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Abstract
Data on anti-tuberculosis drug-induced hepatotoxicity in Sub-Saharan Africa are 
limited, probably because liver function tests are not carried out routinely during 
tuberculosis (TB) treatment in most African countries. We monitored the liver 
function of 112 Tanzanian hospitalized pulmonary TB patients during the first 2 
months (i.e. the intensive phase) of TB treatment. The rate of hepatotoxicity in 
our study was 0.9% (95% CI 0.04 - 4.3%). It is encouraging to find a lower rate of 
anti-tuberculosis drug-induced hepatotoxicity than one would expect based on 
the high prevalence of risk factors such as HIV and hepatitis B.
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With 9 million new cases and almost 2 million deaths in 2007, tuberculosis (TB) 
remains a major cause of illness and death worldwide. The highest incidence 
rate is found in Africa, due to the HIV epidemic. TB is the leading cause of death 
among HIV patients.1
Standard TB treatment consists of a 6-months course with isoniazid, rifampicin, 
pyrazinamide and ethambutol. In a clinical setting, this regimen can cure more 
than 95% of the patients with active TB caused by normally sensitive Mycobacterium 
tuberculosis. However, actual cure rates are lower. Adverse effects disrupt treatment 
adherence, which may cause treatment failure, relapse or drug resistance.2-4 
Isoniazid, rifampicin and pyrazinamide are potentially hepatotoxic drugs. They are 
metabolised in the liver, making this organ vulnerable for injury. Anti-tuberculosis 
drug-induced hepatotoxicity (ATDH) is a serious adverse effect that can be fatal 
if therapy is not interrupted in tim e.56 ATDH occurs in 2-28% of TB patients; the 
variation is large due to different definitions of hepatotoxicity and differences 
between the populations studied.6 Data on ATDH in Sub-Saharan Africa are 
scarce, probably because liver function tests are not carried out during TB 
treatment in most African countries. ATDH is reported to be <2%, but liver 
function was not closely monitored in these studies.7-9
It is important to have a valid estimation of the incidence of ATDH in this region. 
It may help to explain low cure rates and is particularly relevant considering 
concom itant antiretroviral treatment, which exacerbates hepatotoxicity.10 
To estimate the rate of ATDH in an African population, we closely monitored the 
liver function in Tanzanian hospitalized patients during the intensive phase of TB 
treatment.
Methods
This study was conducted between April 2007 and July 2008 at the Kibong'oto 
National Tuberculosis Hospital in Sanya Juu, northern Tanzania. All adults who 
were not on antiretroviral therapy before starting TB treatment, were eligible for 
participation.
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TB was treated according to guidelines of the Tanzanian National Tuberculosis 
and Leprosy Programme. During the intensive phase of treatment, patients with 
a bodyweight <50 kg received 225 mg isoniazid, 450 mg rifampicin, 1200 mg 
pyrazinamide and 675 mg ethambutol daily (three fixed-dose combination [FDC] 
tablets, Novartis®) and patients >50 kg received 300 mg isoniazid, 600 mg 
rifampicin, 1600 mg pyrazinamide and 900 mg ethambutol daily (four FDC 
tablets). All patients received full facility-based directly observed treatment 
(DOT), as they were admitted in the hospital during the intensive phase of 
treatment.
Demographic data were collected before treatment. Hepatitis B surface antigen 
(HbsAg) and hepatitis C virus antibodies were detected with a qualitative rapid 
chrom atographic immunoassay (ACON Laboratories Inc, San Diego, USA). 
Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and 
total bilirubin were determined at baseline and after 2, 4, 6 and 8 weeks of TB 
treatment, using the Roche Reflotron® (Kerkhof Medical Service, The Netherlands). 
Hepatotoxicity was defined as serum ALT > 3 times the upper limit of normal 
(ULN) in the presence of hepatotoxicity symptoms or ALT > 5x ULN without 
symptoms of hepatotoxicity.6 The reference values were 41 U/l for ALT, 40 U/l for 
AST and 17 jumol/L for bilirubin. Every 2 weeks, a research nurse screened the 
patients for symptoms of hepatotoxicity (jaundice, abdominal pain, nausea and 
vomiting).
Parameters are presented as mean (standard deviation; SD) when normally 
distributed or median (interquartile range; IQR) if skewed. Statistical analysis 
was performed using SPSS for W indows (version 14.0; SPSS).
Ethical considerations
Ethical clearance was granted by the Radboud University Nijmegen (The 
Netherlands), the Institutional Review Board of the Kilimanjaro Christian Medical 
Centre (because the study was hosted by this institution) and the Ministry of 
Health of Tanzania. All patients gave written informed consent.
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We included 117 patients in this study. Five patients were excluded from analysis: 
three patients died in the first week of treatment, for reasons other than possible 
drug-induced hepatotoxicity, and two w ithdrew from the study immediately after 
baseline measurements. Of the 112 patients included in the analysis, 98 (87.5%) 
completed the 2-months study period. Eleven (9.8%) were HIV-positive and 6 of 
them started antiretroviral treatment during the intensive phase of TB treatment. 
Table 1 shows the patients' characteristics.
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Table 1 Patient characteristics
Characteristic (N=112)
Age, years Median (IQR) 32 (27-40)
Sex, n (%) Male 88 (78.6)
Weight, kg Mean (SD) 52.4 (7.6)
HIV status, n (%) Positive 11 (9.8)
Negative 90 (80.4)
Unknown 11 (9.8)
Hepatitis B, n (%) Positive 8 (7.1)
Negative 88 (78.6)
Unknown 16 (14.3)
Hepatitis C, n (%) Positive 3 (2.7)
Negative 93 (83.0)
Unknown 16 (14.3)
Study outcome, n (%) Study completed 98 (87.5)
LTF between week 2 and 4 3 (2.7)
LTF between week 4 and 6 5 (4.5)
LTF between week 6 and 8 6 (5.4)
Concomitant drugs, n (%) Antiretroviral drugsa 6 (5.4)
Co-trimoxazole 8 (7.1)
LTF = lost to follow-up; IQR = interquartile range ; SD = standard deviation; 
a Antiretroviral treatment in Tanzania: Combivir® (zidovudine, lamivudine) + efavirenz.
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None of the patients developed hepatotoxicity during the first 2 months of TB 
treatment. Seven patients (6.3%) developed slight ALT increases, all <3 times 
the ULN. The highest ALT observed was 87 U/L; the median of peak ALT values 
during the study period was 12 U/L (IQR 9-21 U/L). The highest AST was 64 U/L, 
with a median peak value of 17 U/l (IQR 12-22 U/L). Table 2 shows the liver 
biochem istry at baseline and during the intensive phase of treatment.
One patient developed hepatotoxicity symptoms in the sixth week of treatment: 
serious abdominal pain, nausea and vomiting, and discolouration of the 
conjunctives after intake of the TB drugs which disappeared again after a few 
hours. Because serum ALT and bilirubin were com pletely normal, this patient did 
not have hepatotoxicity according to our definition. She had lost a lot of weight 
during treatment (from 54 kg to 34 kg) and was using four FDC tablets a day (for 
> 50 kg). Treatment was interrupted and relieved the symptoms, after which she 
continued with three FDC tablets.
Table 2 Liver biochem istry during the intensive phase of treatment
#  ___________________________________________________________  #
Liver function parameter ALT AST Bilirubin
Baseline
Median (IQR) 10 U/l (7-15) 13 U/l (10-18) 11 jumol/l (9-16)
Maximum 53 U/l 91 43 jumol/l
Intensive phasea
Median (IQR) 12 U/l (9-21) 17 U/l (12-22) 13 jumol/l (10-19)
Maximum 87 U/l 64 U/l 47 umol/l
ALT = alanine aminotransferase; AST = aspertate aminotransferase; Bilirubin = total bilirubin; IQR 
= interquartile range; a Based on highest value measured during the intensive phase of tuberculosis 
treatment.
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Three patients developed hyperbilirubinem ia (bilirubin levels > 2.5 times ULN). 
ALT and AST levels were w ithin the normal range and jaundice was not reported 
in these patients. Fourteen patients (12.5%) dropped out of the study. Nine 
patients w ithdrew because they refused to give any more blood samples due to 
cultural beliefs concerning blood; three after week 2, four after week 4 and two 
after week 6 of treatment.
Discussion
This is the first study to date where the liver function is closely monitored during 
TB treatment in a Sub-Saharan African population. None of our 112 Tanzanian 
pulmonary TB patients developed hepatotoxicity during the intensive phase of 
TB treatment. One patient developed symptoms of hepatotoxicity. A lthough her 
liver biochem istry remained normal, the symptoms could have been caused by 
the TB drugs. Therefore, the rate of hepatotoxicity in our study was 0.9% (95% CI 
0.04 - 4.3%) at the most.
Clinical trials with moxifloxacin and a high dose of rifampicin are in preparation in the 
Sub-Saharan African region. Rifampicin-induced hepatotoxicity may be dose-related.11 
It is encouraging to observe that the rate of anti-TB drug-induced hepatotoxicity is 
lower than expected in an area with HIV and hepatitis B. Although case reports of 
moxifloxacin-induced hepatotoxicity have been published, moxifloxacin is considered 
safe and not expected to increase the risk of hepatotoxicity.1213 
Our findings are in line with previous reports which indicate a low rate of ATDH in 
Sub-Saharan African TB patients. Recently, a study from South Africa reported 
that only 2 of 400 TB patients (0.5%) developed hepatotoxicity during treatment.14 
In a trial on co-trimoxazole prophylaxis in Malawian HIV-positive pulmonary TB 
patients, about 2% of the patients developed hepatotoxicity during TB treatment.7 
Since co-trimoxazole can be hepatotoxic in patients with AIDS, the ATDH rate 
may even have been slightly overestimated.15 Two studies from Congo and 
Uganda reported no hepatotoxicity8 and 1% hepatotoxicity9 respectively, during 
standard TB treatment. Even though liver function was not routinely monitored 
and treatment was not directly observed, this indicates that hepatotoxicity during 
TB treatment is not a significant problem.
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It is d ifficu lt to explain why the hepatotoxicity rate is low in Sub-Saharan Africa 
despite the prevalence of risk factors such as HIV and hepatitis B. Hepatotoxicity 
rates of 13-15% have been reported from India and Iran.16 Our study population 
was characterised by a low proportion of women, a relatively young age, 10% 
HIV and 7% hepatitis B carriers. Old age, female sex, malnutrition, HIV, alcohol 
usage, underlying liver disease such as hepatitis and several genetic 
polymorphisms are risk factors for ATDH.56
Several genetic polymorphisms in drug metabolising enzymes have been 
associated with anti-TB drug-induced hepatotoxicity, such as slow acetylator 
status (W-acetyltransferase 2), cytochrome P450 2E1 c1/c1 genotype and a 
glutathione S-transferase M1 homozygote null genotype.17 Slow and intermediate 
acetylators are highly prevalent in African populations.1819 Almost 95% of the 
black South Africans had a CYP2E1 c1/c1 genotype20 and 33% of the Tanzanians 
have a GSTM1 null genotype.21 These studies suggest that ‘high risk genotypes’ 
are prevalent amongst Africans, which would contradict the low rate of 
hepatotoxicity found in our study.
We monitored the liver function for 2 months only. Even though ATDH most often 
occurs in the first 2 months of treatment,6 th is may have slightly underestimated 
the hepatotoxicity rate. Our study was limited to hospitalised patients only, which 
could have overestimated the rate of hepatotoxicity, since generally higher rates 
of hepatotoxicity are seen in hospitalised patients. To estimate the rate of 
hepatotoxicity in Sub-Saharan African patients more accurately, a sim ilar study 
could be performed in a larger group of TB patients who are not hospitalised.
Ten percent of our patients were HIV-positive; six of them had started antiretroviral 
therapy during TB treatment (zidovudine, lamivudine and efavirenz). None 
developed any increase in ALT or AST. Concurrent TB-HIV therapy is often 
complicated by overlapping toxicities and drug-drug interactions.10 Drug toxicity, 
including hepatotoxicity, is a major cause of TB or HIV treatment interruption in 
combined TB-HIV treatm ent.22 Nevirapine is the most hepatotoxic non-nucleoside 
reverse transcriptase inhibitor.23 The majority of the nucleoside reverse 
transcriptase inhibitors (e.g. didanosine and stavudine) are potentially 
hepatotoxic, and hepatotoxicity has been reported fo r some protease inhibitors
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(e.g. ritonavir, indinavir and saquinavir). The worldw ide incidence of hepatotoxicity 
during antiretroviral treatment ranges from 2% to 18%.24 In Sub-Saharan Africa, 
data are conflicting. In the study of Marks et al. (2007), the rate of hepatotoxicity 
during TB treatment in HIV-positive (n=141) and HIV-negative (n=240) TB patients 
was low (0.5%), while 16.3% of the HIV-positive patients received antiretroviral 
treatment.14 These findings are in contrast with another South African study by 
Hoffmann et al. (2007), where 4.6% of the 868 patients who took antiretroviral 
drugs (zidovudine, lamivudine and efavirenz) developed hepatotoxicity (grade 3 
or 4; i.e. ALT > 5 times the ULN) and where the use of TB therapy increased the 
risk of hepatotoxicity e ightfo ld .25 More knowledge on hepatotoxicity during 
combined HIV-TB treatment is warranted, since a significant proportion of the TB 
patient population in Sub-Saharan Africa is HIV-positive and would need 
combined TB-HIV treatm ent.26 A suggestion for future research would be to get 
more insight in country specific rates of hepatotoxicity during TB treatment and 
the effect of HIV and antiretroviral therapy by using data from the national TB 
programmes.
Our study and other studies714 suggest that in the absence of symptoms, the risk 
of missing significant hepatotoxicity in th is population is encouragingly low. If 
further data is confirmatory, routine liver function monitoring during TB treatment 
may not be necessary in Sub-Saharan Africa. Nevertheless, it remains important 
that TB patients receive clear instructions on possible signs and symptoms of 
hepatotoxicity and that they are instructed to visit their doctor in case such 
symptoms occur.
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#Abstract
O bjectives: Fluoroquinolones have a potential role in shortening tuberculosis 
(TB) treatment duration. They are currently used in the treatment of other 
infections. This has raised concerns about development of mycobacterial 
resistance. The current study evaluates the sale of fluoroquinolones (among 
other antibacterials) in Moshi, Tanzania, a country with one of the highest burdens 
of TB in the world.
M ethods: Trained pharmacy assistants registered the sale of fluoroquinolones 
during February and March 2009 to outpatients in Moshi in all 14 pharmacies that 
are authorized to sell antibacterials fo r systemic use. The sale of all antibacterials 
of the Anatomic Therapeutic Chemical (ATC) J01 class was expressed in defined 
daily doses (DDD) per 1000 inhabitants per day (DID). The availability of fluoro­
quinolones in drug outlets that are not authorized to sell antibacterials for 
systemic use was assessed in 15 randomly selected outlets in Moshi.
Results: The sale of antibacterials to outpatients in Moshi by authorized 
pharmacies was 4.99 DID. The sale of fluoroquinolones was 0.62 DID (12% of 
total antibacterial sales). Ciprofloxacin was available in all 15 unauthorized drug 
outlets.
Conclusions: The substantial sale of fluoroquinolones by authorized pharmacies 
and the wide availability of fluoroquinolones in unauthorized drug outlets in 
Moshi constitute a challenge to the use of fluoroquinolones in TB treatment in 
Tanzania. Control of antibacterial use in Tanzania requires the implementation of 
surveillance systems for antibacterial use and resistance, and adequate 
restriction of antibacterial sale to authorized pharmacies only.
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#Introduction
Fluoroquinolones are used to treat a variety of conditions, including genitourinary, 
respiratory tract and gastrointestinal infections, sexually transm itted diseases 
and a number of skin, bone and soft tissue infections.1 In addition, the fluoroqui­
nolones constitute a prom ising class of drugs in the treatment of tuberculosis 
(TB).2 Second and third-generation fluoroquinolones are used in the treatment of 
m ultidrug-resistant (MDR) and extensively drug-resistant (XDR) TB, and in case 
of intolerance to first-line TB drugs.3 Moreover, moxifloxacin and gatifloxacin are 
being evaluated for their potential to shorten TB treatment duration, one of the 
major strategies for TB contro l.2
The use of fluoroquinolones against various infections has raised concerns 
about the risk of development of mycobacterial resistance in patients who are 
co-infected with actively replicating Mycobacterium tuberculosis.4 Importantly, 
reduced mycobacterial susceptib ility to one fluoroquinolone results in reduced 
susceptib ility  to all fluoroquinolones.4
Whereas the European Surveillance of Antimicrobial Consumption (ESAC) project5 
provides data on fluoroquinolone consumption in Europe, and the IMS Health has 
collected similar data for the USA,6 to our knowledge no systematic data regarding 
fluoroquinolone consumption is available for Sub-Saharan Africa. Evaluating the 
extent of fluoroquinolone use in this part of the world with the highest burden of TB7 is 
highly relevant given the role of the fluoroquinolones in current and future TB treatment 
regimens. The aim of this study therefore was to systematically evaluate fluoroqui­
nolone sale among other antibacterials by pharmacies in northern Tanzania.
Methods
Data were collected from 1 February 2009 until 31 March 2009 (the dry, hot season) 
in Moshi, the capital of the Kilimanjaro Region in northern Tanzania. The sale of 
drugs in Moshi is covered by 14 part I pharmacies (pharmacies run by a registered 
pharmacist and allowed to sell both prescription-only and over-the-counter drugs) 
and 105 part II pharmacies (pharmacies authorized to sell drugs for minor conditions, 
but no prescription-only drugs such as antibacterials for systemic use).8 All 14 part I
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#pharmacies, serving a total population of 170,500 (Moshi Urban Municipality, 2009), 
participated in data collection. Pharmacy assistants were trained to register the 
generic name, amount and strength per unit dose of each antibacterial sold to 
outpatients, on pre-designed forms that had been tested during a 1 week pilot 
phase. Antibacterials were classified in accordance with the international Anatomic 
Therapeutic Chemical (ATC) system. Only antibacterials of the ATC J01 class 
(antibacterials for systemic use, excluding antifungals, antibacterials for TB and 
topical antibiotics)9 were included. Data collection was closely monitored by the 
investigators who visited the pharmacies on a daily basis in the first week and at 
least once weekly throughout the remaining period of data collection, and who were 
fulltime available by telephone in case of queries.
Data were expressed in defined daily dose (DDDs) per 1000 inhabitants per day 
(DID).9 To calculate the DID per antibacterial, the total amount (in grams) of the 
antibacterials sold during the study period was calculated first. This amount was 
divided by the DDD conversion factor (ATC/DDD index 2009).9 The DID for each 
antibacterial was calculated by dividing the DDDs by 59 days (the study period) 
and dividing this by 170.5 (to give the value per 1000 inhabitants).
To verify whether antibacterials for systemic use were indeed not available from part II 
pharmacies, 15 randomly selected part II pharmacies (15% of all part II pharmacies) 
were visited by the investigators who requested a dose of ciprofloxacin, without 
referring to the study, but also without showing a prescription.
The study was approved by the Institutional Review Board (IRB) of the Kilimanjaro 
Christian Medical Centre (KCMC) in Moshi.
Results
The sale of antibacterials fo r systemic use (ATC J01 class) is summarized in 
Table 1. The total sale of antibacterials to outpatients in Moshi was 4.99 DID. The 
penicillins accounted for the majority (2.18 DID; 44%) of antibacterials sold, 
followed by the quinolones (0.63 DID; 13%). A wide spectrum of fluoroquinolones 
was available, but ciprofloxacin was sold most frequently (74% of fluoroquino lo­
nes). Contrary to drug sale regulations, ciprofloxacin was available without 
prescription in all 15 part II pharmacies visited.
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Table 1 Antibacterials sold in Moshi, presented in accordance with the ATC
classification (including substance specification for fluoroquinolones) and 
expressed in defined daily doses per 1000 inhabitants per day (DID)
ATC code Corresponding antibacterial (sub)class or 
substance name
DID (% of total)
J01C Penicillins 2.18 (44)
J01CA Penicillins with extended spectrum 1.39
J01CE Beta-lactamase-sensitive penicillins 0.14
J01CF Beta-lactamase-resistant penicillins 0.29
J01CR Combinations of penicillins 0.36
J01M Quinolones 0.63 (13)
J01MA Fluoroquinolones 0.62
J01MA02 Ciprofloxacin 0.46
J01MA06 Norfloxacin 0.04
J01MA07 Lomefloxacin 0.04
J01MA12 Levofloxacin 0.04
J01MA01 Ofloxacin 0.03
J01MA09 Sparfloxacin <0.01
J01MA03 Pefloxacin <0.01
J01MB Other quinolones 0.01
J01F Macrolides, lincosamides and streptogramins 0.61 (12)
J01A Tetracyclines 0.57 (11)
J01E Sulphonamides and trimethoprim 0.33 (7)
J01X Other antibacterials 0.31 (6)
J01XD Imidazole derivatives 0.30
J01XE Nitrofuran derivatives 0.01
J01D Cephalosporins 0.20 (4)
J01B Amphenicols 0.11 (2)
J01G Aminoglycoside antibacterials 0.05 (1)
Total 4.99 (100)
ATC = anatomic therapeutic chemical; DID = defined daily dose per 1000 inhabitants per day.
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#Discussion
To our knowledge, this is the first study in Sub-Saharan Africa in which the sale 
of antibacterials (in particular of the fluoroquinolones) was thoroughly evaluated. 
The total sale of antibacterials to outpatients by authorized drug outlets was 4.99 
DID in Moshi. In comparison, outpatient antibacterial consumption in Europe 
ranged from 9.8 DID in The Netherlands to 31.4 DID in Greece,10 and was 24.92 
DID in the USA.6
The dominant class of antibacterials sold to outpatients in Moshi were the 
penicillins (44%). In Europe and the USA, the penicillins also represent the most 
frequently used antibacterials (46% and 39%, respectively).6 The total sale of 
quinolones to outpatients in Moshi by part I pharmacies was 0.63 DID (fluoroqui­
nolones: 0.62 DID). Outpatient quinolone consumption ranged from 0.25 DID in 
Denmark to 3.10 DID in Portugal,5 and was 2.47 DID in the USA.6 
Given the high burden of infectious diseases in Tanzania and the limited 
d iagnostic facilities resulting in empirical use of antibacterials, higher DIDs had 
been expected from our study. However, we also revealed the unregulated 
availability of antibacterials in part II pharmacies. This finding suggests that the 
sale of antibacterials in northern Tanzania by part I pharmacies is an incomplete 
representation of the availability of antibacterials in reality, and the actual 
antibacterial consumption in Moshi is likely to be higher than found in the current 
study.
Considering the high incidence of active TB infection in Tanzania,7 the widespread 
availability of the fluoroquinolones raises concerns about development of 
mycobacterial resistance. Resistance to the fluoroquinolones reduces second-line 
treatment options for drug-resistant TB and will limit future use of moxifloxacin 
and gatifloxacin in shorter, first-line treatment regimens.
This study has some lim itations. It is unknown whether the antibacterials that 
were sold were actually used by patients. The data represent a single measurement 
period of 2 months in a limited area only, whereas antibacterial consumption 
generally shows seasonal and regional variation.510 No differentiation was made 
between antibacterial sale with and w ithout prescription. Alarmingly, antibacterials 
are available in both ways according to pharmacy assistants.
In conclusion, the substantial and inadequately controlled sale of fluoroquinolones
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#in northern Tanzania constitutes a challenge to the incorporation of fluoroquinolo­
nes in TB treatment. Restricting their use to TB treatment only will pose a major 
practical challenge. To improve control on antibacterial use in Tanzania, the 
implementation of surveillance systems for antibacterial consumption and 
resistance is warranted, and the sale of antibacterials should be restricted to part 
I pharmacies only.
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#Abstract
The aim of this study was to evaluate the sale of antibacterials for system ic use 
to outpatients in Moshi Municipality, northern Tanzania. Trained pharmacy 
assistants of all 14 pharmacies in Moshi that are authorized to sell antibacterials 
for system ic use (part I pharmacies), recorded the sale of antibacterials to 
outpatients by using the Anatomic Therapeutic Chemical (ATC) classification 
and Defined Daily Dose (DDD) methodology, during a 2-months period. The 
unregulated availability of antibacterials in drug outlets that are not authorized to 
sell antibacterials (part II pharmacies), was assessed in 15 randomly selected 
outlets. The total sale of antibacterials was 4.99 DDDs per thousand inhabitants 
per day (DID). The penicillins were sold most frequently (2.18 DID; 44%), followed 
by the quinolones (0.63 DID; 13%), macrolides, lincosamides and streptogram ins 
(0.61 DID, 12%), and the tetracyclines (0.57 DID, 11%). The sale of amoxicillin, the 
individual drug sold most frequently, was 1.28 DID. C iprofloxacin was available in 
all unauthorized drug outlets. Given their wide availability in unauthorized drug 
outlets, the sale of antibacterials by authorized pharmacies is probably an under­
representation of the total sale of antibacterials in Moshi. Regulatory measures 
to control the availability of antibacterials in Tanzania are warranted. Repetition 
of the study in different seasons and in consecutive years could reveal highly 
relevant data on antibacterial consumption trends, which, especially if correlated 
to data on antibacterial resistance, could help to control communicable 
diseases.
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In developing countries where the main causes of death continue to be 
com m unity-acquired infections, the occurrence of antibacterial resistance is a 
great concern.1,2 It is w idely agreed that antibacterial consumption is the single 
most important factor responsible for the development of resistance as it induces 
selective pressure for resistant m icro-organism s to multiply.34 The control of 
antibacterial use in developing countries is hampered by various factors such as 
immature healthcare systems, limited diagnostic facilities and unregulated 
access to drugs. In addition, many developing countries lack surveillance 
systems for antibacterial use and resistance.35 The wide range of formal and 
informal drug outlets through which antibacterials are usually available and the 
unregulated sale of antibacterials with and w ithout prescription, challenge the 
systematic monitoring of antibacterial consumption in developing countries.5 
However, healthcare programmes are being strengthened, the availability of 
drugs is being regulated more extensively, and policy makers are increasingly 
aware of the need of improved drug prescription behaviour.2 Adopting a 
surveillance system for antibacterial use has therefore become a more realistic 
priority in developing countries.
The monitoring of antibacterial use could be of help in developing interventions 
fo r antibacterial drug prescribers, dispensers and users, especially when 
compared to data on antibacterial resistance.4 Moreover, the evaluation of 
antibacterial use over time and between regions can direct the development and 
adaptation of rational drug use guidelines.4,6,7
The World Health Organization (WHO) promotes the use of the Anatomic 
Therapeutic Chemical (ATC) classification and Defined Daily Dose (DDD) system 
for drug utilization studies.7 The ATC/DDD methodology is based on a standardized 
drug classification system (ATC) in which drugs are grouped according to their 
therapeutic, pharm acological and chemical properties, and the use of an 
‘assumed average maintenance dose per day for a drug used fo r its main indication  
in adults’ (DDD) as a fixed measurement unit for drug consumption (www .w hocc. 
no/atcddd). Data on drug prescription or sale are usually presented as numbers 
of DDDs per 1000 inhabitants per day (or, in case of inpatient drug use, as DDDs
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#per 100 bed-days).7 Provided that there is consistency in applied methodology, 
the ATC/DDD system is a valuable tool to monitor drug use over time and to 
compare between regions.6
In this study, the ATC/DDD m ethodology was used to evaluate the sale of 
antibacterials for systemic use to outpatients by pharmacies in Moshi Municipality. 
Moshi is the capital of Tanzania's northern Kilimanjaro Region and has a 
population of 170,500 (Moshi Urban Municipality, 2009). The town is host to one 
of Tanzania's four university teaching hospitals, a governmental regional hospital, 
and several private and public clinics and dispensaries. Drug sale is covered by 
14 part I pharmacies that are run by a registered pharmacist and allowed to sell 
both prescription-only and over-the-counter drugs, and 105 part II pharmacies, 
or so called maduka ya dawa barid i (literally: shops for co ld  drugs), that are 
allowed to sell drugs for m inor conditions, but no prescription-only drugs such 
as antibacterials for systemic use.8 The sale of antibacterials is not systematically 
recorded by pharmacies in Moshi. Therefore, little is known about the extent of 
antibacterial consumption in this part of the world where the burden of infectious 
diseases is high and the occurrence of antibacterial resistance a serious 
concern.9 Data from the current study will help to fill this gap. The data on fluoro­
quinolone sale in Moshi, which are part of the data included here, have already 
been published.10 Fluoroquinolones are of particular concern in light of their role 
in tuberculosis treatment regimens.
Methods
Data were collected from 1 February 2009 until 31 March 2009 from all 14 part I 
pharmacies in Moshi. Pharmacy assistants were trained to document the 
following on pre-designed and pre-tested forms: generic name of each 
antibacterial of the ATC J01 class (antibacterials for system ic use, excluding 
antifungals, antibacterials for tuberculosis and topical antib iotics (www.whocc. 
no/atcddd)) sold to children and adults during the study period (with and without 
prescription), the amount, and strength per unit dose. The investigators visited 
the participating pharmacies frequently (daily in the first week of data collection
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#and at least once weekly in the remaining study period) in order to monitor the 
data collection process closely and to assist in case of queries.
The number of DDDs per antibacterial was obtained by: (i) calculating the amount 
in grams of each dose dispensed (for example, a dose of 14 amoxicillin capsules 
of 250 mg each corresponds to a total amount of 3.5 gram); (ii) summing the total 
amount in grams per antibacterial in all 14 pharmacies; and (iii) dividing this total 
by the DDD conversion factor obtained from the ATC/DDD index 2009 (available 
from: www.whocc.no/atcddd). DDDs per 1000 inhabitants per day (DID) were 
calculated by dividing the number of DDDs per antibacterial by 59 days (the 
study period) and by 170,500 inhabitants, and multiplying by 1000.
To evaluate whether antibacterials for system ic use were indeed not available 
from part II pharmacies, 15 part II pharmacies were visited by one of the 
investigators who asked for a dose of ciprofloxacin for systemic use in each 
pharmacy. The part II pharmacies were randomly selected by using a map of 
Moshi town and picking three pharmacies from each of five different areas of 
Moshi.
The study was approved by the Institutional Review Board (IRB) of the Kilimanjaro 
Christian Medical Centre (KCMC), Tanzania.
Results
The DDDs per 1000 inhabitants per day (DID) of the antibacterial chemical 
subgroups and individual chemical substances are shown in Table 1. In total, 
the antibacterial sale to outpatients by part I pharmacies in Moshi was 4.99 DID. 
The penicillins accounted for the largest sale (2.18 DID; 44% of total sale). The 
quinolones were second most frequently sold (0.63 DID, 13%), followed by 
the macrolides, lincosamides and streptogram ins (0.61 DID, 12%), and the 
tetracyclines (0.57 DID, 11%). Amoxicillin was the individual chemical substance 
sold most frequently (1.28 DID). Other frequently sold antibacterials were 
doxycycline (0.50 DID), ciprofloxacin (0.46 DID), co-trimoxazole (0.33 DID), 
azithromycin (0.30 DID), metronidazole (0.29 DID), cloxacillin (0.28 DID), and 
erythromycin (0.26 DID). Ciprofloxacin was available w ithout prescription in all 
visited part II pharmacies.
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Table 1 Defined Daily Doses (DDDs) per 1000 inhabitants per day (DID)
of antibacterial chemical subgroups and substances sold in Moshi 
Municipality
Antibacterial chemical subgroup DID Chemical substance DID
J01AA Tetracyclines 0.57 Doxycycline 0.50
Tetracycline 0.07
J01BA Amphenicols 0.11 Chloramphenicol 0.11
J01CA Penicillins with extended spectrum 1.39 Ampicillin 0.11
Amoxicillin 1.28
J01CE Beta-lactamase sensitive penicillins 0.14 Benzylpenicillin 0.03
Phenoxymethylpenicillin 0.09
Benzathine 0.01
benzylpenicillin
Procaine benzylpenicillin 0.01
J01CF Beta-lactamase resistant penicillins 0.29 Cloxacillin 0.28
Flucloxacillin 0.01
J01CR Combinations of penicillins 0.36 Amoxicillin/clavulanate 0.03
Amoxicillin/bromhexin 0.06
Co-fluampicil 0.06
Ampicillin/cloxacillin 0.21
J01DB First-generation cephalosporins 0.09 Cefalexin 0.09
Cefadroxil <0.01
J01DC Second-generation cephalosporins 0.03 Cefuroxime 0.03
J01DD Third-generation cephalosporins 0.08 Ceftriaxone 0.06
Cefixime 0.01
Cefpodoxime 0.01
J01EE Combinations of sulfonamides & 0.33 Co-trimoxazole 0.33
trimethoprim
J01FA Macrolides 0.61 Erythromycin 0.26
Clarithromycin 0.05
Azithromycin 0.30
J01FF Lincosamides <0.01 Clindamycin <0.01
J01GB Other aminoglycosides 0.05 Gentamycin 0.05
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Table 1 Continued
Antibacterial chemical subgroup DID Chemical substance DID
J01MA Fluoroquinolones 0.62 Ofloxacin 0.03
Ciprofloxacin 0.46
Pefloxacin <0.01
Norfloxacin 0.04
Lomefloxacin 0.04
Sparfloxacin <0.01
Levofloxacin 0.04
J01MB Other quinolones <0.01 Nalidixic acid <0.01
J01XD Imidazole derivatives 0.30 Metronidazole 0.29
Tinidazole 0.01
J01XE Nitrofuran derivatives 0.01 Nitrofurantoin 0.01
J01XX Other antibacterials <0.01 Spectinomycin <0.01
Total 4.99 4.99
Discussion
To our knowledge, this is the first study in Sub-Saharan Africa in which the ATC/ 
DDD m ethodology was used system atically to evaluate the sale of antibacterials 
to outpatients. The penicillins accounted for the largest part of antibacterial sale 
by part I pharmacies in Moshi (44%), and amoxicillin was responsible for more 
than half of the total sale of penicillins. Other frequently sold broad-spectrum 
antibacterials were doxycycline, ciprofloxacin, co-trimoxazole, azithromycin and 
erythromycin.
The use of the ATC/DDD m ethodology allows for comparison of data between 
regions. The total sale of antibacterials in Moshi by authorized pharmacies was 
4.99 DID; tw ice as low as in The Netherlands, the European country with the 
lowest antibacterial use (9.8 DID in 2003).11 Considering the high burden of 
infectious diseases in Tanzania,1'35 the total DID of antibacterials sold in Moshi is 
surprisingly low. Our study covered all pharmacies in Moshi that are authorized
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to sell antibacterials for system ic use (part I pharmacies), but did not include 
pharmacies that are not authorized to sell antibacterials for system ic use (part II 
pharmacies). Our attempts to buy ciprofloxacin (without prescription) in part II 
pharmacies were successful in all pharmacies that we visited, suggesting that 
antibacterials are more w idely available in Moshi than from authorized drug 
outlets only. Therefore, our findings are likely to be an underestimation of the 
total sale of antibacterials in Moshi.
Inadequate control of antibacterial consumption is a known risk factor for the 
emergence of drug resistance.3 Unfortunately, no data are available on 
antibacterial resistance in northern Tanzania, but limited data are available from 
the Dar es Salaam region. The university teaching hospital in Dar es Salaam 
(Muhimbili National Hospital) implemented an antibacterial resistance 
surveillance programme in 1998, and findings of the first 18 months after 
implementation have been published.9 High rates of resistance of gram-positive 
and gram-negative bacteria were found to ampicillin, co-trimoxazole, tetracycline, 
penicillin, and sulfonamides. The wide unregulated availability and low cost of 
these drugs are thought to have contributed to high rates of resistance.9 
Clearly, regulating the availability of antibacterials is an important strategy in the 
control of antibacterial use and resistance.24 The Tanzanian Food and Drugs 
Authority and the Ministry of Health have adopted a plan to replace the part II 
pharmacies by accredited drug dispensing outlets (ADDOs) in which essential 
drugs (including some antibacterials for systemic use) are sold by trained 
dispensers who are under regulatory supervision.812 In the Kilimanjaro Region 
the process of phasing out the part II pharmacies will start in 2010 (personal 
comm unication with Regional Pharmacist).
Some challenges were faced in using the ATC/DDD m ethodology in Moshi. Drug 
dispensing is documented manually and there are no digital databases available 
through which data on antibacterial sale can be obtained. Calculating total DDDs 
and DIDs from manually collected data is a tim e-consum ing process.
Lim itations to our study include the following. The study was conducted during a 
single, limited period of time and in a small, urban area only. No differentiation 
was made between antibacterials sold by prescription and over the counter. No
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#information was obtained on treatment indications and it is not known whether 
the antibacterials that were sold, were actually consumed. Nevertheless, the 
results of this study could serve as a starting-point for monitoring antibacterial 
sale in northern Tanzania. Repetition of the study (by applying the same ATC/ 
DDD methodology) in different seasons and in consecutive years, could reveal 
highly relevant data on antibacterial consumption trends, which, especially if 
correlated to data on antibacterial resistance, could be of help in the control of 
infectious diseases. Regulatory measures to control the unauthorized availability 
of antibacterials in Tanzania are warranted and the implementation of an electronic 
system to document drug sale by pharmacies is highly recommended.
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#Abstract
O b je c t ive s :  Fluoroquinolones are used in second-line treatment of tuberculosis 
(TB) and have a potential role in shortening TB treatment duration. The wide use 
of fluoroquinolones in the treatment of other infections including respiratory tract 
infections in patients with (undiagnosed) active TB, could result in fluoroquinolone 
resistant Mycobacterium tuberculosis (MTB). We determined the rate of fluoro­
quinolone resistance in MTB isolates obtained from Tanzanian patients and 
linked this to previous fluoroquinolone exposure and mycobacterial resistance to 
rifampicin and isoniazid.
M eth o d s :  A total of 291 MTB isolates were obtained between April 2009 and 
June 2010 from patients with smear-positive pulmonary TB and tested for 
susceptib ility to ciprofloxacin, moxifloxacin, rifampicin and isoniazid. Information 
on previous fluoroquinolone use was obtained by interviewing patients and 
checking their medical files.
R esults :  Only two (0.7%) of the 291 MTB isolates were resistant to ciprofloxacin; 
one of which was intermediately resistant to moxifloxacin as well. These two 
isolates were susceptible to rifampicin and isoniazid. Twenty-two (8%) of the 291 
patients had a history of fluoroquinolone use (median: 7 days, interquartile range: 
5-10). The patients from whom the fluoroquinolone-resistant MTB isolates were 
obtained had no known history of previous fluoroquinolone use.
C o n c lu s io n s :  Our findings indicate that the rate of fluoroquinolone-resistant 
MTB in Tanzanian patients with TB is low and not related to previous, brief 
episodes of exposure to fluoroquinolones. The findings favour future application 
of fluoroquinolones in TB treatment regimens of shorter duration.
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#Introduction
Fluoroquinolones, a class of broad spectrum antibacterial drugs, are pivotal 
second-line drugs in the treatment of m ultidrug-resistant (MDR) tuberculosis 
(TB) and are used as substitute agents in patients who are intolerant to the 
first-line TB drugs.12 Moreover, in vitro and in vivo experiments have shown that 
the newer fluoroquinolones moxifloxacin and gatifloxacin have the potential to 
shorten TB treatment duration; an important strategy in the fight against TB.3-6 
The agents are currently being tested in phase III clinical trials for their role in TB 
treatment regimens of shorter duration.7
A potential problem of using fluoroquinolones in first-line TB treatment is that 
they are prescribed for treatment of a wide variety of bacterial infections, including 
empirical treatment of com m unity-acquired pneumonia.89 Exposure to fluoroqui­
nolone monotherapy in patients with yet undiagnosed active TB can result in the 
emergence of fluoroquinolone-resistant Mycobacterium tuberculosis (MTB) and 
this could jeopardize the application of the fluoroquinolones in TB treatment 
regimens, particularly in regimens of shorter duration.1011 Fluoroquinolone 
resistance in MTB has been observed in a number of studies around the world, 
with resistance rates ranging from <1% to >35%.12-15 In several studies, MTB 
resistance to fluoroquinolones was associated with MDR TB (resistance to at 
least rifampicin and isoniazid),16-20 probably as a consequence of adding a fluo ­
roquinolone to a failing multidrug TB treatment regimen.11 In a number of studies, 
the association between previous fluoroquinolone use for any kind of infection 
and the development of fluoroquinolone resistance in patients with active TB was 
assessed. While the association was confirmed in some studies,1421 other studies 
yielded more am biguous results with respect to the existence of such a 
correlation161922 or showed a risk increment of fluoroquinolone resistance 
development only after substantial (i.e. >10 days) exposure to these drugs.23
The occurrence of fluoroquinolone resistance in MTB and its possible association 
with previous fluoroquinolone exposure has not yet been studied in Tanzania, 
one of the 22 countries with the highest burden of TB.24 In a previous study, we 
assessed the extent of fluoroquinolone use for all kinds of infections in outpatients 
from the Kilimanjaro Region in northern Tanzania. We confirm ed that the fluoro­
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#quinolones are w idely used in Tanzania; they account for 12% of the total sale of 
antibacterial drugs in authorized pharmacies and are readily available in 
unauthorized drug outlets as well.25 In the present study, we determined the 
occurrence of fluoroquinolone resistance in MTB isolates from TB patients in the 
Kilimanjaro Region and we linked this to previous fluoroquinolone exposure and 
resistance to isoniazid and rifampicin.
Materials and methods
Setting
The study was conducted in the Tanzanian Kilimanjaro Region where the annual 
TB case notification rate (new and retreatment cases) is around 178 per 100,000 
population.25 Forty-one percent of TB patients in the region are diagnosed with 
smear-positive pulmonary TB and 59% with smear-negative pulmonary or 
extrapulm onary TB. Thirty-one percent of TB patients are co-infected with 
HIV.2627 TB diagnosis is primarily based on clinical symptoms and Ziehl-Neelsen 
(ZN) smear m icroscopy for the detection of acid-fast bacilli (AFB), complemented 
by radiology in case of AFB-negative smears. At the time this study was 
conducted, no TB culture facilities were available for routine practice in the 
Kilimanjaro Region, and there was no second-line treatment for drug-resistant 
TB. 28
Study population and procedures
We conducted a cross-sectional study between April 2009 and June 2010 in 
patients who were diagnosed with smear-positive pulmonary TB and had not yet 
started TB treatment. Smear-positivity was defined as at least one AFB-positive 
smear out of two sputum samples: one spot and one morning sample.28 District 
TB and Leprosy Coordinators from all seven districts of the Kilimanjaro Region 
were responsible for enrolling patients from their d istrict's  clinics. Because of 
logistical constraints (in particular, long travel times from the most distant 
d istricts to the culture laboratory), convenience sampling was applied, meaning 
that as many patients as logistically possible were enrolled.
Demographic and clinical data such as TB classification (new or retreatment
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#case) and HIV status were collected from medical files. A new TB case was 
defined as a patient who had not received more than 1 month of TB treatment in 
the past. Retreatment cases included patients classified as treatment failures, 
returning after default and relapse cases. Trained clinicians interviewed patients 
on the use of antibacterial drugs with or w ithout prescription in the previous 6 
months (a longer period was expected to result in substantial recall bias) and 
explicitly asked about ciprofloxacin use (the fluoroquinolone that is most 
frequently used in Tanzania).25 Furthermore, medical files were checked for fluo ­
roquinolone prescriptions in the previous 6 months. One spot sputum sample for 
culture and drug susceptib ility testing to isoniazid, rifampicin, ciprofloxacin and 
moxifloxacin was collected from every patient. Ciprofloxacin was selected 
because this fluoroquinolone is sold most extensively in Tanzania,25 and 
moxifloxacin was chosen because this is one of the newer fluoroquinolones with 
the potential to shorten TB treatment duration.6
The study protocol was approved by the Institutional Review Board of the 
Kilimanjaro Christian Medical Centre (KCMC; Moshi, Tanzania) and the National 
Institute for Medical Research (Dar es Salaam, Tanzania). Written informed 
consent was obtained from all participants.
Laboratory analysis
After collection, sputum samples were refrigerated for a maximum of 1 week and 
transported to the TB culture laboratory of the Kilimanjaro Christian Medical 
Centre. After decontam ination, sputum samples were incubated in an automated 
liquid culture system (BACTEC MGIT960, BD Biosciences, Erembodegem, 
Belgium). The content of positive MGIT tubes was inoculated on blood agar 
plates for 24 h to assess possible contam ination, and ZN m icroscopy was done 
to confirm  the presence of AFB. In case of AFB positivity and growth on the 
blood agar plates, MGIT tube sediments underwent renewed decontam ination 
and incubation. In case of AFB positivity and no growth on the blood agar plates, 
concentrated MGIT tube sediments were subcultured on Lowenstein-Jensen 
(LJ) slopes. Growth on LJ slopes was assessed after 8 weeks of incubation and 
the isolates obtained in this way were stored in glycerol at -80°C until transport 
to the National Tuberculosis Reference Laboratory of the National Institute for 
Public Health and the Environment (RIVM) in The Netherlands.
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At the RIVM, the isolates were first identified as MTB complex by spo ligotyp ing.29 
Drug susceptib ility testing was performed using BACTEC MGIT960; the drugs 
included in the panel and their critical concentrations were isoniazid 0.1 mg/L, 
rifampicin 1 mg/L, ciprofloxacin 1 mg/L and moxifloxacin 0.5 m g/L.30 The process 
was controlled using EpiCenter software; standard MGIT960 conditions applied. 
Cultures were incubated an additional 3 days after full appearance of the growth 
control. If growth was detected in a fluoroquinolone-conta in ing tube after the 
additional 3 days incubation but not before, the isolate was labelled ‘intermediately 
resistant'.31
All fluoroquinolone-resistant isolates were subjected to gyrA gene mutation 
analysis using the GenoType MTBDRs/ reverse line blot assay (Hain Lifescience, 
Nehren, Germany).30
The results were discussed with the District TB and Leprosy Coordinators and 
laboratory technicians to provide them with feedback on the quality of ZN 
m icroscopy in the region.
Results
Patient characteristics
A total of 379 sputum samples were collected. MTB isolates were obtained from 
291 of these 379 sputum samples. Thirty samples were culture-negative, 35 
showed growth but no MTB, and 23 were contaminated.
The characteristics of the 291 patients with culture-confirm ed TB are shown in 
Table 1. Twenty-two (8%) of the 291 patients had a history of fluoroquinolone use 
in the previous 6 months: 11 (50%) had used the drug for respiratory symptoms 
and the others for gastrointestinal problems. Seven patients had used fluoroqui­
nolones in the past month and 15 patients between 1 and 3 months ago. The 
median duration of fluoroquinolone use was 7 days (interquartile range (IQR): 
5-10), the maximum duration was 10 days. None of the patients had used the 
fluoroquinolones more than once in the previous 6 months.
Drug susceptibility test results
Isoniazid resistance was found in 26 MTB isolates (8.9%), three of which were
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Table 1 Patient characteristics of the tota l study population (N=291) and by drug resistance pattern
Characteristic Total group 
(N =291)
Patients with pan- 
susceptible MTB 
(n=262)
Patients with 
INH resistant 
MTB 
(n=23)
Patients with RIF 
resistant MTB
(n=1)
Patients with 
INH + RIF 
resistant MTB 
(n=3)
Patients with 
FQ resistant 
MTB 
(n=2)
Age, median (IQR) 35 (27-44) 35 (27-45) 36 (27-42) 25 39 (34-50) 30 (20-40)
Male sex, n (%) 208 (72) 183 (70) 20 (87) 1 (100) 3 (100) 1 (50)
Retreatment cases, n (%)a 29 (10) 27 (10) 0 (0) 0 (0) 1 (33) 0 (0)
HIV-positive, n (%) 63 (22) 55 (21) 6 (26) 0 (0) 1 (33) 1 (50)
Positive history of FQ use, 
n (%)
22 (8) 21 (8) 1 (4) 0 (0) 0 (0) 0 (0)
3 Of the 29 retreatment cases, two were defaulters who returned and 27 were classified as relapse cases. The two patients who returned after default both had 
pan-susceptible MTB isolates.
MTB = Mycobacterium tuberculosis', IQR = interquartile range; INH = isoniazid; RIF = rifampicin; FQ = fluoroquinolone.
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#resistant to rifampicin as well, giving an MDR rate of 1.0%. Mono-resistance to 
rifampicin occurred in one isolate (0.4%). Ciprofloxacin resistance was found in 
two isolates (0.7%): one was intermediately resistant to ciprofloxacin and 
susceptible to moxifloxacin, the other was resistant to ciprofloxacin and 
intermediately resistant to moxifloxacin. Both were susceptible to isoniazid and 
rifampicin. The isolate resistant to ciprofloxacin and intermediately resistant to 
moxifloxacin harboured an A90V mutation in the gyrA gene, but w ild-type 
sequences were detected simultaneously. In the isolate intermediately resistant 
to ciprofloxacin and susceptible to moxifloxacin no gyrA mutations were found.
The characteristics of the patients from whom resistant MTB isolates were 
obtained are shown in Table 1. The two patients with ciprofloxacin resistant MTB 
had no history of previous fluoroquinolone use and had not been treated for TB 
before. The patient from whom the MTB isolate with intermediate resistance to 
ciprofloxacin was obtained, was a 40-year-old HIV-positive woman with a CD4 
count of 3 cells/mm3. The other patient was a 20-year-old HIV-negative man with 
a CD4 count of 478 cells/m m 3. There was no known link between these two 
%  patients. 0  
Discussion
Fluoroquinolone resistance in MTB is uncommon in Tanzania, despite the 
widespread use of these antibacterial drugs in the treatment of bacterial 
infections. The proportion of MTB isolates with fluoroquinolone resistance was 
less than 1% in our study population and there was no association with previous 
fluoroquinolone exposure in the two isolates with fluoroquinolone resistance.
Both fluoroquinolone-resistant isolates were susceptible to rifampicin and 
isoniazid.
Fluoroquinolone resistance in MTB is associated with mutations in the gyrA and, 
to a lesser extent, gyrB  genes of the mycobacterial genome, but these mutations 
are not always present in resistant isolates.1132 Cross-resistance between the 
different fluoroquinolones is common in MTB.33 It is hypothesized that resistance 
to fluoroquinolones with strong bactericidal activity against MTB (such as
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moxifloxacin) is generated through a stepwise process of additive mutations, 
whereas resistance to ciprofloxacin and ofloxacin requires a single mutation 
only.11 This could explain why the MTB isolate with intermediate resistance to 
ciprofloxacin in our study was susceptible to moxifloxacin (and did not have 
mutations in gyrA), and why the isolate with resistance to ciprofloxacin was 
intermediately resistant to moxifloxacin. We found a A90V gyrA mutation in the 
latter isolate but w ild-type sequences were also detected, suggesting a single 
strain with both w ild-type and mutant bacterial populations, as previously 
observed,30 or a mixed infection with two strains.30 Considering that our aim was 
to determine the rate of fluoroquinolone resistance in northern Tanzania and 
relate this to previous fluoroquinolone use, we decided to categorize the MTB 
isolate with intermediate resistance to ciprofloxacin as fluoroquinolone resistant. 
However, the clinical relevance of intermediate fluoroquinolone resistance in 
MTB remains controversial. 31
Low fluoroquinolone resistance rates were also found in two other studies from 
the African continent.1214 In Tunisia, 0.8% fluoroquinolone resistance was found 
in a hospital-based study but the association of fluoroquinolone resistance in 
MTB with previous fluoroquinolone exposure was not investigated.12 In Rwanda, 
the fluoroquinolone resistance rate was 0.6% in a nationwide study. The four 
patients with fluoroquinolone-resistant MTB in th is study all had a history of 
previous fluoroquinolone use (three as part of a second-line TB treatment 
regimen).14
There are a few possible explanations fo r the low fluoroquinolone resistance rate 
and the absence of an obvious association with previous fluoroquinolone 
exposure in our study. As Devasia et al. (2009) showed, the risk of fluoroqui­
nolone resistance in MTB isolates increases particularly after fluoroquinolone 
exposure of more than 10 days.23 In our patient population, fluoroquinolone use 
was restricted to brief treatment episodes (5-10 days) only. Moreover, at the time 
this study was conducted, there was no second-line treatment for MDR TB 
available and thus there was no risk of long-term fluoroquinolone exposure as 
part of a failing second-line TB treatment regimen in MTB. In most regions where 
high (i.e. >15%) fluoroquinolone resistance rates in MTB were observed, its 
occurrence was associated with resistance to rifampicin and isoniazid.15'20'22'3435
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In our study, the rates of isoniazid, rifampicin, and isoniazid plus rifampicin 
(MDR) resistance were low: 8.9%, 0.3% and 1.0%, respectively, and sim ilar low 
rates of MDR TB were found in other studies from Tanzania.2736
This study has some lim itations. Since the prescription and sale of antibacterial 
drugs to patients in Tanzania is not autom atically registered, it was difficu lt to 
obtain reliable information about previous fluoroquinolone use. Furthermore, it is 
unknown how long it takes for MTB to develop fluoroquinolone resistance after 
fluoroquinolone exposure. Devasia et al. (2009) assessed fluoroquinolone 
exposure over a period of 12 months prior to TB diagnosis and found that 
exposure that had occurred more than 60 days before TB diagnosis was 
associated with the highest risk of fluoroquinolone resistance.23 We assessed 
fluoroquinolone use over a period of 6 months (180 days) prior to TB diagnosis 
only, because we expected that fluoroquinolone use longer than 6 months ago 
would be difficu lt for patients to recall.
In conclusion, our findings indicate that the occurrence of fluoroquinolone 
resistance in MTB isolates obtained from Tanzanian patients is limited and not 
related to previous, brief episodes of fluoroquinolone exposure. This is an 
encouraging finding in light of the possible incorporation of fluoroquinolones in 
first-line TB treatment regimens.
Acknowledgements
The authors gratefully acknowledge the assistance of the Tuberculosis Reference 
Laboratory at the National Institute for Public Health and the Environment (RIVM, 
Bilthoven, The Netherlands).
This work was funded by the African Poverty Related Infection Oriented Research 
Initiative (APRIORI), a research network sponsored by the Netherlands-African 
partnership for capacity development and clinical interventions against poverty- 
related diseases (NACCAP) (WOTRO/NACCAP 07.05.203).
Part III -  Preventing non-adherence
#
#Fluoroquinolone resistance in Tanzania | 213
References
1. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of 
pulmonary tuberculosis. Drugs 2007; 67: 2077-2099.
2. World Health Organization. Guidelines for the programmatic management of drug-resistant 
tuberculosis. WH0/HTM/TB/2006.361. Geneva, Switzerland: WHO, 2006.
3. Alvirez-Freites EJ, Carter JL, Cynamon MH. In vitro and in vivo activities of gatifloxacin against 
Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002; 46: 1022-1025.
4. Gillespie SH, Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother 
1999; 44: 393-395.
5. Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In vitro and in vivo activities of 
moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 
1998; 42: 2066-2069.
6. Van den Boogaard J, Kibiki GS, Kisanga ER, Boeree MJ, Aarnoutse RE. New drugs against 
tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob 
Agents Chemother 2009; 53: 849-862.
7. ClinicalTrials.gov. Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening 
Regimens in Pulmonary Tuberculosis (REMoxTB). University College, London. http://www. 
clinicaltrials.gov/ct2/show/NCT00864383?term=tuberculosis+moxifloxacin&rank=3 (Date last 
accessed: 04-03-2011).
8. Oliphant CM, Green GM. Quinolones: a comprehensive review. Am Fam Physician 2002; 65: 
455-464.
9. Dooley KE, Golub J, Goes FS, Merz WG, Sterling TR. Empiric treatment of community-acquired 
pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002; 
34: 1607-1612.
10. Bernardo J, Yew WW. How are we creating fluoroquinolone-resistant tuberculosis? Am J Respir 
Crit Care Med 2009; 180: 288-289.
11. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet 
Infect Dis 2003; 3: 432-442.
12. Soudani A, Hadjfredj S, Zribi M, et al. First report of molecular characterization of fluoroquinolone 
resistant Mycobacterium tuberculosis strains in a Tunisian hospital setting. Clin Microbiol Infect 
2010; 16: 1454-1457.
13. Agrawal D, Udwadia ZF, Rodriguez C, Mehta A. Increasing incidence of fluoroquinolone-resistant 
Mycobacterium tuberculosis in Mumbai, India. Int J Tuberc Lung Dis 2009; 13: 79-83.
14. Umubyeyi AN, Rigouts L, Shamputa IC, et al. Limited fluoroquinolone resistance among 
Mycobacterium tuberculosis isolates from Rwanda: results of a national survey. J Antimicrob 
Chemother 2007; 59: 1031-1033.
15. Grimaldo ER, Tupasi TE, Rivera AB, et al. Increased resistance to ciprofloxacin and ofloxacin in 
multidrug-resistant mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in 
the Philippines. Int J Tuberc Lung Dis 2001; 5: 546-550.
16. Wang JY, Lee LN, Lai HC, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: 
associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 
2007; 59: 860-865.
17. Riantawan P, Punnotok J, Chaisuksuwan R, Pransujarit V. Resistance of Mycobacterium tuberculosis 
to antituberculosis drugs in the Central Region of Thailand, 1996. Int J Tuberc Lung Dis 1998; 2: 
616-620.
18. Bozeman L, Burman W, Metchock B, Welch L, Weiner M. Fluoroquinolone susceptibility among 
Mycobacterium tuberculosis isolates from the United States and Canada. Clin Infect Dis 2005; 40: 
386-391.
Part III -  Preventing non-adherence
#
#214 | Chapter 11
19. Park IN, Hong SB, Oh YM, et al. Impact of short-term exposure to fluoroquinolones on ofloxacin 
resistance in HIV-negative patients with tuberculosis. Int J Tuberc Lung Dis 2007; 11: 319-324.
20. Huang TS, Kunin CM, Shin-Jung LS, Chen YS, Tu HZ, Liu YC. Trends in fluoroquinolone resistance 
of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J Antimicrob 
Chemother 2005; 56: 1058-1062.
21. Ginsburg AS, Hooper N, Parrish N, et al. Fluoroquinolone resistance in patients with newly 
diagnosed tuberculosis. Clin Infect Dis 2003; 37: 1448-1452.
22. Xu P, Li X, Zhao M, et al. Prevalence of fluoroquinolone resistance among tuberculosis patients in 
Shanghai, China. Antimicrob Agents Chemother 2009; 53: 3170-3172.
23. Devasia RA, Blackman A, Gebretsadik T, et al. Fluoroquinolone resistance in Mycobacterium 
tuberculosis: the effect of duration and tim ing of fluoroquinolone exposure. Am J Respir Crit Care 
Med 2009; 180: 365-370.
24. World Health Organization. WHO report 2010. Global tuberculosis control. WHO/HTM/TB/2010.7. 
Geneva, Switzerland: WHO, 2010.
25. Van den Boogaard J, Semvua HH, Boeree MJ, Aarnoutse RE, Kibiki GS. Sale of fluoroquinolones 
in northern Tanzania: a potential threat for fluoroquinolone use in tuberculosis treatment. J 
Antimicrob Chemother 2010; 65: 145-147.
26. Van den Boogaard J, Lyimo R, Irongo CF, et al. Community vs. facility-based directly observed 
treatment for tuberculosis in Tanzania’s Kilimanjaro Region. Int J Tuberc Lung Dis 2009; 13: 
1524-1529.
27. Kibiki GS, Mulder B, Dolmans WM, et al. M. tuberculosis genotypic diversity and drug susceptibility 
pattern in HIV-infected and non-HIV-infected patients in northern Tanzania. BMC Microbiol 2007; 
7: 51.
28. Ministry of Health and Social Welfare. United Republic of Tanzania. Manual of the National 
Tuberculosis and Leprosy Programme in Tanzania. Fifth edition. Dar es Salaam, 2010.
29. Kamerbeek J, Schouls L, Kolk A, et al. Simultaneous detection and strain differentiation of 
Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 1997; 35: 907-914.
30. Van Ingen J, Simons S, De Zwaan R, et al. Comparative study on genotypic and phenotypic 
second-line drug resistance testing of Mycobacterium tuberculosis complex isolates. J Clin 
Microbiol 2010; 48: 2749-2753.
31. Springer B, Lucke K, Calligaris-Maibach R, Ritter C, Bottger EC. Quantitative drug susceptibility 
testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. J Clin 
Microbiol 2009; 47: 1773-1780.
32. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis 2005; 41 Suppl 2: S120-126.
33. Von Groll A, Martin A, Jureen P, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis 
and mutations in gyrA and gyrB. Antimicrob Agents Chemother 2009; 53: 4498-4500.
34. Dewan P, Sosnovskaja A, Thomsen V, et al. High prevalence of drug-resistant tuberculosis, 
Republic of Lithuania, 2002. Int J Tuberc Lung Dis 2005; 9: 170-174.
35. Ramachandran R, Nalini S, Chandrasekar V, et al. Surveillance of drug-resistant tuberculosis in the 
state of Gujarat, India. Int J Tuberc Lung Dis 2009; 13: 1154-1160.
36. Chonde TM, Basra D, Mfinanga SG, et al. National anti-tuberculosis drug resistance study in 
Tanzania. Int J Tuberc Lung Dis 2010; 14: 967-972.
Part III -  Preventing non-adherence
#
#Fluoroquinolone resistance in Tanzania | 215
Part III -  Preventing non-adherence
0
0
#Chapter 12
General Discussion
#
#
#Introduction
In th is thesis, the problem of non-adherence to tuberculosis (TB) treatment is 
addressed in an integral way. The problem is explored from a clin ica l-pharm aco­
logical point of view and from the perspectives of TB patients in part I of the 
thesis. In part II, several direct and indirect methods to measure adherence are 
evaluated for their valid ity and applicab ility  in resource-lim ited settings. The 
studies in part III cover a number of operational and pharm acological strategies 
to prevent non-adherence to TB treatment. Most studies presented in this thesis 
were conducted in the Kilimanjaro Region of Tanzania.
The context: adherence to tuberculosis treatment in Tanzania
Tanzania is one of the 22 countries with the highest burden of TB worldw ide.1 
According to recent estimates of the World Health Organization (WHO), the TB 
incidence is around 183 per 100,000 population per year and 77% of prevalent 
TB cases are detected by the Tanzanian national TB control programme. The 
treatment success rate is estimated at 88% in new cases and 82% in retreatment 
cases.1
The Kilimanjaro Region is an area in northern Tanzania that is almost half the size 
of The Netherlands and inhabited by 1.3 million people who are living in one 
urban and six rural d istricts.2 According to estimates from our studies, the 
region's TB case notification rate was 178 per 100,000 population in 2007, and 
the treatment success rates were 78% and 76% in new and retreatment cases, 
respectively (C hapter 7). The prevalence of m ultidrug-resistant (MDR) TB was 
estimated to be 1.0% in patients with smear-positive pulmonary TB (C hapter 11); 
comparable to national estimates.13
At first glance, the treatment outcom es of TB patients in Tanzania are favourable. 
The national treatment success rate has reached the global target for TB control, 
and MDR TB is still uncommon in the country.1 Nevertheless, we do need to be 
concerned about non-adherence to TB treatment in Tanzania for a number of 
reasons.
First, still almost a quarter of Tanzanian TB patients are not detected by the 
national TB control programme. It is likely that among them are patients who
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refuse to seek biomedical healthcare at all and this, as explained in C hapter 3 
and in the next section, can be regarded as a form of primary non-adherence.4 
Second, the current first-line treatment regimen is known to be highly effective in 
patients with drug-susceptib le TB; it can achieve cure rates of over 95%.5 From 
this point of view and considering that 99% of Tanzanian TB patients have drug- 
susceptible TB, the treatment success rate in Tanzania is unnecessarily low and 
non-adherence is likely to contribute to th is.6
Finally, the estimates of treatment success rates in Tanzania are derived from a 
manual registration system that is prone to errors and incomplete data. For 
example, in 10% of the 2007 cohort of TB patients from the Kilimanjaro Region 
the registered treatment outcome was ‘transferred out' and no follow-up of the 
real outcome was made (C hapter 7). Thus, the epidem iological data on treatment 
outcom es should be interpreted with caution.
In 2007, the Tanzanian national TB control programme launched the Patient 
Centred Treatment (PCT) approach to improve adherence to treatment by TB 
patients. The PCT approach empowers patients to choose between facility-based 
directly observed treatment (DOT), i.e. daily DOT in a healthcare facility, and 
comm unity-based DOT, i.e. DOT provided by a treatment supporter (usually a 
spouse or relative) in the patient's hom e-setting.7 In the absence of reliable 
methods to measure adherence, the effectiveness of the PCT approach is d ifficult 
to assess. Apart from epidem iological data on treatment outcomes and anecdotic 
evidence from healthcare providers suggesting that non-adherence to TB 
treatment is common in Tanzania, little is known about the extent of the problem 
within the PCT approach. Additional interventions to promote adherence to TB 
treatment may be needed, but w ithout a thorough understanding of the 
determ inants of adherence behaviour it is impossible to develop tailored 
interventions. The findings from the studies presented in this thesis and 
summarized in Table 1 provide guidance in how to approach the problem of 
non-adherence to TB treatment in general and in the Tanzanian setting in 
particular.
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Table 1 Summary of the main findings of the studies described in th is thesis
Research question(s)
Part I. Exploring the problem of non-adherence to TB treatment
Chapter 2 Why are we still in the dark with respect to understanding the 
adherence-response relationship in TB treatment and how can 
we get out?
Chapter 3 How is adherence behaviour established in the perception of 
Tanzanian TB patients?
Part II. Measuring adherence to long-term treatment regimens
Chapter 4 Which combination of methods is valid and feasible to measure 
adherence to TB treatment in resource-limited settings?
How adherent are Tanzanian TB patients on community-based
Chapter 5 
Chapter 6
DOT?
Is the use of MEMS to monitor adherence to antiretroviral 
treatment acceptable to Tanzanian HIV-patients?
Could the determination of TB drug concentrations in blood 
(TDM) be a valid method to measure adherence? a
Part III. Preventing non-adherence to TB treatment
Chapter 7 Is community-based DOT in the Tanzanian patient centred TB 
treatment approach an effective alternative to facility-based DOT 
with respect to treatment outcome?
Chapter 8 What are the challenges of developing new TB drugs that could 
shorten treatment ? Which new drugs are currently in clinical 
development?
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Main findings
We lack uniformity in how we define and measure non-adherence, we have no easily 
accessible treatment outcome indicators, and the relationship between adherence and 
response to TB treatment is complicated by factors that are only partly understood. To map 
out the adherence-response relationship in TB treatment, observational and experimental 
studies in patients, and in vitro and animal models are needed.
The main determinant of adherence is the patient’s intention to adhere. The intention to 
adhere is based on knowledge and beliefs about TB treatment and the motivation to get 
cured, and preceded by the decision to seek biomedical healthcare. Furthermore, adherence 
behaviour is influenced by facilitators of and barriers to adherence. The presence of social 
support is the main facilitator of adherence. It also strengthens the patient’s intention to 
adhere by inducing perceived social pressure. Socioeconomic difficulties and substance 
abuse hamper adherence.
MEMS was used as a gold standard to measure adherence and validate other adherence 
measures. The combination of pill counts, clinic attendance for medication refills and the 
ACTG adherence questionnaire is sensitive to identify non-adherent patients and feasible 
for use in resource-limited settings. Patients on community-based DOT had high adherence 
rates (mean: 96.3%, SD: 7.7; MEMS data).
The use of MEMS was readily accepted by Tanzanian HIV-patients on antiretroviral treatment. 
Patients indicated that MEMS use had improved their adherence behaviour, but this effect 
subsided over time. Taking the MEMS medication bottle along on travel occasions was the 
main hurdle to using MEMS.
The application of TDM to individualize TB drug dosing in four patients with relapse TB is 
presented in this study. Low peak plasma concentrations of the TB drugs were found, despite 
adequate adherence. Thus, other factors than non-adherence can result in suboptimal drug 
concentrations and therefore TDM is an inaccurate method to measure adherence.
Treatment success rates were higher in patients on community-based DOT than in patients 
on facility-based DOT (81% and 70%, respectively; p<0.001). Cure rates in the subgroup of 
smear-positive pulmonary TB patients were similar in the patients on community and facility- 
based DOT (73% and 72%, respectively).
The challenges of developing new TB drugs include the limited interest of pharmaceutical 
industries, the scarcity of trial sites with sufficient research capacity, the complex features 
of MTB, and the lack of validated surrogate markers for treatment success. Apart from the 
evaluation of new agents, phase II and III clinical trials are ongoing with higher doses of the 
rifamycins and with the fluoroquinolones moxifloxacin and gatifloxacin.
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Table 1 Continued
Research question(s)
Part III. Preventing non-adherence to TB treatment
Chapter 9 What is the rate of TB drug-induced hepatotoxicity in Tanzanian 
TB patients?
Chapters 10a & 10b To which extent are the fluoroquinolones sold in northern 
Tanzania?
Chapter 11 Is fluoroquinolone resistance in MTB common in patients from 
northern Tanzania and is this related to previous fluoroquinolone 
exposure?
a This research question follows from the presentation of a case series in this chapter. TB = tuberculosis; 
DOT = directly observed treatment; MEMS = medication event monitoring system; ACTG = AIDS clinical 
trials group; SD = standard deviation; HIV = human immunodeficiency virus; TDM = therapeutic drug 
monitoring; MTB = Mycobacterium tuberculosis.
Defining non-adherence to TB treatment: patterns and 
levels
As discussed in C hapter 2, one of the requisites for a thorough exploration of the 
problem of non-adherence to TB treatment is agreement on how to define 
non-adherence. Generally, adherence to a medication regimen is defined as “the 
extent to which patients take medications as prescribed by their healthcare 
providers.”8 The definition is clear with respect to the active role of patients in 
establishing adherence behaviour - the term ‘com pliance’ has been rejected as 
it suggests that patients are expected to passively obey to their docto r’s 
instructions9 - but it reveals little about patterns and levels of medication intake 
that determine the differentiation between adherent and non-adherent patients.4
Patterns of non-adherence
A distinction can be made between patients who fail to take any medication at all 
(primary non-adherence), patients who terminate treatment prematurely, and
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Main findings
TB drug-induced hepatotoxicity is uncommon in Tanzanian patients (0.9% in our study 
population). Since rifampicin is a potentially hepatotoxic drug, the finding is encouraging for 
the development of shorter treatment regimens with high doses of rifampicin.
The fluoroquinolones account for 12% of the total sale of antibiotics by authorized 
pharmacies in northern Tanzania. Moreover, fluoroquinolones are widely available in 
unauthorized drug outlets.
Fluoroquinolone resistance in MTB isolates is uncommon in Tanzania (0.7%). The two 
patients with fluoroquinolone-resistant TB in this study were not previously exposed to 
fluoroquinolones. The finding favours the development of fluoroquinolone-containing TB 
treatment regimens of shorter duration.
patients who  deviate from the prescribed treatm ent regimen in another w ay  such  
as by m eans of brief treatm ent interruptions and irregular drug intake.4 This dif­
ferentiation betw een  patterns of non -adheren ce  should be kept in mind when  
exploring the problem of non -ad heren ce  for a num ber of reasons.
First, the different patterns of non -ad heren ce  are based on different behavioural  
m echanism s that ask  for tailored patient a p p ro a c he s .8-10 In C h a p te r  3, we found  
that som e Tanzanian TB patients refuse to seek  b iomedical healthcare at all 
becau se  of traditional beliefs, lack of knowledge about TB, or fear for stigma.  
This could be regarded as a form of primary non-adherence. From several studies  
including ours, it is known that som e patients do not understand the necessity of 
com pleting  TB treatm ent and stop to adhere  w hen  they start to feel better, 
w hereas  others intend to adhere  but som etim es  forget to take a dose at the 
desired time, resulting in irregular medication intake.11-16 In the preliminary  
theoretical model of adh eren ce  behaviour presented in C h a p te r  3 (page 52) 
several cognitive m echanism s that could explain the different patterns of 
non-ad heren ce  are shown. Provided that the model, which was derived from the
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be valid in larger non-adherent patient populations, it could facilitate the 
development of tailored interventions that address the cognitive mechanisms 
underlying the different patterns of non-adherence.
Second, the different patterns of non-adherence are likely to have a different 
impact on treatment response. As discussed in C hapter 2, it is still incompletely 
understood how non-adherence affects TB treatment response. However, a few 
hypotheses can be drawn. Irregular medication intake could result in periods of 
suboptimal drug concentrations that enable drug-resistant Mycobacterium  
tuberculosis  (MTB) mutants to overgrow the normal susceptible bacilli.17-19 The 
risk is largest in actively m ultiplying bacilli that are typ ica lly present at the onset 
of treatm ent.20 The risk of treatment failure and relapse is related to the duration 
of treatment and the number of doses taken.2122 Premature term ination of 
treatment in the early phase, i.e. when the actively multiplying MTB bacilli are 
being killed,2324 is most likely to result in treatment failure. Termination of 
treatment in the continuation phase could interrupt the process of eradicating 
the (semi-) dormant bacilli and this may lead to relapse TB.25-27 As worked out in 
C hapter 2, observational studies in humans whose adherence is being monitored 
and experimental studies in in vitro and animal models are needed to confirm 
these hypotheses. A thorough understanding of how the various patterns of 
non-adherence affect treatment response will help in the development of 
evidence-based guidelines for the management of non-adherent patients.
Levels of non-adherence
For clinical and research purposes, efforts are made to assess levels of 
adherence, or adherence rates; i.e. the proportion of prescribed doses that 
patients have taken over a specified period, irrespective of the pattern of 
adherence.8 However, as reflected in the studies in part II of this thesis and 
discussed in the next section, measuring adherence to a prescribed treatment 
regimen in order to determine adherence rates is d ifficu lt.4 
Adherence rates are often used to differentiate between adherent and 
non-adherent patients but such a dichotom ization induces several problems. 
First, there is no consensus on what should be considered adequate adherence 
to TB treatm ent.68 The selection of an adherence rate cut-off value that
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and lacks plain scientific evidence.6 Moreover, it ignores the fact that consumption 
of less than the recommended number of doses can be sufficient to attain 
treatment success in some patients.9
Second, from the patients' perspective the lack of consensus on the required 
minimum level of adherence to TB treatment is likely to raise confusion. To avoid 
this, the best strategy is to aim for 100% adherence by all patients. However, this 
implies that patients who take most but not all of the prescribed doses at the 
correct time (i.e. patients who are slightly less than 100% adherent) are classified 
as non-adherent. It could result in stigmatization and affect the relationship 
between patients and healthcare providers.89 Findings from our study (Chapter 
3) and other studies on the determ inants of adherence suggest that the quality 
of the doctor-patient relationship is an important determ inant of adherence 
behaviour.1628 Thus, blaming a patient who missed a single dose of being 
non-adherent could have a detrimental effect on the patient's adherence.
Patterns and levels of non-adherence: implications for clinical practice
Clearly, for an adequate risk assessment of the possible consequences of 
non-adherence, the determination of adherence rates is essential but not 
sufficient; patterns and timing of non-adherence should be considered as well. 
For the development of tailored adherence promoting interventions, differentiating 
between patterns of non-adherence and the underlying cognitive mechanisms is of 
major importance.
The Directly Observed Treatment Short-course (DOTS) strategy that is recommended 
by the WHO and implemented in most countries including Tanzania, incorporates a 
few elements that allow for a basic assessment of patterns and levels of adherence by 
TB patients.1 The third element of the DOTS strategy is the direct observation of 
medication intake by a trained supervisor (DOT).29 In its conventional way -provided 
by healthcare staff at healthcare facilities where patients have to report on a daily 
basis- DOT is an indirect method to monitor patterns and levels of adherence by 
recording the regularity of the patients' clinic attendance. However, the gradual shift 
from DOT provided in healthcare facilities to DOT provided in home-settings does not 
favour the healthcare provider's ability to monitor the patient's level and pattern of 
adherence.3031
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standardized way; i.e. by differentiating between cure, treatment completed, 
treatment failure, death, default, and transferred out.29 This classification helps to 
identify in retrospect non-adherent patients who terminated treatment prematurely, 
but it does not reveal details about levels and patterns of adherence.
In summary, the DOTS strategy is of limited help in getting accurate insights in 
the patterns and levels of adherence by TB patients. More reliable adherence 
measures are urgently needed.
Measuring adherence to long-term treatment regimens
Apart from a clinical purpose, measuring adherence to a prescribed treatment 
regimen can have epidem iological and research purposes. It is performed to 
describe adherence rates in specific populations and monitor medication intake 
of participants in clinical trials. Measuring adherence is important in explorative 
studies of the adherence-response relationship and the determ inants of 
adherence behaviour, and in evaluation studies of the effectiveness of adherence 
promoting interventions.4 The purpose of measuring adherence determines 
which (combination of) method(s) is most appropriate to use.432
Electronic monitoring of adherence: an appropriate gold standard?
In C hapter 4, we used the Medication Event Monitoring System (MEMS) as a 
gold standard to assess adherence rates of Tanzanian patients on community- 
based DOT (an epidem iological purpose) and to determine the valid ity of 
alternative adherence measures that are feasible for use in resource-lim ited 
settings (a research purpose).
MEMS, a medication container (bottle) with in its cap an electronic m icrochip 
that registers time and date of every bottle opening,433 provides detailed 
qualitative and quantitative data on patterns and levels of adherence. It can 
detect periods of non-adherence that are not identified by other adherence 
measures and it allows for an accurate assessment of adherence rates.434 Thus, 
MEMS is an appropriate method to measure adherence for clinical, epidem iolog­
ical and research purposes. Its use has been described in over 250 studies
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standard to measure adherence.4
Electronic monitoring of adherence has lim itations as well. First, it is an indirect 
measure that assumes that every MEMS bottle opening represents medication 
intake. However, patients may accidentally or deliberately open the bottle w ithout 
taking medication, or take out more than one dose at a time for later use.434-37 In 
C h a p te r  5 , we described three patients on antiretroviral treatment who transferred 
their medication to ordinary pill bottles on travel occasions because they did not 
want to travel along with the MEMS bottle. Clearly, treatment periods that are not 
monitored by MEMS should be interpreted with caution as they may represent 
non-MEMS use rather than non-adherence.
Second, MEMS use could improve or impede adherence behaviour in patients 
who are aware that their behaviour is being monitored.838 Two-third of the TB 
patients who participated in the study presented in C h a p te r  4  and used MEMS 
throughout the 6-m onths treatment period, thought that MEMS use had improved 
their adherence behaviour. However, no difference was found between the 
adherence rates of patients who did and who did not th ink that MEMS use had 
altered their behaviour. The HIV-infected patients who participated in the study 
described in C h a p te r  5 and used MEMS over a 3-months period, also thought 
that MEMS use had influenced their adherence behaviour. However, their 
adherence rates decreased over time and then stabilized, suggesting that the 
patients got used to MEMS and returned to their usual behaviour. A decrease of 
the ‘interventional effect' of MEMS with prolonged use has also been observed 
in other studies.3940
Finally, MEMS devices are costly and require the presence of computers at 
medication dispensing facilities to download MEMS data.48 Therefore, the use of 
MEMS may not be affordable for routine clinical practice in resource-lim ited 
settings. Instead, MEMS could be used for research purposes, for example to 
validate cheaper methods to monitor adherence as we did in C h a p te r  4 . Provided 
that patients are instructed on how to use MEMS consistently and that monitored 
periods are long enough for patients to get used to the MEMS bottle, it is 
justifiable to use MEMS as a gold standard to validate alternative adherence 
measures.438
As a result of considerable engineering efforts, the applicab ility  of MEMS devices
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is currently being extended. For example, electronic monitors of pill removal 
from medication blisters (instead of bottles) are now available, and sophisticated 
devices that combine electronic monitoring of pill removal with a direct adherence 
measure that proves pill intake (for example a urine test) are being developed.41 
Such advanced technologies could optimize the suitability  of MEMS as a gold 
standard to measure adherence.
Measuring adherence in routine clinical practice in resource-limited  
settings
The primary aim of measuring treatment adherence in routine clinical practice is 
to identify non-adherent patients (particularly those on community-based DOT 
or self-adm inistered treatment) who could benefit from adherence promoting 
interventions.4 Eligible methods should detect as many tru ly non-adherent 
patients as possible (i.e. have a high sensitivity), and classify a minimum number 
of non-adherent patients incorrectly as adherent (i.e. have a high negative 
predictive value). Furthermore, methods that reveal information about patterns 
and possible causes of non-adherence are highly relevant for this purpose as 
they could serve as starting-points for tailored adherence promoting interventions. 
Finally, eligible adherence measures should be affordable and simple to use.442 
In C hapter 4, we tried to improve the sensitivity and negative predictive value of 
the routinely used combination method of pill counts and clin ic attendance for 
medication refills by adding a third adherence measure. Pill counts are simple 
and inexpensive to use.8 A drawback is that patients may distort pill count data 
accidentally (by forgetting to bring back remaining tablets or medication blisters) 
or purposively (by discarding remaining tablets).48 The method of recording the 
patient's clin ic attendance for medication refills gives an impression of the 
patient's w illingness to adhere to treatment, but clinic attendance does not 
necessarily represent adherence behaviour in patients on community-based 
DOT or self-adm inistered treatm ent.8
Adding a standardized, validated adherence questionnaire such as the Morisky 
scale,43 Brief Medication Questionnaire (BMQ)44 or AIDS Clinical Trials Group 
(ACTG) adherence questionnaire45 to the combination of pill counts and clinic 
attendance could improve the method's validity. Such questionnaires cover 
questions that aim to quantify adherence (e.g. “ During the past 4 days, on how
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that inquire about possible reasons for non-adherence (e.g. “When you feel 
better, do you sometimes stop taking your medicine?”).43 The answers to the 
latter kind of questions, which are most extensively present in the ACTG 
adherence questionnaire,45 can help healthcare providers to understand the 
cognitive mechanisms that underlie non-adherence and consequently offer 
tailored adherence promoting interventions.
Self-reports to measure adherence also have disadvantages. Patients who report 
non-adherence are generally correct, but patients who report high levels of 
adherence may not be.4 The interviewer's communication skills can influence the 
patient's response when the questionnaire is administered verbally, and illiteracy 
may hamper the use of written questionnaires.48 With respect to quantifying 
non-adherence with standardized questionnaires, recall bias could distort the 
quantification of non-adherence over longer time periods.46 
The ACTG adherence questionnaire improved the sensitivity and negative 
predictive value of the pill counts and clinic attendance substantially in our study 
(C hapter 4). As part of a combination of methods to measure adherence, 
validated adherence questionnaires could be a valuable tool to monitor adherence 
of patients under routine clinical care.
The role of direct methods to detect non-adherence
The methods discussed so far, are indirect adherence measures that assume but 
do not prove medication intake. A more objective, direct method to measure 
adherence is to determine drug concentrations in body flu ids (blood, urine, 
saliva) as detecting adequate drug concentrations leaves no doubt about 
medication intake.832
In C hapter 6, we evaluated the applicab ility  of therapeutic drug monitoring 
(TDM) in the process of individualizing TB drug dosing schedules in patients 
who are slow to respond to the standard treatment regimen. We illustrated the 
use of TDM in a case series of four patients with relapse TB, all of whom had 
suboptimal plasma concentrations of the TB drugs despite adequate adherence. 
The study shows an important lim itation of the e lig ib ility  of TDM as a method to 
measure adherence: suboptimal drug concentrations do not always indicate 
non-adherence but can be caused by interindividual variability in pharm acoki­
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netics and absorption problems (such as with diabetes mellitus, HIV-infection or 
gastrointestinal anomalies) as well.47-52
In the study presented in C hapter 4, two measures to detect the presence of TB 
drugs in urine were used: a urine colour test for rifampicine and a test based on 
the Arkansas method to detect isoniazid metabolites in urine. The valid ity of 
urine tests to detect non-adherence can be hampered by interindividual variation 
in the drug elim ination processes and tobacco smoke may affect the sensitivity 
and specific ity of the Arkansas m ethod.453
There are more drawbacks of direct methods to assess the patient's adherence 
to treatment. They cover brief medication intake periods only and thus, patterns 
and levels of adherence are difficu lt to assess with these methods. Moreover, 
their coverage of recent pill use only increases the likelihood of ‘white coat 
adherence', i.e. the phenomenon that patients alter their adherence behaviour 
prior to testing.32 Ideally, tests to detect TB drugs in body flu ids are performed by 
surprise, for example by means of unannounced home-visits to patients. However, 
this has ethical im plications and is too labour intensive for routine clinical 
practice.4 Finally, the methods (TDM in particular) are costly and require 
laboratory expertise and equipment.
Therefore, the role of direct methods to measure adherence to TB treatment is 
limited unless they are combined with other methods to measure adherence 
such as MEMS.41 Instead, TDM is a valuable tool to optimize drug dosing 
schedules in a selected group of TB patients (Chapter 6) and could be used to 
study the intermediate factors in the adherence-response relationship (Chapter 2).
Preventing non-adherence to TB treatment
An important requisite for the development of effective adherence promoting 
interventions is to understand the factors that hamper or facilitate adherence. In 
C hapter 3, we analyzed the experiences of well-adherent TB patients from 
northern Tanzania and developed a prelim inary theoretical model of adherence 
behaviour. In future studies, the valid ity of th is adherence behaviour model 
should be confirmed in non-adherent patients with different patterns of 
non-adherence. In anticipation of such validation studies, the model (page 52)
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could be used to identify possible avenues for adherence promoting strategies.
Avenues for adherence promoting interventions: operational strategies
Health education
We found that the most important determinant of adherence behaviour is the 
patient's intention to adhere and that this intention is preceded by the decision 
to seek biomedical healthcare. The decision to seek biomedical healthcare and 
the intention to adhere to treatment are largely based on knowledge and beliefs 
about TB treatment. Thus, health education interventions are likely to improve 
adherence to treatment by TB patients. Health education at the com m unity level 
could influence healthcare seeking behaviour and reduce TB stigm a,54-58 and 
health education at the individual patient level, preferably repeatedly throughout 
treatment, could improve the patient's understanding of the importance of 
com pleting treatment.115960 Adherence measures that provide detailed information 
about the patient's pattern and level of adherence (such as MEMS or standardized 
adherence questionnaires) could serve as a tool to provide tailored counselling 
and feedback to individual patients.61
Social support
Another determinant of the patient's intention to adhere is the presence of social 
support. Social support networks can induce perceived social pressure (i.e. the 
patient's perception that key-persons in his/her social network disapprove certain 
behaviour)62 and this can strengthen the patient's intention to adhere.1663-65 
Members of the patient's social support network could be involved in TB treatment 
explicitly, fo r example by making them co-responsible for the patient's adherence 
to treatment as is done in comm unity-based DOT programmes.66 We evaluated 
the effectiveness of DOT provided by a treatment supporter from the patient's 
social network (the Tanzanian variant of comm unity-based DOT)7 in two ways: by 
evaluating treatment outcomes of patients on comm unity-based DOT (Chapter 
7), and by assessing their adherence rates (Chapter 4). The results indicate that 
comm unity-based DOT is an effective adherence promoting strategy even 
though anecdotic evidence suggests that DOT is not always applied strictly in 
the patient's home-setting (C hapters 3, 4 and 7). The explanation of the 
effectiveness of community-based DOT programmes is likely to be related to the
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impact of com m unity involvement on the patient's perceived social pressure 
rather than to the actual observation of medication intake.66 
Another way to make use of the adherence promoting effect of social support is 
to organize TB patients into groups so that they can motivate one another to 
adhere to treatment. In Ethiopia, so called ‘TB clubs' were introduced in which 10 
to 15 TB patients from the same com m unity share experiences and help each 
other to adhere to treatment. The strategy was found to improve treatment 
completion rates and increase com m unity awareness about TB.67
Incentives and rem inder cues
A number of studies showed that the provision of monetary and food incentives 
or rem inder cues such as text messages on mobile phones, could facilitate 
adherence, particularly when offered in combination with other adherence 
promoting interventions.68'71 However, not all studies confirm ed that incentives 
improve adherence7072 and our findings (Chapter 3) suggest that incentives and 
reminder cues are unlikely to make a difference in patients who lack the intention 
to adhere. Moreover, the provision of incentives or reminder cues requires 
sustained financial comm itment of governments and/or charity organizations73 
and this may be unrealistic to expect in resource-lim ited settings. Finally, the 
provision of incentives has practical and ethical implications as it will be very 
d ifficu lt to reach consensus on what (cash or in kind) and how much should be 
given to satisfy all patients.
Healthcare service factors
The quality of the relationship between healthcare providers and patients is 
known to affect adherence.15'6374-77 A relationship based on trust, mutual respect 
and concordance has a positive impact on adherence behaviour10,16,28,63 and 
patient empowerment (for example by means of a patient centred treatment 
approach)78 could help to establish such a relationship. Inflexibility of healthcare 
staff to meet patients' requests such as convenient opening hours of clinics and 
decentralized dispensing of medication, can hamper adherence.767980 Hence, 
conceding to patients' needs and requests (again, by means of a patient centred 
treatment approach) will help patients to adhere to treatment.
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Operational strategies com bined: a multifactoria l approach 
Considering the versatility of factors that affect adherence behaviour (Chapter 3), 
the most effective way to improve adherence to the current TB treatment regimen 
is to combine operational strategies.8'7081 The necessity of a multifactorial 
approach to promote adherence to TB treatment is increasingly acknowledged. 
The American Thoracic Society recommends a patient centred treatment 
approach that includes directly observed treatment, adherence ‘enabling’ 
interventions and the provision of incentives.5 Well considered, the DOTS strategy 
is another example of a multifactorial TB treatment approach. It pays particular 
attention to healthcare service factors.2982
The Tanzanian PCT approach combines patient empowerment with offering the 
option of community-based DOT as an alternative to the burdensome 
facility-based DOT.7 The concept of a patient centred treatment approach is 
relatively new in the Tanzanian setting where a hierarchical doctor-patient 
relationship used to be standard.83 Findings in C hapter 3 indicate that elements 
of a paternalistic doctor-patient relationship are still w idely present, and C hapter 
7 reveals that the choice between comm unity- and facility-based DOT is 
sometimes more clinician- than patient-driven. Convincing healthcare providers 
and patients of the im portance of patient empowerment could result in a shift 
towards a more equal relationship between healthcare providers and patients.84 
This may improve the patient's w illingness to adhere to the prescribed treatment 
regimen85 and answer openly and honestly to the questions in adherence 
questionnaires. In the end, a shift towards more patient centred healthcare 
services might even encourage primary non-adherent patients to seek biomedical 
healthcare for TB diagnosis and treatment.
Avenues for adherence promoting interventions: pharmacological 
strategies
Operational strategies to promote adherence to TB treatment are generally 
labour intensive and costly, and they require sustained comm itment of 
governments and healthcare providers. A com pletely different approach to 
improve adherence to TB treatment is a pharm acological strategy: the 
development of sim pler and shorter TB treatment regimens that make treatment 
completion easier.61686
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The process of developing TB treatment regimens of shorter duration is 
challenged by a number of factors that are summarized in C hapter 8. Nevertheless, 
we do have reasons to be optim istic. At present, at least ten different compounds 
are in clinical development, each of which has the potential to shorten TB 
treatment to 3 months or less.8788 Thanks to initiatives such as that of the Pan 
African Consortium for the Evaluation of Antituberculosis Antib iotics (PanACEA) 
in which European research organizations, Sub-Saharan African trial sites and 
pharmaceutical companies are collaborating to conduct phase II and III clinical 
trials in A frica,89-91 the clinical and laboratory capacity to perform large trials with 
new TB drugs is expanding in resource-lim ited settings.92 The PanACEA 
consortium is taking a programmatic approach in which series of consecutive 
studies with moxifloxacin, SQ109 and higher doses of rifampicin are conducted. 
Apart from evaluating regimens in which these agents are incorporated, the 
studies of PanACEA aim to validate biomarkers for treatment response.89-91 The 
availability of such biomarkers could reduce the duration of clinical trials with TB 
drugs substantially.93
Finally, the Bill & Melinda Gates Foundation, Global Alliance for TB Drug 
Development and Critical Path Institute have launched a Critical Path to New TB 
Regimens (CPTR) initiative in 2010. The initiators are collaborating with the 
American Food and Drug Administration (FDA) and the European Medicines 
Agency (EMA) to develop new regulatory approaches to innovative research of 
new TB drug com binations.94 The new regulations should sim plify the complex 
regulatory procedures that have to be followed to get a new TB drug on the 
market.9294 Meanwhile, regimens with ‘old' drugs in revised doses (rifampicin) or 
altered com binations (fluoroquinolones) are most likely to proceed to 
implementation in clinical practice.92
Higher doses of rifam picin to shorten TB treatment duration 
Historical data and results from recent studies suggest that higher than standard 
doses of rifampicin could reduce TB treatment duration.95-100 As discussed in 
Chapter 8, the to lerability of high doses of rifampicin needs to be assessed. 
Within PanACEA, a ‘HIGHRIF' project is being conducted at trial sites in South 
Africa, Uganda and Tanzania.89 One of the trials in the HIGHRIF project is currently 
ongoing in Tanzania's Kilimanjaro Region. The trial aims to evaluate the pharma­
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cokinetics and to lerab ility  of 900 and 1200 mg rifampicin (as compared to the 
standard 600 mg) in a first-line treatment regimen with isoniazid, pyrazinamide 
and ethambutol. In anticipation of this trial, we conducted an observational study 
in which the incidence of TB drug-induced hepatotoxicity was assessed in 
Tanzanian TB patients on first-line treatment with the standard dose of rifampicin 
(C hapter 9). No laboratory-confirm ed hepatotoxicity was observed in th is study 
population. Considering that rifampicin is a potentially hepatotoxic drug,101 this is 
an encouraging finding for the HIGHRIF trial that is ongoing in the same area. 
Provided that higher doses of rifampicin are also tolerated well, this important TB 
drug is a promising candidate to shorten TB treatment duration.
Fluoroquinolones to shorten TB treatment duration
The fluoroquinolones constitute the other class of drugs that are already 
registered for use in second-line TB treatment. Two agents in this class of 
antibacterial drugs, moxifloxacin and gatifloxacin, have the potential to shorten 
TB treatment duration.102 As explained in C hapter 8, a drawback of incorporating 
these agents in first-line TB treatment regimens is the risk of fluoroquinolone 
resistance development by MTB,103 a risk that is possibly aggravated by the fact 
that fluoroquinolones are also used in the treatment of a wide variety of other 
infections.104105 Mono-exposure to a fluoroquinolone in patients who are 
co-infected with (yet undiagnosed) active TB could result in fluoroquinolone 
resistance development in MTB.103106 In C hapters 10 and 11, we assessed this 
risk in patients from the Kilimanjaro Region, where the efficacy of a moxifloxacin- 
containing TB treatment regimen is being evaluated in the ‘REMox' project which 
is also part of the PanACEA consortium .90
We first quantified the extent of fluoroquinolone sale for all kinds of infections by 
authorized pharmacies in Moshi, the capital of the Kilimanjaro Region, and found 
that fluoroquinolones account for 12% of the total sale of antibacterial drugs 
(C hapter 10). Alarmingly, fluoroquinolones were also w idely available in 
unauthorized drug outlets, meaning that the use of these drugs in the community 
is probably much larger than expected based on the sale in authorized 
pharmacies. In a small sub-study, we quantified the presence of active ingredient 
in ciprofloxacin tablets that we obtained from 15 unauthorized drug outlets. 
Fortunately, the tablets (manufactured in India, Korea, Cyprus and Tanzania) all
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contained an adequate amount of active ingredient (unpublished data). In 
C hapter 11, we tested the hypothesis that the risk of developing fluoroquinolone 
resistant TB is higher in patients with than in patients w ithout previous fluoroqui­
nolone exposure. Our study did not confirm  this hypothesis. Although this finding 
is favourable with respect to future implementation of fluoroquinolones in first-line 
TB treatment, concerns remain. Empirical treatment of a pulmonary infection 
with a fluoroquinolone can delay the diagnosis and treatment of TB107108 and 
considering the widespread availability of fluoroquinolones in the community, it 
will be a challenge to limit their use to the treatment of TB only.109110 Urgent efforts 
are needed to restrict the availability of the fluoroquinolones to authorized 
pharmacies and to convince physicians and pharmacists to minimize the 
prescription of fluoroquinolones.
Towards a tuberculosis-free world?
The Stop TB Partnership of the WHO has set an ambitious goal to be achieved 
by the year 2050: “To eliminate TB as a public health problem, defined as a global 
incidence of active TB of less than one case per 1 million population per year.”111 
Although the worldw ide incidence of TB has started to decrease by around 1% 
per year, the absolute number of TB cases is still increasing.1111 Hence, to achieve 
the goal of the Stop TB Partnership, the ongoing transmission of TB must be 
halted urgently.
The fight against TB is most effective when several steps in the cyclic process of 
TB transmission are blocked simultaneously (Figure 1). Two main strategies 
should be combined: avoid exposure of healthy individuals to MTB (Figure 1, 
steps 1-5) and prevent the development of active TB in individuals who have 
been exposed to MTB (Figure 1, steps 6-7).
With respect to avoiding exposure of healthy individuals to MTB, poverty-related 
factors such as poor housing, overcrowding and poor hygiene should be 
addressed (step 1),112 and TB patients who might expose healthy individuals to 
MTB must be diagnosed and treated as early as possible. The latter means that 
patient delays in seeking biomedical healthcare should be minimized (step 2)
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Figure 1 Steps 1-7 to  ha lt the  on g o in g  tran sm iss io n  of tu b e rcu lo s is
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and healthcare service delays in TB diagnosis and treatment initiation must be 
avoided (step 3 ).113114 Once treatment is initiated, an important step is to ensure 
adherence to treatment in order to achieve treatment success (step 4). As 
explained in this thesis, optim izing adherence to TB treatment requires: (i) a 
thorough understanding of the determinants of adherence behaviour and the 
intermediates of the adherence-response relationship; (ii) validation of simple 
and reliable methods to measure adherence; and (iii) development of tailored 
adherence promoting interventions.
Non-adherent patients must be traced and retreated. Treatment failures should 
be identified and acted upon as early as possible, and effective second-line 
drugs for the treatment of MDR TB should become available to all patients (step 5). 
With respect to preventing the development of active TB in individuals who have
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been exposed to MTB, important steps include immunization with newly 
developed vaccines (step 6)115 and the provision of prophylactic treatment to 
patients with latent TB infection who are at increased risk of developing active TB 
(step 7).116 Since the risk of developing active TB is particularly related to 
HIV-infection, diabetes mellitus, malnutrition, smoking and alcohol abuse, battles 
against these com orbid ities are vital in the fight against TB as well.112117 
Clearly, an integral, m ultid iscip linary approach is needed to halt the ongoing 
transmission of TB and achieve a world free of TB in the year 2050. Therefore, 
researchers from several disciplines, as well as governmental and non-govern­
mental organizations, pharmaceutical industries, private and public healthcare 
providers, comm unities and patients should join forces to break the vicious cycle 
of TB transmission.
General D iscussion 
0
#General D iscussion | 239
References
1. World Health Organization. WHO report 2010. Global tuberculosis control. WHO/HTM/TB/2010.7. 
Geneva, Switzerland: WHO, 2010.
2. Tanzania Sensa. 2002 Population and Housing Census. [Online] Available from: http://www. 
tanzania.go.tz/census/tables.htm (Date last accessed: 06-03-2009).
3. Chonde TM, Basra D, Mfinanga SG, et al. National anti-tuberculosis drug resistance study in 
Tanzania. Int J Tuberc Lung Dis 2010; 14: 967-972.
4. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials 
and clinical practice. Clin Ther 1999; 21: 1074-1090.
5. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society (ATS), Centers for 
Disease Control and Prevention (CDS), Infectious Diseases Society of America. Treatment of 
tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
6. Hall RG, Leff RD, Gumbo T. Treatment of active pulmonary tuberculosis in adults: current standards 
and recent advances. Insights from the Society of Infectious Diseases Pharmacists. Pharmaco­
therapy 2009; 29: 1468-1481.
7. Ministry of Health and Social Welfare. United Republic of Tanzania. Manual of the National 
Tuberculosis and Leprosy Programme in Tanzania. Fifth edition. Dar es Salaam, 2010.
8. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497.
9. Steiner JF, Earnest MA. The language of medication-taking. Ann Intern Med 2000; 132: 926-930.
10. Munro S, Lewin S, Swart T, Volmink J. A review of health behaviour theories: how useful are these 
for developing interventions to promote long-term medication adherence for TB and HIV/AIDS? 
BMC Public Health 2007; 7: 104.
11. Kaona FA, Tuba M, Siziya S, Sikaona L. An assessment of factors contributing to treatment 
adherence and knowledge of TB transmission among patients on TB treatment. BMC Public Health 
2004; 4: 68.
12. Harper M, Ahmadu FA, Ogden JA, McAdam KP, Lienhardt C. Identifying the determinants of 
tuberculosis control in resource-poor countries: insights from a qualitative study in The Gambia. 
Trans R Soc Trop Med Hyg 2003; 97: 506-510.
13. O’Boyle SJ, Power JJ, Ibrahim MY, Watson JP. Factors affecting patient compliance with anti-tu­
berculosis chemotherapy using the directly observed treatment, short-course strategy (DOTS). Int 
J Tuberc Lung Dis 2002; 6: 307-312.
14. Shargie EB, Lindtjorn B. Determinants of treatment adherence among smear-positive pulmonary 
tuberculosis patients in Southern Ethiopia. PLoS Med 2007; 4: e37.
15. Martins N, Grace J, Kelly PM. An ethnographic study of barriers to and enabling factors for 
tuberculosis treatment adherence in Timor Leste. Int J Tuberc Lung Dis 2008; 12: 532-537.
16. Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J. Patient adherence to tuberculosis 
treatment: a systematic review of qualitative research. PLoS Med 2007; 4: e238.
17. Drlica K, Zhao X. Mutant selection w indow hypothesis updated. Clin Infect Dis 2007; 44: 681-688.
18. Drusano GL, Louie A, Deziel M, Gumbo T. The crisis of resistance: identifying drug exposures to 
suppress amplification of resistant mutant subpopulations. Clin Infect Dis 2006; 42: 525-532.
19. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc 
Lung Dis 2009; 13: 1320-1330.
20. Gillespie SH. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular 
perspective. Antimicrob Agents Chemother 2002; 46: 267-274.
21. Chang KC, Leung CC, Yew WW, Chan SL, Tam CM. Dosing schedules of 6-month regimens and 
relapse for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174: 1153-1158.
22. Saltini C. Schedule or dosage? The need to perfect intermittent regimens for tuberculosis. Am J 
Respir Crit Care Med 2006; 174: 1067-1068.
General D iscussion
#
#240 | Chapter 12
23. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 
2000; 4: 796-806.
24. Nuermberger E, Grosset J. Pharmacokinetic and pharmacodynamic issues in the treatment of 
mycobacterial infections. Eur J Clin Microbiol Infect Dis 2004; 23: 243-255.
25. Gelband H. Regimens of less than six months for treating tuberculosis. Cochrane Database Syst 
Rev 2000; CD001362.
26. Johnson JL, Hadad DJ, Dietze R, et al. Shortening treatment in adults with noncavitary tuberculosis 
and 2-month culture conversion. Am J Respir Crit Care Med 2009; 180: 558-563.
27. Menzies D, Benedetti A, Paydar A, et al. Effect of duration and intermittency of rifampin on tuberculosis 
treatment outcomes: a systematic review and meta-analysis. PLoS Med 2009; 6: e1000146.
28. Mishra P, Hansen EH, Sabroe S, Kafle KK. Adherence is associated with the quality of profession­
al-patient interaction in Directly Observed Treatment Short-course, DOTS. Patient Educ Couns 
2006; 63: 29-37.
29. World Health Organization. An expanded DOTS framework for effective tuberculosis control. Stop 
TB communicable diseases. WHO/CDS/TB/2002.297. Geneva, Switzerland: WHO, 2002.
30. Frieden TR, Sbarbaro JA. Family observation of antituberculosis treatment. Lancet 2006; 367: 
2055-2056.
31. Frieden TR, Sbarbaro JA. Promoting adherence to treatment for tuberculosis: the importance of 
direct observation. Bull World Health Organ 2007; 85: 407-409.
32. Vrijens B, Urquhart J. Patient adherence to prescribed antimicrobial drug dosing regimens. J 
Antimicrob Chemother 2005; 55: 616-627.
33. Moulding TS. Medication monitors to treat tuberculosis. A supplement to directly observed therapy. 
Am J Respir Crit Care Med 1999; 159: 989-991.
34. Bova CA, Fennie KP, Knafl GJ, Dieckhaus KD, Watrous E, Williams AB. Use of electronic monitoring 
devices to measure antiretroviral adherence: practical considerations. AIDS Behav 2005; 9: 103-110.
35. Matsui D, Hermann C, Klein J, Berkovitch M, Olivieri N, Koren G. Critical comparison of novel and 
existing methods of compliance assessment during a clinical trial of an oral iron chelator. J Clin 
Pharmacol 1994; 34: 944-949.
36. Arnet I, Haefeli WE. Overconsumption detected by electronic drug monitoring requires subtle 
interpretation. Clin Pharmacol Ther 2000; 67: 44-47.
37. Paterson DL, Potoski B, Capitano B. Measurement of adherence to antiretroviral medications. J 
Acquir Immune Defic Syndr 2002; 31 Suppl 3: S103-S106.
38. Wagner GJ, Ghosh-Dastidar B. Electronic monitoring: adherence assessment or intervention? HIV 
Clin Trials 2002; 3: 45-51.
39. Deschamps AE, Graeve VD, Van Wijngaerden E, et al. Prevalence and correlates of nonadherence 
to antiretroviral therapy in a population of HIV patients using Medication Event Monitoring System. 
AIDS Patient Care STDS 2004; 18: 644-657.
40. Deschamps AE, Van Wijngaerden E, Denhaerynck K, De Geest S, Vandamme AM. Use of electronic 
monitoring induces a 40-day intervention effect in HIV patients. J Acquir Immune Defic Syndr 
2006; 43: 247-248.
41. Moulding T, Ellis D, Turk R. Electronic medication monitors: status of development and potential 
for improving effective TB treatment programs. 2010. [Online] Available at: http://www.medication- 
monitors.net (Date last accessed: 06-03-2011).
42. Ruslami R, Van Crevel R, Van de Berge E, Alisjahbana B, Aarnoutse RE. A step-wise approach to 
find a valid and feasible method to detect non-adherence to tuberculosis drugs. Southeast Asian 
J Trop Med Public Health 2008; 39: 1083-1087.
43. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure 
of medication adherence. Med Care 1986; 24: 67-74.
44. Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief Medication Questionnaire: a tool for 
screening patient adherence and barriers to adherence. Patient Educ Couns 1999; 37: 113-124.
General D iscussion
#
#General D iscussion | 241
45. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral 
medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient 
Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS 
Clinical Trials Group (AACTG). AIDS Care 2000; 12: 255-266.
46. Weiser S, Wolfe W, Bangsberg D, et al. Barriers to antiretroviral adherence for patients living with 
HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr 2003; 34: 281-288.
47. Um SW, Lee SW, Kwon SY, et al. Low serum concentrations of anti-tuberculosis drugs and 
determinants of their serum levels. Int J Tuberc Lung Dis 2007; 11: 972-978.
48. Narita M, Hisada M, Thimmappa B, et al. Tuberculosis recurrence: multivariate analysis of serum 
levels of tuberculosis drugs, human immunodeficiency virus status, and other risk factors. Clin 
Infect Dis 2001; 32: 515-517.
49. Holland DP, Hamilton CD, Weintrob AC, et al. Therapeutic drug monitoring of antimycobacterial 
drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. 
Pharmacotherapy 2009; 29: 503-510.
50. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62: 2169-2183.
51. Nijland HM, Ruslami R, Stalenhoef JE, et al. Exposure to rifampicin is strongly reduced in patients 
with tuberculosis and type 2 diabetes. Clin Infect Dis 2006; 43: 848-854.
52. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. Determinants of rifampin, isoniazid, 
pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob 
Agents Chemother 2006; 50: 1170-1177.
53. Guerra RL, Conde MB, Efron A, et al. Point-of-care Arkansas method for measuring adherence to 
treatment with isoniazid. Respir Med 2010; 104: 754-757.
54. Hadley M, Maher D. Community involvement in tuberculosis control: lessons from other health 
care programmes. Int J Tuberc Lung Dis 2000; 4: 401-408.
55. Escott S, Newell J. Don’t forget the bigger picture: the impact of societal issues on a community- 
based TB programme, Swaziland. J Health Organ Manag 2007; 21: 506-518.
56. Okeibunor JC, Onyeneho NG, Chukwu JN, Post E. Barriers to care seeking in directly observed 
therapy short-course (DOTS) clinics and tuberculosis control in southern Nigeria: a qualitative 
analysis. Int Q Community Health Educ 2006; 27: 23-37.
57. Courtwright A, Turner AN. Tuberculosis and stigmatization: pathways and interventions. Public 
Health Rep 2010; 125 Suppl 4: 34-42.
58. Sherman LF, Fujiwara PI, Cook SV, Bazerman LB, Frieden TR. Patient and health care system 
delays in the diagnosis and treatment of tuberculosis. Int J Tuberc Lung Dis 1999; 3: 1088-1095.
59. Dick J, Lombard C. Shared vision--a health education project designed to enhance adherence to 
anti-tuberculosis treatment. Int J Tuberc Lung Dis 1997; 1: 181-186.
60. Liefooghe R, Suetens C, Meulemans H, Moran MB, De Muynck A. A randomised trial of the impact 
of counselling on treatment adherence of tuberculosis patients in Sialkot, Pakistan. Int J Tuberc 
Lung Dis 1999; 3: 1073-1080.
61. De Bruin M, Hospers HJ, Van den Borne HW, Kok G, Prins JM. Theory- and evidence-based 
intervention to improve adherence to antiretroviral therapy among HIV-infected patients in the 
Netherlands: a pilot study. AIDS Patient Care STDS 2005; 19: 384-394.
62. Bartholomew LK, Parcel GS, Kok G, Gottlieb NH. Planning health promotion programs. An 
intervention mapping approach. Second edition. San Francisco, USA: Jossey-Bass, 2006.
63. Arcencio RA, Oliveira MF, Cardozo-Gonzales RI, Ruffino-Netto A, Pinto IC, Villa TC. City tuberculosis 
control coordinators’ perspectives of patient adherence to DOT in Sao Paulo State, Brazil, 2005. 
Int J Tuberc Lung Dis 2008; 12: 527-531.
64. Khan A, Walley J, Newell J, Imdad N. Tuberculosis in Pakistan: socio-cultural constraints and 
opportunities in treatment. Soc Sci Med 2000; 50: 247-254.
65. Ajzen I. The theory of planned behavior. Organizational Behavior and Human Decision Processes 
1991; 50: 179-211.
General D iscussion
#
#242 | Chapter 12
66. Garner P, Volmink J. Families help cure tuberculosis. Lancet 2006; 367: 878-879.
67. Demissie M, Getahun H, Lindtjorn B. Community tuberculosis care through “TB clubs” in rural 
North Ethiopia. Soc Sci Med 2003; 56: 2009-2018.
68. Mishra P, Hansen EH, Sabroe S, Kafle KK. Socio-economic status and adherence to tuberculosis 
treatment: a case-control study in a district of Nepal. Int J Tuberc Lung Dis 2005; 9: 1134-1139.
69. Perlman DC, Friedmann P, Horn L, et al. Impact of monetary incentives on adherence to referral for 
screening chest x-rays after syringe exchange-based tuberculin skin testing. J Urban Health 2003; 
80: 428-437.
70. Volmink J, Garner P. Interventions for promoting adherence to tuberculosis management. 
Cochrane Database Syst Rev 2000; CD000010.
71. Barclay E. Text messages could hasten tuberculosis drug compliance. Lancet 2009; 373: 15-16.
72. Martins N, Morris P, Kelly PM. Food incentives to improve completion of tuberculosis treatment: 
randomised controlled trial in Dili, Timor-Leste. BMJ 2009; 339: b4248.
73. Yao H, Wei X, Liu J, Zhao J, Hu D, Walley JD. Evaluating the effects of providing financial incentives 
to tuberculosis patients and health providers in China. Int J Tuberc Lung Dis 2008; 12: 1166-1172.
74. Naidoo P, Dick J, Cooper D. Exploring tuberculosis patients’ adherence to treatment regimens and 
prevention programs at a public health site. Qual Health Res 2009; 19: 55-70.
75. Widjanarko B, Gompelman M, Dijkers M, Van der Werf MJ. Factors that influence treatment 
adherence of tuberculosis patients living in Java, Indonesia. Patient Prefer Adherence 2009; 3: 
231 -238.
76. Jaiswal A, Singh V, Ogden JA, et al. Adherence to tuberculosis treatment: lessons from the urban 
setting of Delhi, India. Trop Med Int Health 2003; 8: 625-633.
77. Jakubowiak WM, Bogorodskaya EM, Borisov SE, Danilova ID, Lomakina OB, Kourbatova EV. 
Impact of socio-psychological factors on treatment adherence of TB patients in Russia. 
Tuberculosis (Edinb) 2008; 88: 495-502.
78. Macq J, Torfoss T, Getahun H. Patient empowerment in tuberculosis control: reflecting on past 
documented experiences. Trop Med Int Health 2007; 12: 873-885.
79. Mesfin MM, Newell JN, Walley JD, et al. Quality of tuberculosis care and its association with patient 
adherence to treatment in eight Ethiopian districts. Health Policy Plan 2009; 24: 457-466.
80. Sagbakken M, Frich JC, Bjune G. Barriers and enablers in the management of tuberculosis 
treatment in Addis Ababa, Ethiopia: a qualitative study. BMC Public Health 2008; 8: 11.
81. Thiam S, LeFevre AM, Hane F, et al. Effectiveness of a strategy to improve adherence to tuberculosis 
treatment in a resource-poor setting: a cluster randomized controlled trial. JAMA 2007; 297: 380-386.
82. Volmink J, Matchaba P, Garner P. Directly observed therapy and treatment adherence. Lancet 
2000; 355: 1345-1350.
83. Unger JP, Ghilbert P, Fisher JP. Doctor-patient communication in developing countries. BMJ 2003; 
327: 450.
84. Unger JP, Van Dormael M, Criel B, Van der Vennet J, De Munck P. A plea for an initiative to 
strengthen family medicine in public health care services of developing countries. Int J Health Serv 
2002; 32: 799-815.
85. Scambler G. Sociology as applied to medicine Sixth edition. London, UK: Saunders, 2008.
86. O’Brien RJ, Nunn PP. The need for new drugs against tuberculosis. Obstacles, opportunities, and 
next steps. Am J Respir Crit Care Med 2001; 163: 1055-1058.
87. Ginsberg AM. Drugs in development for tuberculosis. Drugs 2010; 70: 2201-2214.
88. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: 
the need and the reality. Lancet 2010; 375: 2100-2109.
89. European and Developing Countries Clinical Trials Partnership (EDCTP). Clinical studies with high 
dose rifampicin and development of clinical research capacity in Africa. 8-4-2010. [Online] Available at: 
http://www.edctp.org/Project profiles.245.0.html?&no_cache=1&tx_viprojects_pi1%5baction%5d= 
show_project&tx_viprojects_pi1%5bid%5d=108 (Date last accessed: 13-03-2011).
General D iscussion
#
#General D iscussion | 243
90. European and Developing Countries Clinical Trials Partnership (EDCTP). Rapid evaluation of 
Moxifloxacin in the treatment of sputum smear positive tuberculosis. 31-01-2009. [Online] Available 
at: http://www.edctp.org/Project-Profiles.245.0.htm l?&no_cache=1&tx_viprojects_pi1[action] = 
show_project&tx_viprojects_pi1[id]=78 (Date last accessed: 13-03-2011).
91. European and Developing Countries Clinical Trials Partnership (EDCTP). Evaluation of a novel TB 
drug (SQ109) to shorten and simplify TB treatment. 28-10-2010. [Online] Available at: http://www. 
ed c tp .o rg /P ro je c t-P ro file s .2 4 5 .0 .h tm l? & n o _ ca ch e  = 1& tx_v ip ro jec ts_p i1  [a c tio n ] = show_ 
project&tx_viprojects_pi1[id]=107 (Date last accessed: 13-03-2011).
92. Ginsberg AM. Tuberculosis drug development: progress, challenges, and the road ahead. 
Tuberculosis (Edinb) 2010; 90: 162-167.
93. Perrin FM, Lipman MC, McHugh TD, Gillespie SH. Biomarkers of treatment response in clinical 
trials of novel antituberculosis agents. Lancet Infect Dis 2007; 7: 481-490.
94. Spigelman M, Woosley R, Gheuens J. New initiative speeds tuberculosis drug development: novel 
drug regimens become possible in years, not decades. Int J Tuberc Lung Dis 2010; 14: 663-664.
95. Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978; 3: 108-127.
96. Kenny MT, Strates B. Metabolism and pharmacokinetics of the antibiotic rifampin. Drug Metab Rev 
1981; 12: 159-218.
97. Kreis B, Pretet S, Birenbaum J, et al. Two three-month treatment regimens for pulmonary 
tuberculosis. Bull Int Union Tuberc 1976; 51: 71-75.
98. Steingart KR, Jotblad S, Robsky K, et al. Higher-dose rifampin for the treatment of pulmonary 
tuberculosis: a systematic review. Int J Tuberc Lung Dis 2011; 15: 305-316.
99. Diacon AH, Patientia RF, Venter A, et al. Early bactericidal activity of high-dose rifampin in patients 
with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 
2007; 51: 2994-2996.
100. Ruslami R, Nijland HM, Alisjahbana B, Parwati I, Van Crevel R, Aarnoutse RE. Pharmacokinetics 
and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis 
patients. Antimicrob Agents Chemother 2007; 51: 2546-2551.
101. Tostmann A, Boeree MJ, Aarnoutse RE, De Lange WC, Van der Ven AJ, Dekhuijzen R. Antituberculosis 
drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008; 23: 192-202.
102. Gillespie SH, Kennedy N. Fluoroquinolones: a new treatment for tuberculosis? Int J Tuberc Lung 
Dis 1998; 2: 265-271.
103. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet 
Infect Dis 2003; 3: 432-442.
104. Oliphant CM, Green GM. Quinolones: a comprehensive review. Am Fam Physician 2002; 65: 
455-464.
105. Bernardo J, Yew WW. How are we creating fluoroquinolone-resistant tuberculosis? Am J Respir 
Crit Care Med 2009; 180: 288-289.
106. Ginsburg AS, Hooper N, Parrish N, et al. Fluoroquinolone resistance in patients with newly 
diagnosed tuberculosis. Clin Infect Dis 2003; 37: 1448-1452.
107. Wang JY, Hsueh PR, Jan IS, et al. Empirical treatment with a fluoroquinolone delays the treatment for 
tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006; 61: 903-908.
108. Dooley KE, Golub J, Goes FS, Merz WG, Sterling TR. Empiric treatment of community-acquired 
pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002; 
34: 1607-1612.
109. Chiang CY. State of the Art series on drug-resistant tuberculosis: it’s time to protect fluoroquinolo­
nes. Int J Tuberc Lung Dis 2009; 13: 1319.
110. Sterling TR. The WHO/IUATLD diagnostic algorithm for tuberculosis and empiric fluoroquinolone 
use: potential pitfalls. Int J Tuberc Lung Dis 2004; 8: 1396-1400.
111. World Health Organization. The global plan to stop TB. 2011 -2015. Transforming the fight towards 
elimination of tuberculosis. Geneva, Switzerland: WHO, 2010.
General D iscussion
#
#244 | Chapter 12
112. Lonnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis epidemics: the 
role of risk factors and social determinants. Soc Sci Med 2009; 68: 2240-2246.
113. Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of 
tuberculosis. BMC Public Health 2008; 8: 15.
114. Sreeramareddy CT, Panduru KV, Menten J, Van den Ende J. Time delays in diagnosis of pulmonary 
tuberculosis: a systematic review of literature. BMC Infect Dis 2009; 9: 91.
115. Kaufmann SH, Hussey G, Lambert PH. New vaccines for tuberculosis. Lancet 2010; 375: 
2110-2119.
116. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet 2003; 362: 887-899.
117. Creswell J, Raviglione M, Ottmani S, et al. Tuberculosis and non-communicable diseases: 
neglected links, missed opportunities. Eur Respir J 2010; doi: 10.1183109031936.00084310.
General D iscussion
#General D iscussion | 245
#
General D iscussion 
0
0
#Summary
Samenvatting
List of Publications
Dankwoord / Acknowledgements
Curriculum Vitae
#
#
0
#Summary
Sum m ary | 249
An integral approach of non-adherence to tuberculosis 
treatment
Despite the availability of effective treatment, tuberculosis (TB) continues to be a 
global health problem that affects more than 9 million people each year. It is the 
second leading cause of death from infectious diseases worldwide, after human 
im m unodeficiency virus (HIV) infection. TB and HIV are ‘brothers in harm', 
particularly in Southern and East Africa where up to 50% of TB patients are 
co-infected with HIV.
HIV is not the only driver of the ongoing burden of TB; another important factor 
is non-adherence by patients to the 6-m onths TB treatment regimen, for example 
by irregular medication intake or term ination of treatment all together. 
Non-adherence can result in treatment failure, relapse and drug-resistant TB. 
Such unfavourable treatment outcom es cause severe health problems in 
individual patients and are a threat to public health as unsuccessfully treated 
patients can transm it the disease to others.
One of the global strategies to prevent non-adherence to TB treatment is Directly 
Observed Treatment (DOT): daily observation of medication intake by a trained 
supervisor. In its conventional form (provided by staff in healthcare facilities), 
DOT is cumbersome to patients and healthcare providers. Therefore, alternative 
strategies to prevent non-adherence to TB treatment are urgently needed.
In this thesis, two important questions concerning non-adherence to TB treatment 
are addressed. The first question is how adherence to long-term treatment 
regimens can be measured; the second question is how non-adherence to TB 
treatment can be prevented.
Most of the studies presented in this thesis were conducted in the Kilimanjaro 
Region of Tanzania, one of the 22 countries with the highest burden of 
TB worldwide. Each year, 183 per 100,000 inhabitants of Tanzania develop active 
TB (compared to less than 8 per 100,000 in The Netherlands). To prevent
Sum m ary
#
#non-adherence, the Tanzanian TB control programme prescribes DOT to all 
patients. However, the provision of DOT by staff of healthcare facilities has 
started to overload the healthcare system and this led to the introduction of a 
Patient Centred Treatment (PCT) approach in 2007. The PCT approach empowers 
patients to choose where and by whom DOT is provided: by staff in the healthcare 
facility  (the conventional facility-based DOT) or by a treatment supporter in the 
home-setting (community-based DOT). Most patients opt for community-based 
DOT but since this type of DOT is applied out of sight of healthcare providers, its 
effectiveness is d ifficu lt to assess. The question of how non-adherence to TB 
treatment can be measured in patients on community-based DOT is therefore 
highly relevant to healthcare providers in Tanzania.
In Part I of this thesis, the problem of non-adherence to TB treatment is explored 
from a clin ical-pharm acological point of view and from the perspectives of TB 
patients. In C hapter 2, the relation between non-adherence and treatment 
outcome is analyzed to understand why it is so difficu lt to predict the impact of 
different levels and patterns of non-adherence on TB treatment outcome. In the 
case of HIV for example, it is known that patients should take at least 95% of the 
medication as prescribed in order to maintain viral suppression. Such information 
is not available fo r TB because the relation between treatment adherence and 
outcome is influenced by complex drug, host, and pathogen factors that are only 
partly understood. Furthermore, the three main consequences of non-adherence 
(treatment failure, relapse and drug-resistant TB) result from different drug-host- 
pathogen mechanisms. Additional research is needed to predict how and in 
which way non-adherence to TB treatment affects treatment outcome.
In C hapter 3, the determ inants of adherence behaviour are explored. We 
interviewed Tanzanian patients on comm unity-based DOT about the factors that 
affect adherence to TB treatment, and used their experiences to develop a 
theoretical model of adherence behaviour. An important and often neglected 
first step towards adherence is the patient's initial decision to seek biomedical 
healthcare. Knowledge and traditional beliefs of TB play a role in this decision. 
Once TB treatment is prescribed to a patient, the most important determinant of 
adherence is his or her intention to adhere, which follows from knowledge and 
beliefs about TB treatment (for example, the knowledge that TB is a curable
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#disease) and the motivation to get cured. Social support is another determinant 
of the intention to adhere: the perception that key-persons from a social network 
disapprove non-adherence motivates patients to be adherent (so-called 
‘perceived social pressure'). Patients with a strong intention to adhere manage 
to cope with perceived barriers to adherence and create an enabling environment in 
which the use of reminder cues plays an important role. If our model of adherence 
behaviour proves to be valid in larger patient populations, it could help healthcare 
providers to identify patients who might be at risk of non-adherence and offer 
tailored adherence promoting interventions.
In Part II of this thesis, several methods to measure adherence are evaluated. 
Measuring adherence is difficult as there is no simple, reliable and affordable 
method available. A sophisticated method that is increasingly regarded as the 
‘gold standard' is electronic monitoring of medication intake with a Medication 
Event Monitoring System (MEMS); a pill bottle with in its cap a m icroelectronic chip 
that registers date and time of every bottle opening. MEMS may not be affordable 
for routine use in resource-limited settings, but can be a valuable tool for research 
purposes. In the study described in Chapter 4, we used MEMS as a gold standard 
to validate simple adherence measures that could be used in clinical practice of 
resource-limited settings. We found that the reliability of the routinely used 
combination of pill counts and monitoring the patient's clinic attendance for 
medication refills can be improved by adding a standardized questionnaire in 
which patients report on their adherence behaviour and the possible difficulties 
they encounter. The latter has an additional advantage: it can help healthcare 
providers to offer tailored adherence promoting assistance to their patients.
To get an impression of how the use of MEMS is perceived by Tanzanian patients, 
we interviewed patients with HIV from the Kilimanjaro Region after they had used 
their antiretroviral medication from a MEMS bottle for 3 months (Chapter 5). The 
use of MEMS bottles was readily accepted by these patients and they did not 
mind that their adherence behaviour was being monitored. However, two 
drawbacks were observed: (1) MEMS bottle openings do not always represent 
pill intake and patients may take out several pills at a time for later use; and (2) 
MEMS use may (unintentionally) improve the patient's adherence behaviour. 
Clearly, MEMS data should always be interpreted with caution.
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assume rather than proof that the patient actually took the medication. In Chapter 6, 
we present a method that confirms medication intake: the determination of TB 
drug concentrations in blood (therapeutic drug monitoring, TDM). In this study, 
TDM was not used to monitor treatment adherence, but to guide the process of 
adjusting TB drug dosages in patients with relapse TB who had low drug 
concentrations despite adequate adherence. Apparently, low drug concentrations 
do not necessarily indicate non-adherence. They can be attributable to natural 
variation in drug absorption and elim ination processes, and to malabsorption 
problems in patients with for example diabetes mellitus or HIV-infection. Thus, 
although TDM can be a useful method to optimize drug dosages in selected 
groups of patients, its app licab ility  to measuring adherence is limited.
In pa rt III of this thesis, two different strategies to prevent non-adherence are 
considered: the Tanzanian PCT approach that incorporates community-based 
DOT as an alternative to facility-based DOT, and shortening treatment duration 
with altered treatment regimens. The effectiveness of the PCT approach is 
evaluated in C hapter 7. We found high treatment success rates in patients on 
community-based DOT; sim ilarly high to those of patients on facility-based DOT. 
This finding suggests that the PCT approach is an appropriate adherence 
promoting strategy. However, as known from C hapter 2, treatment outcome is 
an indirect and hence unreliable indicator of adherence. Therefore, we also 
measured the actual adherence rates of 50 patients on community-based DOT 
with MEMS (Chapter 4). The average adherence rate was 96% in the patients 
who completed treatment, and only one patient was less 80% adherent. Based 
on the results from these two studies we conclude that community-based DOT as 
part of the PCT approach can be an effective strategy to prevent non-adherence. 
The literature review in C hapter 8 summarizes the challenges of developing TB 
treatment regimens of shorter duration and provides an overview of the new 
drugs that are currently in clinical development for this purpose. Pharmaceutical 
industries and non-profit organizations are increasingly jo ining forces to 
streamline the process of drug development, and the pipeline of potential drug 
candidates is growing. Nevertheless, it will take at least another decade to get 
the new TB drugs fu lly tested, registered and accessible to patients. A faster
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#alternative is to revise drugs that are already registered for use in TB treatment 
such as rifampicin and the fluoroquinolones.
The potential of higher than standard doses of rifampicin to shorten TB treatment 
duration is currently being evaluated in the Kilimanjaro Region. Rifampicin can 
cause liver toxic ity and it is unsure whether high doses of rifampicin are tolerated 
well by patients. In the study presented in C hapter 9, we showed that TB drug 
induced liver toxic ity is rare in Tanzanian patients who are treated with the 
standard dose of rifampicin. This is a favourable finding in light of the possible 
use of higher doses of rifampicin in treatment regimens of shorter duration. 
Fluoroquinolones are a class of antib iotics that are registered for the treatment of 
m ultidrug-resistant TB and a wide range of other bacterial infections. Two new 
drugs in th is class, moxifloxacin and gatifloxacin, have the potential to shorten 
TB treatment duration and studies with moxifloxacin are currently ongoing in the 
Kilimanjaro Region. It is feared that the use of fluoroquinolones for other bacterial 
infections induces resistance in TB bacilli. This could be a barrier to the 
incorporation of fluoroquinolones in shorter TB treatment regimens. The studies 
in C hapters 10a and 10b show that fluoroquinolones are used extensively in the 
Kilimanjaro Region: they account for 12% of the total sale of antib iotics in 
pharmacies and are w idely available in grocery shops that are not officially 
authorized to sell these drugs. In the study presented in C hapter 11, we assessed 
the occurrence of fluoroquinolone-resistant TB in patients from the Kilimanjaro 
Region and investigated whether this was related to previous use of fluoroqui­
nolones by these patients. Fortunately, the rate of fluoroquinolone resistance 
was low (<1%) and not related to previous fluoroquinolone use. This finding is 
encouraging for the development of fluoroquinolone-conta in ing TB treatment 
regimens of shorter duration.
In summary, non-adherence to TB treatment is a significant contributor to the 
ongoing transmission of TB; it has dramatic consequences for individual patients 
as well as for public health. While awaiting the development of treatment regimens 
of shorter duration that will facilitate adherence, patient centred strategies such 
as community-based DOT could help to improve adherence to TB treatment. 
Theoretical models of adherence behaviour can be valuable to predict who might 
be non-adherent and to develop tailored adherence promoting interventions.
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Sophisticated methods to measure adherence could be used to evaluate the 
effectiveness of such interventions in research settings. Combinations of simpler 
adherence measures can help healthcare providers to monitor their patients’ 
adherence in routine clinical practice, particularly when medication intake occurs 
outside the healthcare facility.
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Een integrale benadering van therapie-ontrouw in de 
behandeling van tuberculose
Ondanks de beschikbaarheid van een effectieve behandeling is tuberculose (TBC) 
nog steeds een wereldwijd gezondheidsprobleem dat ieder jaar meer dan 9 miljoen 
mensen treft. TBC is na het Humaan Immunodeficiëntie Virus (HIV) de belangrijkste 
doodsoorzaak onder de infectieziekten in de wereld. TBC en HIV gaan vaak samen 
op, met name in Zuidelijk en Oost Afrika waar tot wel 50% van de TBC patiënten ook 
besmet is met HIV.
HIV is niet de enige stuwende kracht achter het blijven voortbestaan van TBC. Een 
andere belangrijke factor is therapie-ontrouw door patiënten, bijvoorbeeld door 
onregelmatige medicatie inname of het voortijdig afbreken van de 6 maanden 
durende behandeling. Therapie-ontrouw kan leiden tot het falen van de TBC 
behandeling, het terugkeren van de ziekte na een ziektevrije periode en de 
ontwikkeling van medicatie-resistente TBC. Deze ongunstige behandeluitkomsten 
veroorzaken niet alleen ernstige gezondheidsproblemen in individuele patiënten, ze 
vormen ook een bedreiging voor de volksgezondheid omdat ongenezen TBC 
patiënten de ziekte kunnen overdragen op mensen in hun omgeving.
Een van de wereldwijd toegepaste strategieën om therapie-ontrouw door TBC 
patiënten te voorkomen, is Directly Observed Treatment (DOT): de dagelijkse 
observatie van medicatie inname door een hiervoor getrainde supervisor. Helaas is 
DOT erg arbeidsintensief en een last voor patiënten wanneer het wordt toegepast op 
de meest gangbare manier, namelijk door personeel in gezondheidszorgfaciliteiten. 
Het vinden van alternatieve strategieën om de therapie-trouw van TBC patiënten te 
bevorderen is daarom van groot belang.
In dit proefschrift staan twee belangrijke vragen centraal die betrekking hebben op 
het probleem van therapie-ontrouw in de TBC behandeling. De eerste vraag betreft 
hoe therapie-trouw gemeten kan worden; de tweede vraag is hoe therapie-ontrouw 
voorkomen kan worden.
Sam envatting
#
#De meeste studies die in dit proefschrift staan, zijn uitgevoerd in de noordelijke 
Kilimanjaro Region van Tanzania. Tanzania is een van de 22 landen in de wereld die 
samen 80% van alle TBC patiënten huisvesten. Elk jaar ontwikkelen 183 van iedere 
100.000 mensen in Tanzania TBC. Ter vergelijking, in Nederland is dat aantal minder 
dan 8. In de strijd tegen TBC schrijft het Tanzaniaanse TBC controle programma 
DOT voor aan alle patiënten. Het verstrekken van DOT door personeel in klinieken 
heeft echter geleid tot een overbelasting van het gezondheidszorgsysteem en 
daarom is een aanpassing van de strategie geïntroduceerd. Sinds 2007 kunnen 
TBC patiënten in Tanzania kiezen waar en door wie DOT aan hen wordt verstrekt: op 
de gebruikelijke wijze in de kliniek (facility-based DOT) of in de thuissituatie door een 
bekende of familielid (community-based DOT). De meeste patiënten kiezen voor 
laatstgenoemde optie. Echter, omdat deze vorm van DOT zich buiten het zicht van 
gezondheidswerkers afspeelt, is het moeilijk te bepalen hoe effectief de strategie is 
voor wat betreft het voorkómen van therapie-ontrouw. De vragen over hoe therapie- 
ontrouw voorspeld en gemeten kan worden in patiënten onder community-based 
DOT, zijn daarom uitermate relevant voor gezondheidswerkers in Tanzania die 
verantwoordelijke zijn voor adequate behandeling van TBC.
De studies in Deel I van dit proefschrift verkennen het probleem van therapie-on- 
trouw in de TBC behandeling vanuit een klinisch-farmacologisch perspectief en 
vanuit de ervaringen van patiënten. In H o ofd s tuk  2 wordt het verband tussen thera- 
pie-ontrouw en behandeluitkomst geanalyseerd om te kunnen begrijpen waarom 
het zo moeilijk is om de gevolgen van verschillende patronen van therapie-ontrouw 
voor het genezingsproces te voorspellen. In het geval van HIV-behandeling 
bijvoorbeeld, is het bekend dat patiënten tenminste 95% van hun medicijnen moeten 
innemen zoals voorgeschreven om ervoor te zorgen dat het virus onderdrukt blijft. 
Zulke informatie is niet bekend voor de TBC behandeling, omdat de relatie tussen 
therapie-trouw en behandeluitkomst wordt beïnvloed door complexe medicatie-, 
gastheer-, en ziekteverwekker-gerelateerde factoren waarover maar weinig bekend 
is. Bovendien liggen verschillende biologische mechanismen ten grondslag aan de 
drie hoofdgevolgen van therapie-ontrouw (falen van de behandeling, terugkeren 
van de ziekte, en de ontwikkeling van resistente TBC). Deze mechanismen moeten 
afzonderlijk uitgeplozen worden in aanvullend onderzoek om te kunnen voorspellen 
hoe en in welke mate therapie-ontrouw het genezingsproces beïnvloedt.
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#In H oofds tuk  3 worden de determinanten van therapie-trouw gedrag onderzocht. 
We interviewden Tanzaniaanse TBC patiënten onder community-based DOT over de 
factoren die therapie-trouw beïnvloeden, en ontwikkelden een theoretisch model 
van therapie-trouw gedrag op basis van de ervaringen van deze patiënten. Een 
belangrijke, maar vaak vergeten eerste stap in de richting van therapie-trouw is de 
beslissing van patiënten om naar de kliniek te gaan voor diagnose en behandeling. 
Deze beslissing hangt samen met de kennis en traditionele opvattingen van patiënten 
over TBC. Als de diagnose eenmaal is gesteld en de behandeling voorgeschreven, 
dan is de belangrijkste voorspeller van therapie-trouw gedrag het voornemen (de 
intentie) van patiënten om therapie-trouw te zijn. Deze intentie volgt uit de kennis en 
opvattingen die de patiënt over de TBC behandeling heeft (zoals de kennis dat TBC 
te genezen is mits de behandeling wordt voltooid), en uit een duidelijke motivatie om 
beter te worden. De aanwezigheid van een sociale netwerk is een andere determinant 
van de intentie om therapie-trouw te zijn: als patiënten het gevoel hebben dat 
belangrijke personen uit hun sociale netwerk therapie-ontrouw gedrag afkeuren 
(perceived social pressure), zullen ze sneller geneigd zijn om therapie-trouw te zijn. 
Een sterke intentie om therapie-trouw te zijn helpt patiënten om obstakels te 
overwinnen, en om in hun omgeving hulpmiddelen te vinden die ervoor zorgen dat 
ze de medicatie niet vergeten. De waarde van ons theoretische model van 
therapie-trouw gedrag zal geëvalueerd moeten worden in grotere patiënten 
populaties. Als het model inderdaad toepasbaar blijkt te zijn, dan kan het gezond­
heidswerkers helpen om een inschatting te maken van welke patiënten mogelijk the- 
rapie-ontrouw zijn of worden, en om interventies op maat te ontwikkelen die de 
therapie-trouw bevorderen.
In D eel II van dit proefschrift worden verschillende methoden om therapie-trouw te 
meten onderzocht. Het meten van therapie-trouw is ingewikkeld omdat er geen 
simpel, betrouwbaar en betaalbaar meetinstrument bestaat. Een geavanceerde 
methode die steeds meer als de ‘gouden standaard' wordt gezien om therapie-trouw 
te meten, is het gebruik van een elektronisch systeem genaamd Medication Event 
Monitoring System (MEMS). Dit is een medicatie pot met in de deksel een micro- 
elektronische chip die de datum en tijd van iedere opening van de pot registreert. 
Het routinematig gebruik van MEMS in de klinische praktijk is onbetaalbaar voor de 
meeste landen waar veel TBC voorkomt, maar MEMS is wel een geschikt instrument
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voor onderzoeksdoeleinden. In de studie die wordt beschreven in H oofdstuk 4, is 
MEMS gebruikt als de gouden standaard om de betrouwbaarheid van een aantal 
simpele meetinstrumenten te bepalen die gebruikt kunnen worden in de klinische 
praktijk. Het bleek dat de betrouwbaarheid van de gangbare combinatie methode 
van het tellen van overgebleven pillen en het registeren van de frequentie waarmee 
patiënten de kliniek bezoeken om nieuwe medicatie op te halen, verbeterd kon 
worden door patiënten een standaard vragenlijst over therapie-trouw te laten 
invullen. In de vragenlijst staan ook vragen die betrekking hebben op de mogelijke 
problemen die patiënten ervaren bij de dagelijkse inname van hun medicatie. De 
antwoorden op deze vragen kunnen gezondheidswerkers helpen om patiënten 
adequaat te adviseren over hoe therapie-trouw vergemakkelijkt kan worden.
Om een indruk te krijgen van hoe patiënten uit Tanzania het ervaren om MEMS te 
gebruiken, zijn patiënten met HIV geïnterviewd nadat zij gedurende 3 maanden hun 
HIV-medicatie uit MEMS potten hadden gebruikt (Hoofdstuk 5). De patiënten hadden 
geen moeite met het gebruik van MEMS en ook niet met het feit dat hun therapie-trouw 
gedrag via de MEMS pot werd geregistreerd. Wel kwamen er twee valkuilen van 
MEMS aan het licht: (1) Het openen van de MEMS pot betekent niet altijd een 
daadwerkelijke pil inname en sommige patiënten nemen meer dan één dosis tegelijk 
uit de pot voor later gebruik; en (2) Het gebruik van MEMS kan de therapie-trouw van 
patiënten verbeteren. Het is daarom van belang dat de informatie die verkregen wordt 
met MEMS, altijd kritisch wordt geïnterpreteerd.
De methoden om therapie-trouw te meten die tot dusver zijn besproken, hebben een 
gemeenschappelijk nadeel: ze berusten op de aanname dat patiënten hun medicatie 
daadwerkelijk hebben ingenomen, maar bewijzen dat niet.
In H oofdstuk 6 wordt een methode besproken die medicatie inname wél bewijst, 
namelijk het bepalen van medicijnspiegels in het bloed van de patiënt. Deze methode 
wordt ook wel Therapeutic Drug Monitoring (TDM) genoemd. In de studie die we 
presenteren wordt TDM echter niet gebruikt voor het meten van therapie-trouw, 
maar om op geleide van medicijnspiegels de dosering van de medicatie aan te 
passen in individuele patiënten met ongenezen TBC en lage medicijnspiegels, 
ondanks goede therapie-trouw. Blijkbaar betekenen lage medicijnspiegels niet altijd 
dat de patiënt therapie-ontrouw is. Andere oorzaken van lage spiegels zijn natuurlijke 
variaties in de medicijn opname- en uitscheidingsprocessen, en stoornissen in de 
opname van medicijnen uit het maag-darmstelsel, bijvoorbeeld bij patiënten met
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#diabetes mellitus of HIV. Om deze reden is TDM van beperkte waarde voor het meten 
van therapie-trouw.
In Deel III van dit proefschrift komen twee verschillende strategieën aan bod om 
therapie-ontrouw te voorkomen: (1) de Tanzaniaanse benadering die TBC patiënten 
laat kiezen tussen facility-based DOT en community-based DOT, en (2) het verkorten 
van de TBC behandeling om de therapie-trouw te vergemakkelijken.
In H oofdstuk 7 wordt de effectiviteit van de Tanzaniaanse DOT strategie geëvalueerd. 
Het behandelsucces blijkt net zo groot te zijn in patiënten onder community-based 
DOT als in patiënten onder facility-based DOT. Op grond hiervan zouden we kunnen 
concluderen dat de strategie effectief is. Echter, zoals we weten uit H oofdstuk 2, is 
behandeluitkomst een indirecte en dus onbetrouwbare graadmeter voor therapie- 
trouw. Daarom hebben we de daadwerkelijke therapie-trouw van 50 patiënten onder 
community-based DOT ook gemeten met MEMS (H oofdstuk 4). Het gemiddelde 
niveau van therapie-trouw was erg hoog in de patiënten die de TBC behandeling 
voltooiden: gemiddeld werd 96% van de voorgeschreven pillen ingenomen en bij 
slechts één patiënt was dat minder dan 80%. Op basis van de resultaten van deze 
beide studies kan worden geconcludeerd dat community-based DOT als onderdeel 
van een programma dat patiënten laat kiezen tussen facility-based DOT en commu­
nity-based DOT, een effectieve methode kan zijn om therapie-trouw te bevorderen. 
In H oofdstuk 8 wordt een overzicht van de literatuur gepresenteerd met betrekking 
tot de obstakels in de ontwikkeling van een kortere TBC behandeling. Daarnaast 
worden de nieuwe medicijnen besproken die de behandelduur mogelijk kunnen 
verkorten en momenteel voor die eigenschap worden getest in klinische studies. De 
farmaceutische industrie en non-profit organisaties werken gelukkig in toenemende 
mate samen om het ingewikkelde proces van de ontwikkeling van nieuwe medicijnen 
te stroomlijnen. Er komen steeds meer veel belovende middelen bij. Desalniettemin 
zal het nog minimaal 10 jaar duren voordat nieuwe medicijnen de lange weg van 
onderzoek naar toepassing in de klinische praktijk hebben afgelegd. Een sneller 
alternatief is het herzien van medicijnen die al geregistreerd zijn voor gebruik in de 
TBC behandeling, zoals rifampicine en de fluoroquinolonen.
De mogelijkheid om de TBC behandelduur te verkorten met behulp van hoge 
doseringen rifampicine wordt momenteel onderzocht in de Kilimanjaro Region. 
Rifampicine kan leverschade veroorzaken en het is onbekend of hoge doseringen
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van het middel goed worden verdragen door patiënten. In de studie die wordt 
beschreven in H oofdstuk 9, laten we zien dat de door TBC medicatie veroorzaakte 
leverschade in ieder geval nauwelijks voorkomt in Tanzaniaanse patiënten die 
behandeld worden met rifampicine in de gebruikelijk dosering. Dit is een 
veelbelovende bevinding in het kader van de toepassing van hoge doseringen 
rifampicine in TBC behandelschema's van kortere duur.
Fluoroquinolonen zijn antibiotica die geregistreerd staan voor gebruik in de 
behandeling van multiresistente TBC en andere bacteriële infecties. Twee nieuwe 
middelen (moxifloxacine en gatifloxacine) in deze groep van antibiotica kunnen 
mogelijk de TBC behandelduur verkorten. Moxifloxacine wordt momenteel voor dit 
doel getest in de Kilimanjaro Region. Echter, men vreest dat het veelvuldige 
gebruik van fluoroquinolonen voor andere infecties resistentie veroorzaakt in de 
TBC bacillen. Dit zou een groot obstakel kunnen zijn voor de toepassing van 
fluoroquinolonen in TBC behandeling van kortere duur. De studies in Hoofdstukken 
10a en 10b tonen aan dat fluoroquinolonen in de Kilimanjaro Region inderdaad op 
grote schaal in de behandeling van allerlei infecties worden gebruikt: 12% van alle 
verkochte antibiotica zijn fluoroquinolonen en daarnaast zijn de middelen ook nog 
vrij verkrijgbaar in kruidenierswinkels die deze medicijnen officieel niet mogen 
verkopen. In de studie in H oofdstuk 11 wordt onderzocht in welke mate resistentie 
tegen fluoroquinolonen voorkomt in TBC patiënten uit de Kilimanjaro Region, en of 
dit gerelateerd is aan eerder gebruik van fluoroquinolonen door deze patiënten. 
Gelukkig komt er nauwelijks fluoroquinolonen-resistentie voor in TBC bacillen van 
patiënten uit de Kilimanjaro Region (in minder dan 1%) en lijkt het niet gerelateerd te 
zijn aan eerder gebruik van fluoroquinolonen. Deze bevinding is gunstig voor het 
gebruik van fluoroquinolonen in een TBC behandeling van kortere duur.
Samengevat, therapie-ontrouw in de behandeling van TBC heeft dramatische 
gevolgen voor zowel individuele patiënten als de algemene volksgezondheid. In 
afwachting van de ontwikkeling van een kortere behandeling die de therapie-trouw 
vergemakkelijkt, kan gebruik worden gemaakt van patiënt gerichte strategieën zoals 
community-based DOT om de therapie-trouw van TBC patiënten te verbeteren. 
Theoretische modellen van therapie-trouw gedrag zijn van waarde bij het voorspellen 
van wie mogelijk therapie-ontrouw is, en zulke modellen kunnen een uitgangspunt 
vormen voor de ontwikkeling van gepaste therapie-trouw bevorderende interventies.
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Geavanceerde methoden om therapie-trouw te meten moeten ingezet worden om 
de effectiviteit van zulke interventies te evalueren. Combinaties van simpelere 
methoden kunnen gezondheidswerkers helpen om de therapie-trouw van hun 
patiënten in de gaten te houden, zeker wanneer de daadwerkelijke medicatie 
inname zich buiten het zicht van de gezondheidwerker afspeelt.
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